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CO-TRANSCRIPTIONAL SPLICING AND FUNCTIONAL ROLE OF PKCβ IN
INSULIN-SENSITIVE L6 SKELETAL MUSCLE CELLS AND 3T3-L1
ADIPOCYTES
Eden Kleiman
ABSTRACT
PKCβII is alternatively spliced during acute insulin stimulation in L6 skeletal
muscle cells. This PKCβII isoform is critical in propagating GLUT4 translocation.
PKCβ protein and promoter dysfunction correlate with human insulin resistance. TZD
treatment ameliorates whole-body insulin-resistance. Its primary target is adipocyte
PPARγ, which it activates upon binding. This causes both altered circulating serum FFA
concentrations and adipokine secretion profile. How TZDs affect the intracellular
signaling of skeletal muscle cells is unknown. RT-PCR and Western blot analysis
showed that TZDs elevated PKCβII by a process that involves co-transcriptional splicing.
PGC1α overexpression most closely resembled TZD treatment by increasing PKCβII
protein levels and keeping PKCβI levels relatively constant. Use of a heterologous PKCβ
promoter driven PKCβ minigene demonstrated that PPARγ could regulate the PKCβ
promoter, but whether this is direct or indirect is unclear. SRp40 splicing factor has been
shown to dock onto the PGC1α CTD and influence splicing. SRp40, through
overexpression and silencing, appears to play a part in PKCβ promoter regulation.
PKCβ promoter regulation was also studied in 3T3-L1 cells. TZDs were
experimentally shown to have no role in PKCβ promoter regulation despite PPARγ
xvii

activation. Chromatin immunoprecipitation assays revealed PU.1 as a putative PKCβ
transcription factor that can cross-talk with the spliceosome, possibly through SRp40
which was also associated with the PKCβ promoter. 3T3-L1 adipocyte differentiation
revealed a novel developmentally-regulated switch from PKCβI to PKCβII, using
western blot and Real-Time PCR analysis. Pharmacological inhibition of PKCβII using
CGP53353 and LY379196 blocked [3H]2-deoxyglucose uptake and revealed a functional
role for PKCβII in adipocyte ISGT. CGP53353 specifically inhibited phosphorylation of
PKCβII Serine 660 and not other critical upstream components of the insulin signaling
pathway. Subcellular fractionation and PM sheet assay pointed to PKCβII-mediated
regulation of GLUT4 translocation to the PM. Co-immunoprecipitation between PKCβII
and GLUT4 allude to possible direct interaction. Western blot and immunofluorescence
assays show PKCβII activity is linked with Akt Serine 473 phosphorylation, thus full Akt
activity. Western blot and co-immunoprecipitation suggested that insulin caused active
mTORC2 to directly activate PKCβII.

Data support a model whereby PKCβII is

downstream of mTORC2 yet upstream of Akt, thereby regulating GLUT4 translocation.

xviii

INTRODUCTION
Protein Kinase C: Brief History
Protein Kinase C (PKC) was discovered by Nishizuka and coworkers as a histone
protein kinase isolated from the rat brain that could be activated by limited proteolysis
[1], Ca2+ and (phospho)lipids [2] or phorbol esters and phospholipids [3]. Diacylglycerol
(DAG), an early product of signal-induced inositol phospholipid breakdown, enhanced
the affinity of PKC for calcium and thereby activating it [4]. Phorbol esters, which
promoted tumors, were able to substitute for DAG in PKC activation [3]. This activation
by phorbol esters was believed to be the reason PKC was a tumor promoter [5; 6],
bringing it to the forefront on cancer research [7]. Early biochemical studies and
purifications indicated PKC represented a group of several isoenzymes [8]. The major
breakthrough came from cloning cDNAs of PKC isoforms, mostly from brain cDNA
libraries. PKCβ cDNA has been cloned from various sources including bovine, human,
rat and mouse [9].
Signaling and Physiolocial Impact
PKC′s role in signal transduction was first demonstrated in release of serotonin
from platelets [10; 11]. A variety of agonist-induced cellular responses involve PKC
including hormones, neurotransmitters and some growth factors [12]. One of the main
pathways activated by PKC is the MEK-ERK pathway which promotes proliferation and
differentiation [13]. However, there are many other signaling cascades of which PKC is
1

at the epicenter. Figure 1 illustrates the many proposed effects of protein kinase C
activation [14].
In cancer signaling, PKC is also involved in cellular adhesion. This allows for
cancer cell invasion via integrin binding, activation of metalloproteinases and expression
of extracellular matrix proteins. Inhibition of PKC reduces invasiveness [14]. A PKCβ
selective inhibitor, Enzastaurin, has recently been evaluated for its potential as an
anticancer agent in lung cancer [15].
PKC is also involved in the PI3K-Akt pathway [14]. This places PKC in the
middle of the insulin signaling cascade. PKC is involved in insulin-stimulated glucose
uptake as a downstream effector of PI3K-PDK1 [16]. As proof of its central role in
insulin signaling, PKC dysregulation is associated with many diabetic complications such
as diabetic nephropathy, diabetic retinopathy and cardiovascular disease [17; 18].
PKC Family and Structure
The Protein Kinase C family are serine/threonine kinases that are members of the
AGC (cAMP-dependent, cGMP-dependent, and protein kinase C) family of protein
kinases which have structural features in common (includes PKA, PKB and PKC). AGC
kinases contain highly conserved catalytic domains (motifs required for ATP/substratebinding and catalysis) and a regulatory domain that keeps that enzyme in an inactive
conformation. PKC regulatory domains occupy the amino terminal and contain an
autoinhibitory pseudosubstrate domain (sequence where alanine substitutes for
serine/threonine phosphoacceptor site) and two distinct plasma membrane targeting
modules, C1 and C2. PKC isoforms are classified based on differences in their amino
terminal regulatory domain (Figure 2) and cofactor requirement [14; 19; 20; 21].
2

The PKC family comprises 10 isozymes and their splice variants grouped into 3
classes based on co-factor requirement [21]. Conventional PKC (cPKC) isoforms include
α, γ, βI and alternatively spliced βII. Starting at the N-terminal, cPKCs are allosterically
regulated by the pseudosubstrate which as mentioned before resembles a substrate
binding domain [20]. This was discovered by using peptides based on the sequence and
showed that they were effective competitive inhibitors of PKC [22]. Activation of PKC
(and downstream signaling) necessitates the release of the pseudosubstrate domain from
the kinase core (Figure 3) [6; 23].
Antibodies targeting the pseudosubstrate domain resulted in co-factor independent
PKC activation [24]. PKC is resistant to proteolysis when inactive (pseudosubstratekinase core binding) but highly sensitive to proteolysis in the pseudosubstrate domain
(specific Arginine within) when active. The activation of PKC is dependent on
pseudosubstrate unmasking [25]. cPKCs contain a C1 domain that binds DAG/PMA.
The C1 domain consists of tandem (roughly 50) residue sequences, named C1A and C1B.
C1A and C1B domains both have a zinc finger (Zn2+) held by 6 cysteines and 2
histidines. This is used for DAG/phorbol ester binding [19]. The C1B domain contains
a Tyrosine at position 22 making it a weak DAG responder [21]. The C2 domain binds
calcium and subsequently binds anionic/acidic phospholipids [19]. Ca2+ is bound by a βsandwich structure composed of eight β-strands creating two flat sheets connected with a
short helix hinge. This β sandwich can bind 2-3 calcium ions. It is this positively
charged ion that helps interact with negatively charged phospholipids such as
phosphatidylserine [26]. The double positive symbol (Figure 2) in the cPKC C2 domain
represents a basic patch (located in the distal area of the Ca2+-dependent lipid binding
3

site) that specifically recognizes PIP2 and distinguishes cPKC from other PKCs (among
other things) in terms of activation [21]. Novel PKCs (nPKCs) include δ, ε, θ, η. δ/θ or
ε/η could be further subdivided based on structural features. nPKCs have C1 and C2
domains, however, the order is switched relative to cPKCs (Figure 2). The nPKC C2
domain (C2-like) lacks the acidic residues necessary for calcium binding. This is the
main pharmacological difference between cPKCs and nPKCs. As shown in Table 3,
nPKCs are maximally activated by DAG/PMA and phosphatidylserine without the
requirement for calcium [19]. nPKCs have stronger DAG responsiveness compared to
cPKCs due to a tryptophan at position 22 (Figure 2) in the C1B domain [21].

Atypical

PKCs (aPKCs) include ζ, ι/λ. They lack a calcium sensitive C2 domain and have an
atypical C1 domain with only one cysteine-rich membrane-targeting structure that binds
PIP3 or ceramide (not DAG or PMA). Upstream of the C1 domain is a PB1 domain that
mediates interactions with other PB1-containing scaffolding proteins such as PAR-6 and
MEK5. The activity of aPKCs are regulated mainly by protein-protein interactions and
PDK-1 mediated phosphorylation [19].
The PKC ATP-binding domain (C3) contains a lobe with β-sheets with a glycinerich ATP-binding loop with the consensus GXGXXG. It has an invariant lysine which
structures the enzyme for phosphoryl-transfer. The C4 domain is predominantly αhelical and contains the activation loop segment that positions magnesium and peptide
substrates for catalysis. In between the C3 and C4 lobes of the kinase domain, there is a
“gatekeeper” residue (methionine in PKCβII) that controls access to a cavity in the ATP
binding pocket. The V5 domain contains highly conserved priming/regulatory
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phosphorylation sites (discussed in further detail below) that play a crucial role in
structuring the catalytic pocket [19].
PKC μ and ν are considered by some to constitute a fourth class of PKCs named
Protein Kinase D [20]. Initially, human PKD (PKCμ) was discovered followed by the
murine ortholog PKD [27; 28]. PKD is a serine/threonine kinase that consists of an Nterminal regulatory domain and a C-terminal catalytic domain. The N-terminal domain
has 2 cysteine-rich, zinc finger-like motifs and a pleckstrin homology (PH) domain.
Cys1 and Cys2 domains (Figure 2) bind DAG/PMA with high affinity [29]. The PH
domain is involved in protein:protein interactions as well as PH domain-dependent
autoinhibitory intramolecular interactions that maintain the enzyme in an inactive state
with low basal activity in resting cells. An interesting connection exists between PKD
and nPKCs. nPKCs activate PKD by phosphorylating them at highly conserved serine
residues in the activation loop which relieves autoinhibition [30].

PKD2 and PKD3

have also recently been added to the list. PKD is distinct from PKC with respect to
structural and enzymatic properties. For instance, PKD does not phosphorylate many
bona-fide PKC substrates. PKD family members have been grouped into the
calcium/calmodulin-dependent protein kinase (CaMK) based on catalytic domain
structure and substrate specificity. However, unlike CaMK, PKDs are activated
indirectly by calcium through DAG production [29].
Recently, another group of PKCs has been discovered. Protein kinase C-related
kinase (PRK) consists of at least three members, PRK1-3. PRKs are insensitive to Ca2+,
DAG and phorbol esters but can be activated by limited proteolysis and phospholipids.
Both PRK1 and PRK2 can bind activated RhoA GTPase proteins, which increases their
5

activity. This binding occurs in the HR1 domain. It is composed of three repeats of a 55
amino acid motif. In PRK1, the first HR1 repeat (HR1a) binds to activated GTP-RhoA
complex but not to the inactive GDP-bound form. HR1b is the second motif and binds
(less affinity) to either active of inactive RhoA. The HR1c repeat does not bind RhoA
and its function is unknown [31; 32].
PKCβ Gene
PKCβI and PKCβII are derived from alternative splicing of the same pre-mRNA
from the same gene (16p11.2 in humans). The region of splicing that determines the β
isoform is the V5 region. Rat and rabbit PKCβI and PKCβII cDNAs encode proteins
composed of 671 and 673 amino acids, respectively. The difference in the C-terminal V5
exon is a PKCβI product that is 50 amino acids and a PKCβII product that is 52 amino
acids (Figure 4) [33; 34]. This is also the case for human PKCβ [35].
Figure 5 depicts the possible products arising from PKCβ alternative splicing [33;
36]. Splice sites 1 & 2 are shown. However, it is predicted that additional splice sites
are possible. These additional splice sites may be involved in conferring additional
stability for the mature RNA (unpublished observation). The stop codon in the PKCβII
exon prevents the PKCβI exon from being translated (Figure 4 & 5). The intronic SRp40
binding site binds phosphorylated SRp40 (Figure 4). This splicing factor promotes
PKCβII exon inclusion [37; 38].
PKCβ V5 Domain
Since PKβI and PKCβII are identical up to the V5 region, then it is logical that
this domain distinguishes the two isoforms in terms of subcellular location (at rest and
activated) and function, even within the same cell type [19]. A classic example was
6

deciphered by the Cooper lab. In BC3H-1 myocytes, insulin treatment induced the
alternative splicing of the PKCβII exon. Within 15 minutes of insulin treatment, basal
PKCβI was replaced by the PKCβII isoform. It was hypothesized that PKCβII, as
opposed to PKCβI, had a more significant role in glucose uptake. Subsequent
overexpression of PKCβII in NIH-3T3 cells resulted in enhanced insulin-stimulated
glucose uptake [39]. PKCβII′s unique role was further confirmed by experiments
utilizing a C-terminal truncated PKCβII that acted as a dominant negative and
pharmacologic inhibition via CGP53353 (a specific PKCβII inhibitor). Both mutant
PKCβII and CGP53353 inhibited L6 skeletal muscle insulin-stimulated glucose uptake
[40]. Another example of diametrically opposed PKCβ isoform function is in A10
vascular smooth muscle cells (rat). Here, PKCβI stimulates A10 growth while PKCβII
inhibits A10 growth [41]. Distinct localizations are possible as well based on the V5
region. In cardiomyocytes, PKCβI localizes to the cytosol and perinuclear region and
translocates to the nucleus following PMA treatment. PKCβII associates with fibrillar
cytoskeletal structures at rest and translocates to the cell periphery and perinuclear region
upon PMA treatment. Here, PKCβII co-localizes with RACK1 [42].
The V5 region shows specificity in its substrate targets. For instance, PKCβII activates
PLD, whereas PKCβI does not [19].
PKC Tissue Expression
Select mammlian cells and tissues are listed below (Table 1) to give a general
overview of PKC isoforms expression (either mRNA or protein detection) [11; 12; 43;
44; 45; 46; 47; 48; 49; 50; 51; 52]. Distibution may vary between species.
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Table 1. PKC Isoform Tissue/Cell Expression
PKC isoform
Cell /Tissue
α
βI
βII
γ
δ
ε
Brain
+
+
+
+
+
+
Central
+
+
+
+
+
Nervous
Tissue
Heart
+
+
+
+
+
Small
?
?
?
+
?
Intestine
Kidney
+
+
+
+
+
Liver
+
+
+
+
+
Airways
+
+
+
+
+
Smooth
Muscle
Lung
+
+
+
+
+
Neutrophil
+
+
+
+
?
Monocyte
+
+
+
+
+
Macrophage
+
+
+
+
+
Eosinophile
+
+
+
+
+
Platelet
+
+
+
+
+
T+
+
+
+
+
Lymphocyte
B+
+
+
+
+
Lymphocyte
Vascular
+
+
+
+
+
Smooth
Muscle
Retina
+
+
+
+
+
Spleen
+
+
+
+
+
Testis
+
+
+
+
+
Ovary
+
+
+
+
+
Pancreas
+
+
+
?
+
Thymus
+
+
+
?
Fibroblast
+
+
+
+
+
Skeletal
+
+
+
+
+
muscle
Adipocyte
+
+
+
+
+
+
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η
?
+

Ζ
+
+

Θ
?
+

λ/ι
?
+

μ
?
+

+
?

+
?

+
?

+
+

?
?

?
?
+

+
+
+

?
+
+

?
+
+

+
?
+

+
?
+
+
?
+

+
+
+
+
+
+

+
?
+
?

+
?
+
?
?

+
?
+
+
+
?
?

+

+

?

?

?

+

?

?

+

?

?
+
?
?
?
?
?
+

+
?
+
+
?
?
+
+

?
?
?
?
?
?
?
+

?
+
+
+
+
?
?
+

?
?
?
?
?
?
+
+

+

+

+

+

+

PKC Size [12]
Table 2. PKC Isoform Size
α
βI
βII
Amino
672
671
673
Acids
Daltons 76,7 76,79 76,93
99
0
3

γ
697

δ
673

Ε
737

η(L)
683

θ
707

ζ
592

λ
586

78,36
6

77,51
7

83,47
4

77,97
2

81,57
1

67,740

67,200

PKC Activation
Newly translated PKCs are unphosphorylated and associated with the
cytoskeleton. Maturation (catalytic competence) must take place in order for PKC to
translocate to the plasma membrane [53]. Before this maturation, interaction with the
plasma membrane is very weak [19]. Using PKCβII as a model, physiological stimuli
initiate one of three phosphorylations necessary for catalytic competence (Figure 6).
First, threonine 500 in the activation loop is phosphorylated by PDK1. This is the ratelimiting step in the processing of PKC [20]. This phosphorylation aligns the active site
with the downstream sites. Next, Threonine 641 is phosphorylated in the proline-rich
turn motif via mTORC2 [54; 55]. Phosphorylation at this site locks the protein in a
catalytically competent, thermally stable and phosphatase-resistant conformation. Also,
this phosphorylation may serve as a docking pad for protein interactions [20]. Based on
the sequence surrounding this motif, 14-3-3 protein is speculated to bind. Lastly, the
hydrophobic motif is autophosphorylated at Serine 660 (S660). This hydrophobic site is
the least conserved among PKCs. This phosphorylation is not essential for function, but
without it they have less thermal stability and increased phosphatase sensitivity [20]. It
should be noted that mammalian target of rapamycin complex 2 (mTORC2) is involved
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in PKC′s intrinsic kinase activity by regulating phosphorylation of the turn motif which
leads to autophosphorylation at the hydrophobic motif [21; 56].
Once the C-terminal serine and threonines are phosphorylated, PKCβII assumes
its mature conformation. Subsequent dephosphorylation at Threonine 500 (T500) would
not alter its mature status. However, dephosphorylation at the turn motif abolishes kinase
activity. The three phosphorylation sites are conserved suggesting most PKCs undergo
similar processing. The exceptions would be aPKCs. The aPKCs have a glutamic acid
instead of serine and threonine in the hydrophobic motif. PKCδ, for example, T505 in
the activation loop is not required because of the negative charge brought about by
Glutamic acid at residue 500. Ultimately these phosphorylations are required for
intracellular localization of PKCs [53].
In the traditional model of PKC activation, agonists promote phosphoinositide
hydrolysis to produce DAG and IP3 generation which mobilizes calcium. Calcium, a
soluble ligand, binds to the C2 domain to increase PKC′s affinity for PhosphatidylSerine
(PS). This interaction is relatively weak, however, once anchored to membranes the C1A
domain interacts with DAG. The interaction between C1A and DAG would not be
possible if it were not for PS binding to C2 which disrupts an electrostatic C1A/C2
interdomain binding. The C1A domain now penetrates the lipid bilayer to bind DAG.
When both C1A and C2 domains are engaged with the membrane, the pseudosubstrate
domain is expelled from the substrate-binding pocket which facilitates full PKC
activation [19; 57].

DAG is thought to induce membrane alterations (inverted

miscelles) improving the hydrophobic interaction with proteins that can integrate with the
plasma membrane [58].
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The traditional model of PKC activation was thought to be punctuated by
cytoplasmic to plasma membrane translocation. However, this is not the case with every
PKC isoform. PKCs can be targeted to many intracellular locations for activation [53].
Again, using PKCβII as an example, translocation to the plasma membrane is initiated by
acute PLC-derived DAG accumulation. However, in cells that display a biphasic DAG
response, catalytically active PKCβII is released from the plasma membrane to go to the
pericentron region (subset of recycling endosomes containing small GTPase Rab11) [59;
60]. Pericentronic localization is due to PLD-derived DAG (Figure 7). PKCβII at this
location can control the trafficking of continuously recycling membrane signaling
proteins such as caveolin-1. PKCβII pericentron accumulation can be inhibited by PP1
(protein phosphatase I) stimulation via ceramide. PP1 dephosphorylates PKCβII at the
activation loop [19].
A detailed overview of cPKC activation is shown in Figure 8. * was inserted to
remind the reader that mTORC2 does not constitutively phosphorylate PKCβII in all
cases. It has been shown in mouse embryonic fibroblasts (MEFs) that this is the case [54;
55]. However, our data concerning 3T3-L1 adipocytes suggests that mTORC2
phosphorylation is mediated by insulin [52]. It has also been reported that in HEK293
cells, mTORC2 is activated via insulin stimulation [61]. This would suggest that whether
cPKCs are constitutively or agonist-induced phosphorylated depends on the cell type.
.

As stated above, DAG can be produced by disparate mechanisms.

De novo synthesis is one way DAG is induced (Figure 9). There are two main pathways
for this biosynthesis. One is from glycerol-3-phosphate as a result of triacylglycerol
mobilization. The other is use of dihydroxyacetone-3-phosphate, which is a glycolysis
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intermediate. These two precursors undergo several modifications. These include two
acylation steps that give rise to lysophosphatidic acid (LPA) and then phosphatidic acid
(PA). PA can subsequently be transformed into DAG through PA phosphohydrolases
(PAPs) [58]. DAG production in response to stimuli has many facets (Figure10). Acute
DAG is produced via agonist-induced hydrolysis of phosphatidylinositol 4,5bisphosphate PIP2 by PLC. PLD-mediated hydrolysis of phosphatidylcholine (PC)
produces another type of DAG [53]. The initial DAG (PLC-dependent) is
polyunsaturated and consists of the following three types; 1-steroyl-2-arachidonoyl-snglycerol (SAG), 1-steroyl-2-doxosahexaaenoyl-sn-glycerol (SDG) and 1-steroyl-2eicosapentaenoyl-glycerol (SEG) [62; 63; 64]. PKC isotypes are differentially activated
by DAGs. SDG activates PKCα and PKCδ most powerfully. PKCβI is activated by
SDG and SEG rather than SAG [53]. PLD-derived DAG is monounsaturated or saturated
[64]. Polyunsaturated DAG is frequently transient with sustained DAG being
predominantly monounsaturated (generally sc-2 acyl group) [65]. To generate DAG,
PLD hydrolyzes phosphatidylcholine to PA and choline. PA is a bioreactive lipid
whereas choline is not thought to participiate in intracellular signaling [66]. PLD-derived
PA is further processed by phosphatidic acid phosphohydrolases (PAPs) into DAG (1palmitoyl 2-oleoyl-sn-glycerol). DAG can be converted back to PA via phosphorylation
by diacylglycerol kinases (DGKs). In addition, PA can be deacylated by phospholipase
A2 (PLA) to form monoacylated LysoPA. LysoPA can also be converted back to PA by
lysophosphatidic acid acyltransferases (LPAAT) [67; 68]. PLA hydolization of
phospholipids can also liberate free fatty acids [12]. Fatty acids activate PKCs in an
isotype-specific manner [53; 69]. PKCβ (along with α, γ and ε) are activated by fatty
12

acids with carbon lengths between C13 and C18 in vitro. Cis unsaturated fatty acids
including oleic, linolenic, arachadonic and docosahexaenoic acids are all produced from
phospholipids via PLA. These fatty acids allow PKC to exhibit almost full activity in the
presence of Ca2+ concentrations less than 1μM. This effect is enhanced by the copresence of DAG [12; 70; 71]. PC can also be converted to DAG by two other routes
besides PLD-derived. One is a PC-PLC catalyzed pathway that releases choline
phosphate to produce DAG. The other is the conversion of ceramide to sphingomyelin
catalyzed by sphingomyelin synthase (SMS). SMS manufactures sphingomyelin from
phsophatidylcholine by catalyzing replacement of a glycerol molecular by ceramide,
resulting in the release of DAG [58; 65].
The following table (Table 3) summarizes the main activators of the various PKC
isoforms [12; 20; 72; 73; 74; 75; 76; 77; 78] (activation may vary across species and
cell/tissue type):
Table 3. PKC Isoform Activators
α
βI
βII
γ
PS
+
+
+
+
Ca2+
+
+
+
+
DAG
+
+
+
+
FFA
+
+
+
+
LysoPC +
+
+
+

δ
+
+
+
+

ε
+
+
+
+

η(L)
+
+
?
?

θ
+
+
+
+

ζ
+
+
+

λ
+
+
+

Tyrosine phosphorylation can mediate PKC activation in the absence of PS.
PKCα, βI, δ, γ, and ζ can be tyrosine phosphorylated induced by hydrogen peroxide [79].
In skeletal muscle, PKCδ undergoes insulin-induced tyrosine phosphorylation
(activation) directly via Src tyrosine kinase which leads to insulin receptor (IR) activation
[80]. Almost all PKCs can be proteolytically cleaved at the V3 region by the calciumactivated protease calpain to produce a cofactor independent free catalytic subunit known
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as protein kinase M (PKM). Calpain exists as two distinct isoforms that have a low (μ)
and high (m) requirement for Ca2+, millimolar and micromolar respectively [43; 81].
Even though proteolysis is normally responsible for PKC downregulation, cleavage at the
hinge region renders PKC constitutively active [82]. All PKCs except PKCδ contain
PEST sequences (hydrophilic polypeptide segments enriched in proline (P), glutamic acid
(E), serine (S) and threonine (T)) that target them for degradation by the
ubiquitin/proteosome pathway. Dephosphorylation of actived PKCs predisposes them to
this degradation pathway [43; 83; 84].
Oxidation is another way to regulate PKC activity. PKCs isolated from tissues
have been shown to be oxidized by a variety of agents including peroxide, Nchlorosuccinimide and periodate. This oxidation requires Fe2+ and the resultant PKC is
constitutively active. For oxidized cPKCs, Ca2+ and phospholipids are not required for
this type of activation [43; 85]. Oxidation can also negatively regulate PKC activity. Nchlorosuccinimide and hydrogen peroxide reduce phorbol ester binding to PKC,
indicating oxidation of the C1A domain [86]. Oxidation represents a unique type of
regulation whereby initial oxidation causes constitutive activity and further oxidation
causes inactivation [43].
Yet another mode of activity regulation is nitrosylation. PKC contains thiol
residues which may serve as substrates for S-nitrosylation. PKC disulphide bridge
formation following nitrosylated thiols result in irreversible inactivation and loss of
phorbol ester binding. S-nitrosylation also prevents calpain access to PKC [43; 81; 87;
88]. It was reported that 100μM peroxynitrite leads to tyrosine nitration of PKCβII and
PKCα [89].
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Steroid hormone binding has also been shown to activate certain PKC isoforms.
The C2 domain of PKCα binds aldosterone whereas the C2 domain of both PKCα and
PKCδ bind 17 β-estradiol. Both interactions result in PKC activation [90]. PKCs α, γ,
and ε are activated by 1 α,25-dihydroxyvitamin D3. In this instance, the C1 domain (most
likely the zinc fingers) is responsible for binding, not the C2 domain. This interaction
mediates a steroid hormone rapid “non-genomic” response [91].
PKC Intracellular Distribution
The traditional model of PKC subcellular localization comes from studies of
PKCα. In this model, PKCα is cytosolic in the basal state. Upon activation, it
translocates to the plasma membrane. However, this is an oversimplification since PKC
isoforms are not restricted to these two compartments. As mentioned above, PKCβII
translocates from the plasma membrane to the pericentron in a biphasic manner [19].
PMA induced ceramide (formed from the salvage pathway) prevents translocation of
PKCβII to the pericentron (a.k.a. juxtanuclear compartment) [92]. PKCs can also
translocate to specialized membrane compartments such as lipid rafts or caveolae. Lipid
rafts and caveolae contain sphingolipids, cholesterol, saturated fatty acids and signaling
proteins. The differences between the two are that lipid rafts do not contain caveolin and
caveolae do not contain glycosyl-phosphatidylinositol-anchored proteins. Caveola form
flashlike invaginations in the PM by oligomerization and association with lipid rafts.
Caveola are detergent-resistant as opposed to lipid rafts. PKCδ and PKCζ exert their
signaling effect through these domains. PKCδ is involved in ceramide production.
Ceramide is formed in lipid rafts and is involved in raft fusion. PKCδ activates acid
sphingomyelinase (ASM) which hydrolyzes sphingolmyelin to ceramide [93; 94; 95].
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This ceramide accumulation at the plasma membrane leads to recruitment and activation
of PKCζ [96]. Several cell lines have cPKCs and nPKCs (both activated and resting)
recovered in the caveolae fraction [19; 97; 98].
The Golgi complex is another area where PKC can localize. For example, PKCδ
and PKCθ (both ceramide activated) induce apoptosis from the Golgi [99; 100]. PKCε
modulates secretion (via binding to RACK substrate) from the Golgi complex [19; 101].
Interleukin-3 (IL-3) treatment has been shown to induce PKCβI and PKCβII nuclear
localization in hematopoietic cells [102]. PKCη localizes to the ER, nuclear membrane
and the Golgi upon PMA treatment and serum starvation [103]. PKCδ activated by
phorbol esters causes mitochondrial translocation from the cytoplasm, which causes
cytochrome c release and subsequent apoptosis in human U-937 myeloid leukemia cells
[104]. Lastly, PKCβII can localize to the cytoskeleton (F-actin) , which in turn increases
its autophosphorylation [105]. Clearly, PKC intracellular localization is dependent on
many factors including isoform, cell type, agonist treatment, etc. Therefore, their direct
effect (as well as indirect) would seem to extend to nearly every intracellular organelle.
PKC Anchoring Proteins and Substrates
The first anchoring protein discovered that could localize PKC near its intended
substrate was RACK1 (Receptor for activated C kinase 1). RACK1 specifically binds
activated PKCβII with a Kd of 1nM in vitro. This binding specificity is due to the V5
region (as well as the C2 domain) of PKCβII which differs from PKCβI (as mentioned
above). However, RACK1 is not a substrate for PKCβII. This interaction allows for
proper localization and targeting of the substrate [106; 107; 108; 109].

An example of

altered subcellular localization would be TCDD (2,3,7,8-Tetrachlorodibenzo-p-dioxin)
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activation of RACK1 in cerebellar granule cells. This activation causes RACK1-PKCβII
association and subsequent PKCβII translocation from the cytosol to membrane fraction
[110].
Another important example of PKCβII-RACK1 interaction that has implications
for insulin signaling is found in CHO cells. Here, PMA or dopamine D2 receptor agonist
induced PKCβII activation causes its association with RACK1 and subsequent
translocation to the Golgi apparatus. This movement is inhibited by PLC inhibitor
ET18OCH3 [111]. As mentioned above, PLC is needed to generate DAG and IP3
(inositol triphosphate) for PKC activation.
An example of a PKCβII substrate would be lamin B. During proliferative
stimuli in human promyelocytic (HL60) leukemia cells, activated PKCβII (via nuclear
membrane activation factor (NMAF)) translocates to the nucleus and phosphorylates
lamin B which leads to mitotic nuclear envelope membrane breakdown [112]. Recently,
PKCβII was shown to phosphorylate substrate MARCKS (myristoylated alanine-rich Ckinase substrate), perpetuating skeletal muscle cell ISGT (insulin-stimulated glucose
transport) [113].
An example for PKCβII that would include both the anchor and substrate comes
from cardiac myoctes. Here, activated PKCβII translocates from the cytosol to the
plasma membrane as well as the perinucleus where it binds RACK1. This association
brings PKCβII near the L-type calcium channels where it can phosphorylate and inhibit
the channel [114; 115]. Regulation of L-type calcium channels is important for insulin
release from pancreatic β islet cells [116].
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Anchoring proteins regulate PKC distribution but do not necessarily have to bind
activated PKCs. Unphosphorylated, phosphorylated but inactive and phosphorylated and
active PKCs are all targets. RACKs may bind active phosphorylated PKCs, but CG-NAP
anchoring protein binds and localizes newly synthesized (unphosphorylated) PKCε to the
Golgi/centrosome [117]. AKAP (A Kinase Anchoring Protein) position phosphorylated
inactive PKCs near the substrate [118]. STICKs (Substrates That Interact with C Kinase)
bind phosphorylated inactive PKCs and then release them following their
phosphorylation [119]. PICK1 (Protein Interacting with C Kinase 1) has been shown to
bind activated PKCα positioning it for eventual phosphorylation of GluR2 (AMPA-type
glutamate receptor subunit 2) which results in GluR2 release from synaptic anchors and
in receptor transport from the synaptic membrane [120].
PKCβ Promoter
Much of the knowledge of PKCβ promoter comes from the work of Hannun lab.
Here, up to 2200 bp upstream of the human transcriptional start site was analyzed. The
region near the start site is very GC-rich (>80%) and lacks identifiable TATA or CAAT
boxes. TATA and CAAT elements are found further upstream at -530 and -395,
respectively. This is reverse of the normal order. The most important area for promoter
activity was -111 to -40. Some of the factors identified in this study are included in the
following table (Table 4):
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Table 4. PKCβ Promoter Transcription Factors
Factor
Binding site
Oct BP
ATGCAAAT
Sp1
GGGCGG
E12/47
GCAGGTGG
AP2
CTF/NF-1
AP1
TFIID

CCCCACCCC
GCCAAT
TGAGTCA
TATAAA

PKCβ promoter location
ATGCAAAT (-76)
GGGCGG (-94,-63)
GCAGCTGG (-110, -26,
+18)
CCCCACCCC (-330)
CCAAT (-395)
TGAGTGAC (-442)
TATAAA (-530)

Another important discovery is that phorbol esters transcriptionally up-regulate
the PKCβ promoter (basal promoter element) in K562 erythroleukemia cells. Upregulation of the PKCβ promoter may be a way for phorbol esters to relieve the negative
regulation that they have on PKCβ protein down-regulation [121]. The PKCβ promoter
and its regulators need more illumination. This is especially paramount given that a
functional PKCβ promoter polymorphism in humans has been linked to insulin resistance
with reduced expression of PKCβII [122].
PKC Inhibitors
PKCs are attractive targets for therapeutic intervention given their various cellular
roles. However, the plethra of interacting proteins and many secondary messenger
systems coupled with cellular and tissue-specific variability for each PKC isozyme
renders specific drug targeting difficult. The following table (Table 5) from Twelves et
al. represents the main PKC inhibitors in use today [14]:
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Table 5. PKC Inhibitors
Drug
Class
PMA
Phorbol ester

Admin
Specificity
Intravenou Non-specific
s

Staurosporine

Indolocarbazole

PKC412
(midospaurin)

Indolocarbazole

UCN01

Indolocarbazole

Go6976

Indolocarbazole

Byrostatin 1

Macrocyclic
lactone

Tamoxifen

Nonsteroidal
anti-oestrogen
Indolocarbazole

Oral
Oral

cPKCs>nPK
Cs
Activates
cPKCs &
nPKCs
Acts as
antagonist in
presence of
agonist
PKCs α,β,γ
non selective
PKCβ

Indolocarbazole

Oral

PKCβ

Antisense oligo

Intravenou PKCα
s
Intravenou PKCα
s

Bisindoylmalei
mide
LY317615
(enzasautaurin)
ISIS3521
(aprinocarsen)
ISIS9606

Antisense oligo

Intravenou Poor
s
specificity,
inhibits other
Ser/Thr and
Tyr kinases
Oral
PKCs
α,β,γ,δ,ε,η:
also inhibits
Tyr
pathways
Intravenou cPKCs>nPK
s
Cs

Intravenou
s
Intravenou
s

Status
PKC activator; in a
phase I trial in
haematological
malignancy
Preclinical

Potentiates treatment
with doxorubicin or
vinblastine; in phase II
trials
Potentiates treatment
with cisplatin,
mitomycin C,
camptothecin or 5FU; in
phase II trials
Potentiates treatment
with cytosine
arabinoside, paclitaxel,
tamoxifen or vincristine

Used in treatment of
diabetic retinopathy
Potentiates treatment
with gemcitabine, 5FU,
cisplatin or radiotherapy
Phase I and Phase II
trials
Not developed further in
clinic

Other pertinent drugs include Ruboxistaurin (LY333531) which is a macrocyclic
bisindolymaleimide drug developed by Eli Lilly being being tested for use as therapy in
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diabetic macular oedema and other diabetic angiopathies, including diabetic retinopathy,
diabetic peripheral neuropathy and diabetic nephropathy [123]. It is a competitive
reversible inhibitor of PKCβ [124]. LY379196 is an analog of LY33531 which will be
used in studies detailed in the RESULTS section. The following table (Table 6)
represents the IC50 spectrum for LY379196 [125]:
Table 6. LY379196 Inhibitor IC50 Spectrum
Enzyme
IC50 (μM)
PKCα
0.6
PKCβI
0.05
PKCβII
0.03
PKCγ
0.6
0.7
PKCδ
5
PKCε
PKCζ
48
PKCμ
0.3
Cyclic AMP Kinase
>100
Ca2+ -calmodulin Kinase
5
Casein Kinase
>100
Src Tyrosine Kinase
4.4
The other PKC inhibitor used is CGP53353 (4,5-Bis(4-fluoroanilino)phthalimide)
synthesized by Novartis. It is a selective inhibitor of both Epidermal Growth Factor
Receptor (EGFR) as well as PKCβII. The following table represents the IC50 spectrum
for CGP53353 [126]:
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Table 7. CGP53353 Inhibitor IC50 Spectrum
CGP53353
IC50 (μM)
EGF receptor intracellular domain
0.7
v-abl kinase
>50
c-src kinase
50
c-lyn kinase
>150
c-fgr kinase
>150
Csk
>100
TPK-I1B kinase
>150
Cyclic AMP-dependent protein kinase
>500
Phosphorylase kinase
>500
Protein kinase CK-1
>200
Protein kinase CK-2
>200
Cdc2/cyclin B
>10
PKCα
1.9
PKCβI
3.8
PKCβII
0.41
PKCγ
22
>500
PKCδ
>500
PKCε
PKCζ
>500
>500
PKCη
The Mochly-Rosen lab has been working on drugs that disrupt protein interaction
domains. First generation drugs were short peptides that bound to specific PKC RACKs
to disrupt anchoring and subsequent function of PKC isozymes. Second generation
peptide design inhibits PKC binding to its substrate. This is expected to block the
function related to phosphorylation of that substrate without affecting PKC translocation,
binding to RACK or phosphorylation of another substrate. These peptides are 6-10
amino acids long and are derived from one of the interacting domains thereby blocking
the association of two proteins. Even though the binding surface for PKC is large and
flat, these peptides are highly selective and effective. They serve as potential drugs in
treating human disease [26].
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Glucose Transporter 4
Glucose is a fundamental source of energy for eukaryotic cells [127]. It is the
precursor for the synthesis of glycoproteins, triglycerides and glycogen as well as
providing an important source of energy by generating ATP through glycolysis. Glucose
is polar so it does not readily cross the hydrophobic plasma membrane. Therefore,
specialized carriers are needed to bring glucose into the cell [128].

The uptake of

glucose into a cell involves a family of transport proteins called GLUTs (glucose
transporter) which shuttle sugar across the cell surface [127]. GLUT4 is the major
insulin-responsive glucose transporter. GLUT4 is highly expressed in striated muscle
and adipose tissue. It is responsible for postprandial removal of glucose from the
circulation [127; 129]. In the basal state, GLUT4 slowly but continuously cycles
between the plasma membrane and other intracellular compartments. Only 5% of total
GLUT4 is localized at the plasma membrane in the basal state. Insulin treatment (or
exercise in the case of skeletal muscle) induces an acute response where within 2-3
minutes, GLUT4 exocytosis dramatically increases concomitant with a small decrease in
endocytosis. At this point, 50% of the GLUT4 have been relocated to the plasma
membrane. Removal of the insulin signal subsequently decreases the rate of exocytosis
and the trafficking of GLUT4 returns to basal status [127; 129; 130; 131].

Exocytosis

and endocytosis occur without the need for continuing protein synthesis [132]. Insulinstimulated glucose transport (ISGT) due to irregularities in GLUT4 trafficking is severely
disrupted in type 2 diabetes [130].
GLUT4, like other GLUTs (13 known), is a 12 transmembrane domain-containing
protein [133]. Figure 11 shows GLUT insertion structure in the plasma membrane [127].
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GLUT4 is widely dispersed to many organelles throughout the cell. These include the
plasma membrane, sorting endosomes, recycling endosomes, the TGN (trans-Golgi
network) and vesicles that mediate the movement of GLUT4 between these
compartments [127].
Molecular regulation of GLUT4 via insulin involves several discrete steps (Figure
12) [134]. The first step would be biogenesis of GLUT4 storage vesicles (GSVs). This is
where the majority of GLUT4 is found and where the majority of GLUT4 translocates
following insulin treatment (skeletal muscle and 3T3-L1 adipocytes) [135]. The second
step would be translocation. Translocation is thought to involve cytoskeletal elements
such as actin and microtubules [134]. In 3T3-L1 adipocytes, cortical actin
remodeling/polymerization and well as actin comet tailing (representative of actin-based
motility) on GLUT4-containing vesicles was critical for insulin-stimulated translocation
[136; 137]. Also in 3T3-L1 adipocytes, the kinesin motor (moving toward plus end
[plasma membrane] of microtubule) was critical for GLUT4 translocation [138]. The
third step is tethering. This is a low-affinity interaction between GSVs and the plasma
membrane arbitrated by a tethering complex [134]. Tethering involves what is referred to
as the “exocyst complex.” This complex is responsible for the initial interaction of
GLUT4 vesicles with the plasma membrane in 3T3-L1 adipocytes. Exo70, Sec6 and
Sec8 are some of the recently identified components of the exocyst complex [139]. The
fourth step is docking. This is the assembly of the trans SNARE (soluble Nethylmalemide-sensitive factor attachment protein (SNAP) Receptor) complex. It is the
final committed step before fusion between GSVs and the plasma membrane [134]. In
3T3-L1 adipocytes, VAMP2 (vesicle-associated membrane protein 2) and
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VAMP3/cellubrevin represent v-SNARE proteins (protein complexes in the vesicle
compartment) and syntaxin 4 represents t-SNARE proteins (receptor complex at the
plasma membrane) [140]. The fifth step is fusion. This is where the lipid bi-layers of the
GSV and the PM amalgamate [134]. Frohman et al. has shown that activated PLD1
(phospholipase D 1) plays a rate-limiting step in insulin-stimulated fusion of GSVs with
the PM in 3T3-L1 adipocytes [141]. Corroborating this finding is the observation that
PA (product of PLD1 mediated hydrolysis) serves as an anchor for mammalian
components of the SNARE complex [142]. PA has also been purported to act as a
fusogenic lipid by lowering the activation energy for membrane bending during
generation and expansion of fusion pores [143]. PA is also capable of activating
phosphatidylinositol 4-phosphate 5-kinase thereby increasing the levels of
phosphatidylinositol 4,5-bisphosphate, critical for exocytosis [141]. In L6 skeletal
muscle cells, insulin-stimulated PKCβII causes retention of PLD1 at the PM and
subsequent fusion of GLUT4 [113]. GLUT4 can translocate and fuse with both caveolae
and non-caveolar lipid rafts [144]. The sixth step is endocytosis [134]. GLUT4 has
been shown to be internalized via clathrin-mediated endocytosis (CME). This has been
demonstrated in 3T3-L1 adipocytes and L6 myotubes [132]. Interestingly, caveolae
associated GLUT4 internalized faster than non-caveolar lipid raft after removal of insulin
[144].
3T3-L1 adipocytes have been used as the gold standard for GLUT4 trafficking.
In these cells, GLUT4 is mostly located in the perinuclear region and the cytoplasm to a
lesser extent [134; 145]. Insulin induces a 10-fold increase in glucose uptake. Rat
adipocytes have an even greater response (20-fold increase in glucose uptake) whereas
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human adipocytes only respond with a 2-3 fold increase in insulin-stimulated glucose
uptake. In L6 myotubes (the only skeletal muscle cell line that expresses GLUT4),
GLUT4 is expressed mostly in perinuclear regions as well as being dispersed along
discrete bodies in the cytosol. Insulin induces a 2-fold increase in glucose uptake in this
cell line [145].
In 3T3-L1, as mentioned above, most GLUT4 reside in GSVs near the TGN.
Even before GLUT4 is expressed in differentiated adipocytes, there is a reservoir
compartment (what will eventually be the GSV). A protein called insulin-responsive
aminopeptidase (IRAP) is localized to this storage compartment and has very similar
trafficking to that of GLUT4. Once GLUT4 is expressed, it enters this storage
compartment [130]. Regardless of whether insulin stimulation has occurred or not,
GLUT4 and IRAP are not retained at the plasma membrane. They are rapidly
internalized with half times of 3-10 minutes [130; 146]. GSV formation requires Golgilocalized γ-ear-containing Arf-binding protein (GGA) in order to sort GLUT4 from the
TGN [147]. Sortilin (also part of the TGN and endosomal membrane) is also necessary
for GSV formation as well as for GLUT4 protein stability [148]. Sortilin most likely
serves as the cargo adaptor linking GLUT4 to GGA coated transport vesicles. Sortillin
does this by binding to GGA′s VHS cargo-binding domain with its VHS consensus
binding motif (DxxLL) [129]. In differentiating adipocytes, sortillin is expressed prior to
GLUT4 [148].
The GLUT4 N-terminal FQQI domain and C-terminal LL domain are both
required for proper trafficking of GLUT4. The FQQI domain is important in transferring
GLUT4 away from the endosome system [149]. The LL domain is important in shuttling
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GLUT4 between the TGN and GSVs [150]. Both domains are required for proper
endocytosis [130]. Trafficking steps of GLUT4 can be summarized by Figure 13 [130].
It is important to note that the perinculear reticular GLUT4 storage compartment and
dispersed vesicular GLUT4 storage compartment are further sub-classifications of GSVs.
It is also noteworthy to point out that v-SNARE VAMP2 (in addition to IRAP)
colocalizes with GLUT4 in PR-GSC. The ratio between the two proteins is kept fairly
constant in the DV-GSC. This would suggest a role for VAMP2 in direct fusion with the
PM [151]. aPKCs have been suggested to serine phosphorylate VAMP2, possibly
localizing GSVs at sites of actin remodeling and subsequent PM insertion [152].
Figure 13 is not a hundred percent accepted model. There are two main models
concerning GLUT4 storage and cycling in 3T3-L1 adipocytes [153]. Model 1 (which
more closely resembles Figure 13) asserts that GLUT4 from every compartment
eventually reaches the PM in the basal state, GLUT4 intracellular storage is dynamic and
that GSV is distinct from the transferrin-positive TGN [154]. Model 1 also asserts that
insulin promotes two routes for GLUT4 mobilization towards the PM. The direct route
comes from the GSV. The indirect route goes from the GSV to the ERC to the PM [153].
The two routes possible to get to the PM are supported by the presence of VAMP2 in
insulin-dependent GLUT4 recycling [140; 155]. Model 2 proposes that only a fraction of
GLUT4 reaches the PM in the basal state, that insulin increases GLUT4 amount available
for translocation, and that part of the transferrin receptor negative GLUT4 compartment
interfaces with the TGN [156]. Increasing insulin causes more GLUT4 to accumulate at
the non-cycling pool, which is then translocated to the PM through a single exit route
(GSVs to PM). The non-cycling pool contains few “latent GLUT4 molecules” which are
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not mobilized in response to insulin. It is hypothesized that these latent GLUT4
molecules are synthesized early in cellular life and exhibit non-insulin responsiveness
[157]. The main differences between the two models are the extent to which GLUT4
recycles in the basal state, the presence of a static/latent pool of GLUT4, the TGN being
a storage site for GLUT4 and the number of routes insulin-stimulated GLUT4 can take to
get to the PM [153].
Akt
Protein Kinase B (Akt) belongs to a family of ubiquitously expressed
serine/threonine kinases that was discovered by cloning using a probe specific for PKA
[158]. Akt shares 65% homology with PKA and 77% homology with PKC. Three
mammalian isoforms exist, α (1), β(2), γ(3) (Figure13), which are products of different
genes [159]. The three isoforms share 90% homology between each other [160]. All
three isoforms contain an N-terminal PH domain, which is a roughly 100 amino acid
domain that can bind phosphatidylinositol lipids (e.g. PIP2) as well as PKC and other
proteins during signaling [161]. Downstream of the PH domain is the catalytic domain
and finally the C-terminal domain [159]. Rat Akt3 contains a truncated C-terminal
domain whereas human Akt3 contains a full-length C-terminal domain [160; 162].
Akt was identified as an oncogene early on. First, Akt1 amplification was
detected in gastric adenocarcinoma [163]. It was then shown that Akt2 was amplified in
two ovarian carcinoma cell lines [164]. The breakthrough in Akt research came using the
PI3K inhibitor, wortmanin. This led to the discovery that Akt was a downstream target
of PI3K activated by PDGF and EGF [165; 166]. The lipid-binding PH domain of Akt
was essential for this PI3K-mediated activation in response to these ligands [166].
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Binding of the PH domain to lipids is not the only way Akt is activated. Phosphatase
inhibitor experiments showed that Akt activity was controlled by reversible
phosphorylations on both serine and threonine residues [167]. The next step was
showing that insulin stimulation resulted in Akt phosphorylation at residues T308 and
S473 [168]. At this point, complete Akt activation necessitates lipid binding via the PH
domain as well as phosphorylation by at least one upstream kinase. Previous
observations indicate that Akt kinase activity requires PI3K and that Akt is potently
activated by products of PI3K, PIP2 and PIP3. This led to the discovery of PDK1 (3phosphoinositide-dependent protein kinase 1) [169]. This ended up being the kinase
which is responsible for phosphorylation of Akt at T308. However, the kinase
responsible for phosphorylating Akt on S473 has remained controversial and only
recently been proposed (mTORC2). Mutation of either T308 or S473 in Akt1 does not
prevent the other residue from being phosphorylated in response to insulin, suggesting
the phosphorylations can occur independently [170]. Akt phosphorylated at only the
PDK1 site has 10% of the activity compared to when it is phosphorylated at both T308
and S473 [171]. However, the threshold of activity required for substrate
phosphorylation may differ so that Akt phosphorylated at only T308 may be sufficiently
active to phosphorylate certain targets [172]. Figure 15 illustrates the mechanism of Akt
activation [57; 169; 173; 174; 175]. A controversial additional pathway for Akt
activation has been proposed for skeletal muscle cells. In this two-step model for Akt
activation, insulin triggers the assembly of β-arrestin-2, c-Src and Akt. This allows c-Src
to phosphorylate Akt on Tyrosine 315 (Y315) and Y326 which is required for
downstream phosphorylations of Akt at S473 and T308. This may not apply to fat cells
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because in muscle and liver, but not fat, β-arrestin-2 expression is reduced ~50% in
insulin-resistant animal models [176].
As with any kinase, there is a mechanism to turn it on as well as one to turn it off.
Recently discovered PHLPP proteins put the brakes on Akt and PKC activation. PHLPP
is a Ser/Thr-specific phosphatase (PH domain leucine-rich repeat protein phosphatase).
Once Akt is phosphorylated, its activity no longer relies on secondary messengers. In
contrast, PKC is only active when bound to DAG. Dephosphorylation of PKC would
promote degradation [177].

PHLPP1 and PHLPP2 specifically dephosphorylate the

hydrophobic motif (S473) of Akt, resulting in decreased activity. PHLPP needs the PDZbinding motif in order to accomplish this dephosphorylation [177]. PHLPP1 and
PHLPP2 dephosphorylate the hydrophobic motif of cPKCs and nPKCs but not aPKCs
because they contain a Glutamic acid at this position [171]. As alluded to earlier, cells
deficient in the mTORC2 complex have decreased PKC phosphorylation at the
hydrophobic motif which suggests that this complex contributes to phosphorylation of
PKC at this site [178]. This possibly puts PHLPP in opposition of mTORC2 [177].
There is abundant evidence that Akt plays a role in insulin-dependent glucose
disposal by directing GLUT4 vesicles to the PM. Initially it was reported that insulin
rapidly and persistently activates Akt in traditional target tissues such as muscle and fat
[179]. The connection between Akt and insulin′s metabolic actions was firmly
established when constitutively active Akt mimicked insulin in eliciting high levels of
glucose transport and GLUT4 translocation in adipocytes in the absence of insulin [180].
More specifically, insulin causes Akt association with GLUT4 vesicles in rat adipocytes
which results in phosphorylation of associated proteins [181; 182]. Suspected proteins
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phosphorylated by Akt include sortilin and SCAMPs (secretory carrier-associated
membrane proteins) which are involved in membrane trafficking and fusion of GLUT4
[182]. SNARES are also thought to be an important Akt substrate [183]. Inhibiting Akt
activity by antibodies, substrate peptides and dominant-negative constructs partially
blocks insulin-stimulated GLUT4 translocation in fat and muscle [184; 185].
Insulin is responsible for a host of outcomes, besides glucose homeostasis, that
are mediated at least in part via Akt. For instance, insulin mediates vasodilation of blood
vessels promoting peripheral tissue glucose disposal [186]. Akt is able to exert its effect
here by phosphorylating/activating endothelial nitric oxide (NO) synthase, thus
increasing NO production [187].
Insulin mediates protein synthesis in muscle and fat cells by enhancing initiation
and elongation steps in protein translation. Evidence suggests that Akt modulates the
activity of translational components [179]. Constitutively active Akt increases protein
synthesis in L6 muscle cells and 3T3-L1 adipocytes [188; 189].

Insulin-stimulated

protein synthesis is blocked by dominant inhibitory Akt mutant in 3T3-L1 adipocytes
[190].
Lipogenesis (converting incoming sugar to fatty acids) is an insulin regulated
event. Akt is thought to play a crucial role by inhibiting GSK-3 (glycogen synthase
kinase 3). GSK-3 normally phosphorylates ATP citrate lyase (decreasing its activity), an
enzyme that catalyzes the conversion of citrate and CoA to acetyl-CoA and oxaloacetate
in the cytosol. This step is a major source for the biosynthesis of fatty acids, cholesterol
and acetylcholine [191]. In addition, Akt also increases the transcription of fatty acid
synthase, an enzyme that catalyzes several steps converting malonyl-CoA and acetyl31

CoA to long-chain fatty acids [192]. Constitutively active Akt has been shown to induce
high levels of lipogenesis in quiescent 3T3-L1 adipocytes [193]. At the same time Akt is
turning on genes for lipogenesis, it has been reported to help block lipolysis in adipocytes
by inhibiting hormone-sensitive lipase (HSL). HSL is activated by PKA
phosphorylation, and PKA activity is activated by cAMP. Use of a dominant-negative
mutant as well as constitutively active kinase showed Akt reduces cAMP concentrations
by stimulating cyclic nucleotide phosphodiesterase PDE-3B via phosphorylation [193;
194].
Insulin promotes glycogen synthesis from the glucose that is driven into the cell.
It does this by activating glycogen synthase (GS) which adds glucosyl groups to growing
polysaccharide chains, which is the final step in glycogen synthesis. Akt is able to exert
its effect on this pathway. GS is negatively regulated by C-terminal serine
phosphorylations by GSK3. Akt is able to inhibit GSK3, thus relieving the inhibitory
phosphorylation and activating GS [179]. In adipocytes, a GSK3β mutant that is
insensitive to Akt results in insulin-stimulated GS suppression [195]. Similarily,
constitutively active Akt in L6 skeletal muscle dramatically blocks GSK3 activity and
can activate GS without insulin. In the same cells type, dominant-negative Akt resulted
in over 50% inhibition of insulin-stimulated GS activation [189; 196].
Blood sugar levels are maintained by insulin through promotion of glucose uptake
as well as suppressing hepatic glucose output. The liver is the main organ to respond to
insulin in terms of reducing its glucose production. Akt is thought play a role here by
suppressing glycogenolysis but promoting glycogen synthesis (likely similar to skeletal
muscle and fat). Akt may exert influence on PEPCK (phosphoenolpyruvate
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carboxykinase) and G6Pase (glucose-6-phosphatase). PEPCK catalyzes the early
committed step in gluconeogensis and G6Pase regulates the terminal step for both
gluconeogenesis and glycogenolysis before glucose is released from the liver. There is
still controversy as to whether Akt really inhibits these genes [179]. Very recently, Akt
activation was shown to stimulate APPL1 (Adaptor protein, phosphotyrosine interaction,
PH domain and leucine zipper containing 1), which potentiates insulin-stimulated
inhibition of hepatic glucose output [197]. In 3T3-L1 adipocytes, the interaction of Akt
with APPL1 is required for insulin-stimulated GLUT4 translocation, even though insulin
causes their dissociation [198].
A role for Akt in pancreatic cells has also been proposed. This is because
pancreatic regeneration is associated with an increase in IRS2 and activated Akt in
proliferating duct cells [199]. Overexpression of active Akt1 in β cells of transgenic mice
leads to a significant expansion of β-cell mass (cell number and cell size) [200]. Insulin
signaling via PI3K and Akt was critical in preventing ER stress and thus β cell
dysfunction [201].
As if Akt did not do enough, it has also recently been implicated (Akt1) in
adipocyte differentiation [202]. Figure 16 summarizes the pivotal role Akt plays across
various tissues [179].
Physiological relevance of Akt in insulin resistance, and thus T2DM, extends
beyond cell culture. Akt activity has been found to be reduced in adipocytes [203] and
muscle [204] obtained from T2DM patients . However, there have also been
antagonizing reports that Akt activity is normal from diabetic muscle tissue where PI3K
activity is reduced [205]. These contradictory findings have also been reported in rodent
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models of obesity and insulin resistance [179]. Mice with adipocyte insulin resistance
had been found to have reduced IRS and PI3K activity but normal Akt activity [206].

In

Zucker rats that were insulin resistant obese, activation of PI3K was much more impaired
than either Akt1 or Akt2. In adipocytes, Akt2 activation actually increased slightly [207].
Etiology of T2DM is not well understood and this may have something to do with the
heterogeneity of results. However, targeted disruption of Akt2 (expressed highly in
muscle and fat) in mice presents a phenotype resembling human impaired glucose
tolerance [208]. Akt2 knockout mice display severe impairment in whole-body glucose
disposal [179]. Interestingly, Akt1 knockout mice do not display insulin resistance [209].
This suggests distinct physiological roles for different Akt isoforms.
Akt can regulate alternative splicing by acting as an SR protein kinase and
directly phosphorylating the RS domain [210]. This has a major impact on the insulin
signaling cascade as Akt can phosphorylate SRp40 [211] thus regulating PKCβ
alternative splicing. Akt can also regulate other SR kinases such as Clk/Sty (CDC-like
kinase 1) (LAMMER family of protein kinases) giving it an even broader role in insulinmediated alternative splicing [212].
Insulin Signaling and Involvement of PKC, GLUT4 and Akt
To give a broad general overview, insulin signaling involves two distinct
branches. One defined by the Rho-family GTPase TC10 (also referred to as CAP/Cbl
pathway) and the other by phosphatidylinositol 3-kinase (PI3K) [213]. Briefly, the
insulin receptor (IR) is a member of the family of transmembrane receptors with intrinsic
tyrosine kinase activity [214]. Some or all of the insulin receptor is constitutively bound
to lipid rafts [215]. The mature IR is composed of two extra-cellular α- and two
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transmembrane β-subunits disulfide linked into an α2β2-heterotetrameric structure [216].
Alternative splicing gives rise to two IR isoforms, IR-A and IR-B [216]. IR-A is
expressed in the developing fetus as well as adult pancreatic β-cells, whereas IR-B is
expressed in adult muscle, adipose and liver. IR-A is regulated by IGF-II (insulin-like
growth factor-II) whereas IR-B is regulated by insulin. Insulin binds to the extracellular
α-subunits which induces a conformational change that allosterically regulates the
intracellular β-subunit tyrosine kinase domain. Ensuing is a series of intermolecular
trans-autophosphorylations generating multiple phospho-tyrosine sites [133; 216].
Tyrosine phosphorylation at the juxtamembrane Y960 is required for binding IRS1-4.
This is important for propagating the insulin signaling cascade. Phosphorylation at
Y1146, Y1150, Y1151 in the kinase activation domain relieves pseudosubstrate
inhibition further enhancing the tyrosine kinase activity [216]. Other scaffolding proteins
recruited to the IR are Gab1, Shc, SIRPS, Cbl and APS [133]. IRS2 knockout cells show
a major defect in insulin-stimulated glucose transport [217]. IRS is able to bind IR via its
C-terminal PH domain and phosphotyrosine-binding domain (PTB) [218]. This
facilitates binding to PI3K, which has a pivotal role in metabolic and mitogenic actions of
insulin and IGF1 [219]. Because of PI3K′s crucial role in propagating the insulin
signaling pathway, it deserves further digression.
PI3Ks catalyze the transfer of the γ-phosphate of ATP to the D3 position of
phosphoinositides. PI3Ks can be grouped into three classes based on substrate specificity
[220]. Only class I PI3Ks have been shown to activate Akt in cells. In cells, class I
PI3Ks prefer PtdIns(4,5)P2 as a substrate. The resulting PtdIns(3,4,5)P3 can then go on
to give rise to PtdIns(3,4)P2 via 5′ inositol phosphatases. Class I PI3Ks are heterodimers
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made up of a roughly 110 kDa catalytic subunit (p110) and an adaptor/regulatory subunit.
Class I PI3Ks that bind tyrosine kinases and heterotrimeric G-protein coupled receptors
are referred to as Class IA and Class IB PI3Ks respectively. Class IA PI3Ks are diverse
with three catalytic p110 isoforms (p110α, p110β and p110δ, each encoded by different
genes) and seven adaptor proteins (generated by alternative splicing of three genes: p85α,
p85β and p55γ) [170]. The p85 adapter subunit, starting from the N-terminus, contains a
Src homology 3 (SH3) domain, a breakpoint-cluster-region homology (BH) domain
flanked by two proline-rich regions and two C-terminal SH2 domains spaced by an interSH2 (iSH2) region. The iSH2 mediates tight binding between p85 to the catalytic
subunit [221; 222; 223]. The catalytic subunit possesses intrinsic serine kinase activity.
The regulatory subunit p85α S608 can be phosphorylated by the p110α catalytic subunit
which reduces lipid kinase activity [224]. P110δ can not phosphorylate regulatory
subunits but can undergo autophosphoryaltion [224]. As far as insulin stimulation is
concerned, class IA PI3K activation is accomplished by translocation to the plasma
membrane and binding with its two SH2 domains (one N-terminal, the other C-terminal)
to tyrosine-phosphorylated pYMXM and pYXXM motifs on IRS [220; 225].
As mentioned, PI3K produces PIP3, which binds to the PH domain of a variety of
signaling molecules altering their activity and/or subcellular localization [226].
Phosphatidylinositol-3-phosphates regulate three main classes of signaling effectors: the
AGC family of serine/threonine protein kinases (which include PKCs), guanine
nucleotide-exhange proteins of the Rho family of GTPases and the TEC family of
tyrosine kinases. PI3K might also activate the mTOR/FRAP pathway and be involved in
PLD1 regulation, which leads to hydrolysis of phosphatidylcholine and increases in PA
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and DAG [225; 227]. The best characterized AGC target of PI3K is phosphoinositidedependent kinase 1 (PDK1), one of the serine kinases that phosphorylates and activates
Akt. PDK1 has an N-terminal kinase domain and a C-terminal PH domain which has a
higher affinity (in vitro) for PtdIns(3,4,5)P3 and PtdIns(3,4)P2 than other PIs such as
PtdIns(4,5)P2. Its affinity for PIs is higher than that of Akt [170]. PDK1 was discovered
for its ability to phosphorylate Akt Thr 308 in vitro [169]. In unstimulated cells, PDK1 is
mainly cytosolic with relatively little PM localization [228].

With agonist stimulation

(e.g. insulin) PDK1 phosphorylates Akt1 on T308 and the equivalent residues in Akt2,3.
This phosphorylation of Akt is enhanced over 1000-fold in the presence of lipid vesicles
containing miniscule amounts of PtdIns(3,4,5)P3 or PtdIns(3,4)P2 but not PtdIns(4,5)P2 or
other PIs [169]. Akt binds with its PH domain to PtdIns(3,4,5)P3 or PtdIns(3,4)P2 which
alters its conformation so that T308 becomes accessible to PDK1 [170].
For a long time, there was no consensus as to the identity of the kinase “PDK2” or
“hydrophobic motif kinase” responsible for S473 phosphorylation of Akt. Several
candidates had been proposed including PDK1, integrin-linked kinase (ILK) and Akt
itself and DNA-PKcs. However, the identity of the kinase complex responsible has now
been firmly established as mTORC2 [174; 229]. Due to the pertinence of mTOR in this
study, it necessitates further digression.
mTOR is a member of the phosphoinositide 3-kinase-related kinase (PIKK)
family of proteins [230]. mTOR is a target of rapamycin, a macrolide antibiotic and
immunosuppresent of the phosphoinositide kinase family. The mTOR kinase exists in
two complexes, mTORC1 and mTORC2. mTORC1 consists of mTOR, mLST8,
RAPTOR (regulatory-associated protein of mTOR) and PRAS40 (proline-rich Akt
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substrate 40 kDa). RAPTOR positively regulates mTOR activity and acts as a scaffold
recruiting mTORC1 substrates. PRAS40 negatively regulates mTORC1 activity
depending on its phosphorylation state. [231]. Activated mTOR can phosphorylate
PRAS40 relieving mTORC1 of substrate competition [232]. The best known targets of
mTORC1 include ribosomal protein S6 kinases (S6K1 and S6K2 in mammals) and
eukaryotic initiation factor 4E (eIF-4E)-binding protein 1 (4E-BP1). S6K1 is activated
by phosphorylation and regulates ribosomal protein translation and ribosome biogenesis.
S6K1 also acts as a feedback inhibitor of insulin induced PI3K-Akt pathway. It does this
by directly phosphorylating and inhibiting IRS1 on S270. Phosphorylation of 4E-BP1 by
mTOR decreases 4E-BP1 affinity for eIF-4E leading to translation of cap-dependent
mRNAs [231; 233].
The mTORC2 protein complex consists of mTOR, RICTOR (rapamycin
insensitive companion of mTOR), mLST8/GβL (mammalian LST8 /G-protein β-subunit
like protein), SIN1 (stress-activated-protein-kinase-interacting protein 1) and Protor
(protein observed with Rictor) (collectively called mTORC2). Rapamycin acutely
inhibits mTORC1 but is needed for much longer incubations to have an effect on
mTORC2 [234]. mTORC2 can phosphorylate Akt S473 in 3T3-L1 adipocytes. This
along with phosphorylation of T308 results in fully activated Akt [174; 234; 235].
mTORC2 also phosphorylates Akt at the turn motif T450 [54; 55]. mTORC2 regulates
organization of the actin cytoskeleton through phosphorylation of PKCα [236]. SIN1
maintains mTORC2 complex integrity thereby regulating phosphorylation of Akt S473
[229; 237].

It is not known how the interaction between mTORC2 and Akt is facilitated

[238]. Alternative splicing of mSin1 gives rise to at least five isoforms, three of which
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assemble into mTORC2 to generate three distinct mTORC2s. Two of these mTORC2s
are regulated by insulin [239]. mTORC2 is also regulated by two tumor suppressors
called tuberous sclerosis complex protein 1 and 2 (TSC1 and TSC2). Within the TSC1TSC2 complex, TSC1 stabilizes TSC2, while TSC2 acts as a GTPase activating protein
(GAP) for the small GTPase Rheb (Ras homolog enriched in brain). GTP bound Rheb
activates mTORC1 which is involved in promoting cell growth and proliferation through
its main substrate ribosomal S6 kinases (S6K1 and S6K2). The mTORC1 complex is
inhibited if the TSC1-TSC2 complex is active by stimulating the conversion of RhebGTP to Rheb-GDP. The TSC1/TSC2 complex activates mTORC2 and thus Akt in a
manner that is independent of Rheb, mTORC1 and mTORC1-mediated feedback effects
on PI3K. Endogenous TSC1 and TSC2 co-immunoprecitate with exogenously expressed
mTOR [234; 240]. However, the TSC1-TSC2 complex can only associate with
mTORC2, not mTORC1 [240]. In response to growth factors, Akt phosphorylates TSC2
directly. Phosphorylation of TSC2 impairs the ability of the TSC1-TSC2 complex to act
as a GAP towards Rheb, which allows Rheb-GTP to accumulate and potently activate
mTORC1. This will eventually lead to negative regulation of Akt because activated
mTORC1 will target S6K1/2 which will block insulin signaling as mentioned above
[234]. DEPTOR (dishevelled, egl-10, pleckstrin (DEP) domains and interacts with
mTOR) is an mTOR interacting protein whose expression is negatively regulated by
mTORC1 and mTORC2. DEPTOR normally functions to inhibit mTORC1 and
mTORC2 pathways. However, when overexpressed, it relieves the negative feedback
inhibition of Akt, thus causing Akt activation [241].
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Many additional factors converge on mTORC1 (including mTORC2) thereby
regulating protein synthesis as well as insulin signaling. Akt phosphorylates TSC2 at
S939, S981 and T1462. The serine phosphorylations allow binding of the cystolic anchor
14-3-3. This disrupts binding between TSC1 and TSC2. Akt can phosphorylate PRAS40
at T246 resulting in dissociation of PRAS40 from mTORC1. PRAS40 is also a substrate
of both mTORC1 and mTORC2. S183 and S221 are phosphorylation residue targets of
mTORC1 and mTORC2, respectively. TNFα signaling to Akt, induces IKKα (inhibitor
of nuclear factor-κB kinase α), which is able to activate Raptor and thus mTORC1.
IKKβ, also downstream of TNFα signaling pathway, is able to inhibit TSC1 by
phosphorylation at S487 and S511 [230]. mTOR is able to sense cellular energy levels
by monitoring cellular the ATP:AMP ratio via AMP-activated protein kinase (AMPK)
[242]. Cellular stress activates AMPK, especially when AMP levels are high. AMPK
(phosphorylated and activated by LKB1) phosphorylates TSC2 at S1345, increasing its
GAP activity towards RheB-GTP, inhibiting mTORC1. AMPK can also phosphorylate
Raptor at S792, leading to 14-3-3 binding and inhibition of mTORC1 [230]. The Wnt
pathway, involved in cell growth control, is linked to mTORC1 activation. Wnt signaling
inhibits GSK3β. GSK3β phosphorylates and inhibits TSC2 on S1341 and S1337 (after
priming phosphorylation of TSC2 on S1345 by AMPK). Akt and RSK (ribosomal S6
kinase) can also phosphorylate and inhibit GSK3β. Hypoxic conditions work to inactive
mTORC1 through hypoxia-inducible factor 1α (HIF1α) and REDD1. REDD1 competes
with TSC2 for 14-3-3 binding. Low nutrient conditions inhibit mTORC1. Rag proteins
(Ras small GTPases comprised of four members) are capable of activating mTORC1 in
an amino acid sensitive manner. RAG proteins form heterodimers of RAGA or RAGB
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with RAGC or RAGD. During conditions where there are sufficient amino acids GTPbound RAG complex activates mTORC1, likely by changing the subcellular localization
of mTORC1 and bringing it into close proximity with RheB. The Ras-ERK pathway
activates mTORC1 by phosphorylating TSC2 at S664 and S1798 by ERK and RSK
(ribosomal S6 kinase), respectively. RSK can also activate Raptor via phosphorylations
at S719, S721 and S722. Some of the many pathways converging on mTORC1 are
displayed in Figure 17 [230; 242].
The conversion of PA from PC by PLD1 is integral for both mTORC1 and
mTORC2 activation. Structural studies have shown that PA binds to the FRB (FKBP
rapamycin binding) domain of mTOR. PA is in competition for this site with rapamycin
which is associated with FKBP12 (FK506 binding protein 12). PLD1 through PA
facilitates formation of mTOR complexes. mTORC2 binds PA more strongly than
mTORC1 which explains why higher concentrations of rapamycin are needed to inhibit
mTORC2 versus mTORC1 [243].
Growth factors stimulate mTORC2 activity with some mTORC2 subunits
undergoing phosphorylation. The kinases responsible for these phosphorylations are
unknown.

There is preliminary evidence that Ras may be responsible for some of these

phoshorylations [238]. mTORC1 and mTORC2 activity can be distinguished based on
the phosphorylation status of mTOR. Activated mTOR is phosphorylated between its
catalytic domain and FATC (Frap, ATM, TRRAP, C-terminal) domain near the Cterminus at T2446, S2448 and S2481 [61]. T2446 is phosphorylated in response to
nutrient availability [244]. mTORC1 is predominantly phosphorylated on S2448 while
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mTORC2 is predominantly phosphorylated at S2481. S2481 is a rapamycin-insensitive
autophosphorylation site [61; 245].
Activated Akt has many target substrates involved in glucose homeostasis.
SNARE associated protein synip has been identified as an Akt substrate.
Phosphorylation of synip via Akt might allow for insulin-dependent dissociation of synip
from syntaxin 4 which would allow SNARE pairing between syntaxin 4 and VAMP2
thereby facilitating GSV fusion with the PM in adipocytes [246; 247]. A very promising
Akt substrate was identified using a phosphor Ser/Thr Akt substrate (PAS) antibody.
This protein was AS160 (Akt substrate of 160kDa), originally named TBD1D4 [246].
AS160 is abundant in muscle and adipose tissues [246; 248]. There are six putative Akt
substrate motifs on mouse AS160. In 3T3-L1 adipocytes, insulin stimulated (likely
through Akt) phosphorylation in five of the six putative Akt substrate motifs (S318,
S341, S570, S588, T642, T751) [249]. In muscle cells, insulin, AMPK agonists or
contractile activity have been shown to cause AS160 and GLUT4 translocation [250].
AS160 contains two N-terminal PTB domains and a C-terminal Rab-GAP (Rab GTPaseactivating protein) domain. This led to the hypothesis that Akt-mediated AS160
phosphorylation (and inactivation) regulates GLUT4 translocation via regulation of GAP
activity towards Rab proteins [251]. A second Rab-GAP substrate of Akt is TBC1D1
(tre-2/USP6, BUB2, cdc16 domain family member 1), which regulates insulin-stimulated
GLUT4 trafficking [252]. RUVBL2 (RuvB-like protein 2) has been identified as an
AS160 substrate critical for insulin-stimulated phosphorylation of AS160 in 3T3-L1
adipocytes [253]. The current thinking is that Rab-GAP activity promotes hydrolysis of
GTP to GDP by Rab proteins on GSVs. In the inactive form, GDP-bound Rabs are
42

unable to cause GLUT4 translocation to the PM. However, with insulin treatment,
AS160 is phosphorylated which leads to inactivity of Rab-GAP. This would enable
GSV-associated Rabs to load up on GTP and elicit GLUT4 translocation. So far, the
Rab14 isoform has emerged as the most likely Rab responsible for GLUT4 translocation
in 3T3-L1 adipocytes [252]. Rab 10 has also been implicated in adipose cells [254]. In
L6 muscle cells, the AS160-substrate Rab8A isoform seems to be involved in GLUT4
translocation [255]. Rab8A and Rab10 are both able to bind myosin Va and Vb,
molecular motors responsible for localization of Rabs and GLUT4 translocation [254].
Munc18c is a putative target of Akt-controlled Rab activity. Munc18c is a member of the
Sec1p/Munc18 (SM) family of proteins. Munc18c is thought to keep syntaxin4 (tSNARE) in a closed conformation. Rab activity causes dissociation of Munc18c from
syntaxin4 allowing syntaxin4 to interact with VAMP2 (v-SNARE) and SNAP23 (23kDa
synaptosomal-associated protein) (t-SNARE) [129; 183]. Recent in vitro experiments
also point to a Mucn18c role in fusion by anchoring VAMP to syntaxin [129].
In adipocytes AS160 phosphorylation at Thr642 promotes interaction with 14-33 protein. This interaction is critical in insulin-stimulated (Akt-dependent) suppression of
AS160′s inhibitory role in GLUT4 translocation in adipocytes [252; 256]. 14-3-3 binding
to AS160 in L6 cells is not enhanced as a result of insulin-stimulation. However, AMPKmediated phosphorylation of AS160 Ser237 did enhance binding [257].
Using the same PAS antibody mentioned above, phosphoinositide 5-kinase
PIKfyve (phosphoinositide kinase for five position containing a Fyve finger) was
identified as a potential Akt substrate. It is phosphorylated at S318 (inactivated) in
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response to insulin. This effect is blocked by wortmannin. Inactivated PIKfyve is
associated with enhanced insulin-stimulated GLUT4 translocation [258].
In addition to Akt and its downstream effectors, PKCλ/ζ is downstream targets of
PI3K signaling that have been suggested to play a role in insulin-induced GLUT4
translocation [259; 260; 261]. However, there is some controversy as to PKCλ/ζ′s role in
insulin-stimulated GLUT4 translocation [262]. After phosphorylation of PKCλ/ζ by
PDK1, it is recruited to lipid rafts in a TC10-dependent manner via Par3 and Par6. Par6
and PKCλ/ζ both contain PB1 (Phox and Bem1) domains required for heterodimer
complex formation. Par3 has three PDZ domains that specifically bind to both Par6 and
PKCλ/ζ [263].
Before moving on to the other half of the insulin pathway, it should be noted that
PI3K activation can be attenuated by PIP3 dephosphorylation via 3′ phosphatases such as
PTEN (phosphatase and tensin homolog) [264] or 5′ phosphatases such as SHIP2 (SH2containing 5′-inositol phosphatase 2) [265]. PTEN action on PIP3 yields
phosphatidylinositol 4,5-bisphosphate whereas SHIP2 action on PIP3 yields
phosphatidylinositol 3,4-bisphosphate [152]. Both PTEN and SHIP2 can negatively
regulate insulin signaling [266; 267]. However, in 3T3-L1 adipocytes, PTEN, and not
SHIP2, is able to inhibit PI3K-dependent insulin signaling [268]. Insulin action can also
be attenuated by protein tyrosine phosphatases (PTPases) which catalyze
dephosphorylation of the receptor and its substrates (e.g. IRS). The most prevalent is the
cytoplasmic PTP1B. PTP1B-/- mice are resistant to diet-induced obesity [225]. In L6
skeletal muscle cells, Ghosh et al. have shown that ceramide-activated protein
phosphatase (CAPP) is able to dephosphorylate Akt and SRp40 resulting in decreased
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PKCβII alternative splicing. The PP1-like CAPP, in this case, is stimulated by TNFα,
which in turn stimulates de novo and hydrolysis pathways of ceramide generation. This
ceramide allosterically activates the CAPP responsible for suppressing PKCβII
expression [269].
The other pathway critical for insulin-stimulated glucose uptake is the CAP/Cbl
pathway. Upon insulin stimulation, Cbl is phosphorylated with the help of APS (adaptor
protein containing a PH and SH2 domain). APS has a PH domain required for membrane
localization and an SH2 domain that interacts with the phosphorylated receptor. APS
needs to be phosphorylated in order to recruit Cbl. It interacts with an atypical SH2
domain of Cbl. APS and Cbl are recruited to the receptor as dimers. Once at the insulin
receptor, Cbl is tyrosine phosphorylated in the C-terminus. This tyrosine
phosphorylation also requires another adaptor protein, CAP (Cbl-associated protein).
CAP interacts with Cbl through a C-terminal SH3 domain [136; 270]. Once Cbl has been
phosphorylated, Cbl-CAP dissociate from the receptor and translocate to lipid
raft/caveolae microdomains in the PM. This is mediated by interaction of the CAP SoHo
(sorbin homology) domain with flotillin [271]. Lipid raft-bound Cbl recruits another
adaptor protein named CrkII. An SH2 domain of CrkII interacts with phospho-Cbl.
CrkII forms a constitutive complex with C3G (CRK SH3-binding guanyl nucleotideexchange factor (GEF)). C3G (acting as an insulin-stimulated GEF) catalyzes the
exchange of GTP for GDP for the G protein TC10 [272]. TC10 has a C-terminal CAAX
sequence specifying farnesylation and palmitoylation responsible for targeting to lipid
rafts [273]. TC10 localization to lipid rafts (caveolin positive) is required for insulininduced activation [273; 274]. Activated TC10 provides a second signal to GLUT4 in
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parallel with activation of the PI3K pathway [272]. This may involve stabilization of
cortical actin, critical for GLUT4 translocation [225]. Rac is the G protein equivalent to
TC10 in skeletal muscle cells that is responsible for actin remodeling [275]. Several
effectors of TC10 have been proposed. One is CIP4 (Cdc42-interacting protein 4) which
contains 1 FCH domain, 2 coiled-coil domains and 1 SH3 domain. The FCH domain
(part of larger F-BAR domain) interacts with microtubules, the F-BAR domain regulates
membrane curvature and the second coiled-coil domain interacts with GTP-bound TC10.
In addition, CIP4 interacting proteins include Gapex-5, a RasGAP and VPS9 domaincontaining protein that functions as a guanine nucleotide exchange factor (GEF) for
Rab31. Rab31 is a Rab5 subfamily GTPase involved in TGN-to-endosome trafficking.
Insulin recruits the CIP4/Gapex-5 complex to the PM decreasing Rab31 activity in 3T3L1 adipocytes [276]. Rab31 may possibly function in retention of GSVs, therefore,
inhibition of Rab31 would allow for release of this GLUT4 population [129]. Gapex-5 is
also part of the TC10/Gapex-5/Rab5 axis that mediates insulin-stimulated production of
phosphatidylinositol 3-phosphate [PI(3)P]. PI(3)P is an important regulator of GLUT4
vesicle trafficking, regulating translocation of GSVs to the PM . To accomplish this
TC10 (via Gapex-5) must activate Rab5, a multifunctional GTPase that recruits a
network of effectors regulating internalization of proteins from the cell surface,
homotypic fusion of early endosomes, formation of clathrin-coated vesicles and motility
of early endosomes on microtubules. Phosphoinositide synthesis and turnover are also
regulated by Rab5 via recruitment of two distinct PI3-kinases, VSP34 and PI3K-p110β as
well as PI phosphatases including type II PI5-phosphatase and type 1α PI(3,4)P2 4phosphatase. Because spatial and temporal distribution of phosphoinositides is critical
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for ISGT, Rab5 is a critical regulator of insulin action. In order to accomplish Rab5
activation, several upstream processes must occur. Gapex-5 is bound to Rab31 (active)
in the unstimulated state which promotes intracellular retention of GLUT4. Insulin
activates TC10 which recruits CIP4/Gapex-5 to the PM. Dissociation of Gapex-5 from
Rab31 (now inactive) allows for GLUT4 translocation to begin. At the PM, Gapex-5
(likely acting as a GEF) activates Rab5 by causing dissocation of Rab5 from RabGDI
(Rab GDP dissociation inhibitor). Rab5, which is now GTP loaded (active), can assist in
ISGT [277; 278].
TC10 also interacts with Exo70, a component of the exocyst complex. This is
important for tethering and docking of secretory vesicles. Additional components of the
exocyst complex are Sec3, Sec5, Sec6, Sec8, Sec10, Sec15, Exo84 and the C-terminal of
a protein called Snapin which binds to the coiled-coil domain of Exo70. This complex is
necessary for glucose uptake in 3T3-L1 adipocytes [152; 279]. Other factors important
for propagating TC10-regulated tethering and docking include SAP97, a MAGUK
(membrane-associated guanylate kinase) family member. Sec8 associates with the PDZ
domain of SAP97 and recruits it to lipid rafts. SAP97 is expressed in lipid rafts
(localization not influenced by insulin) and anchors the exocyst complex to lipid rafts
[215]. The exocyst complex is non-fusogenic. Fusion involves the SNARE complex
which is capable of inducing the fusion reaction. This includes VAMP2 (v-SNARE on
GSVs) and Syntaxin4 (t-SNARE) and SNAP23 (t-SNARE). Syntaxin4 interacting
partners are Munc18c, Synip and Tomosyn, all of which appear to inhibit syntaxin from
binding VAMP or SNAP. Insulin-dependent Akt2 phosphorylation of Synip on S99
leads to dissociation of Synip from syntaxin4, allowing for assembly of SNARE47

complex. Activated PKCζ complexes with 80K-H and Munc18c to promote VAMP2
binding to syntaxin4 that enhances GLUT4 fusion. This suggests both a negative and
positive regulatory effect of Munc18c. PLD1 product, phosphatidic acid (PA) accelerates
the rate of fusion when incorporated with the syntaxin/SNAP23 acceptor membrane
[129]. DOC2B (double C2-like domains, beta), a SNARE related protein, is a very
recent discovery. It is a positive SNARE regulator of insulin-stimulated GLUT4 fusion.
It has two C2 domains and translocates to the PM during insulin treatment in a Ca2+
dependent manner [280]
TC10 is also thought to influence actin cytoskeleton dynamics. 3T3-L1
adipocytes contain cortical actin that lines the surface of the PM. This cortical actin
contains punctate filamentous F-actin that emanate from the organized caveolae-rosettes
where TC10 is segregated. This F-actin structure is referred to as Cav-actin. Interference
with TC10 abolished cav-actin formation. TC10 is thought to regulate both Cav-actin
and cortical actin structures [281]. The organization of F-actin is entirely different in
myotubes, which are present as stress fibers running longitudinally [152]. It is also
thought that TC10 influences massive actin polymerization in the peri-nuclear regions via
downstream effector N-WASP protein (neural Wiscott-Aldrich syndrome protein).
TC10, along with caveolins and flotillin, is detected in the TGN endosomes localized in
the peri-nuclear regions. This region (as mentioned above) is implicated as a major
storage site for GSV in 3T3-L1 adipocytes [282; 283]. TC10 inhibition using c. difficile
toxin B completely shuts down both cortical actin and peri-nuclear actin rearrangements
and greatly reduces insulin-stimulated GLUT4 translocation [284]. N-WASP protein
contains a VCA (Verprolin, cofilin, acidic) domain. When N-WASP is bound to TC10,
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the VCA domain is exposed and activates the Arp2/3 complex resulting in de novo actin
polymerization in response to extracellular stimuli [285]. This actin polymerization
(actin comet-tails) is the driving force for vesicle movement and is involved in membrane
trafficking events [286]. Activated TC10 differentially regulates two distinct population
of F-actin in 3T3-L1 adipocytes. It depolymerizes cortical F-actin beneath the PM and
greatly increases F-actin polymerization in the perinuclear region [282].
Insulin stimulation causes GSVs to migrate toward cortical actin along
microtubules. The kinesin motor thought to be responsible for this is KIF5B (kinesin
family member 5B). KIF5B is responsible for transporting GSVs along microtubules in a
PI3K independent manner in 3T3-L1 adipocytes [287]. Work from several groups has
helped to bridge the myosin motor, actin cytoskeleton and the exocyst complex as it
relates to 3T3-L1 GLUT4 translocation to the PM.

After GSVs have migrated along

microtubules, translocation requires both the actin cytoskeleton and the rapid movement
of GLUT4 along linear tracks which is likely mediated by molecular motors. A key
component of the molecular motor near actin filaments is the unconventional myosin
Myo1c (Myosin 1c) protein which is present in GSVs. Myo1c functions independent of
PI3K and helps control the movement of GSVs to the PM [288]. Myo1c travels along the
actin cable in order to reach the PM. This will likely take GSVs to F-actin where TC10
(and the exocyst complex) is located [136]. GTPase RalA mediates the coordination
between Myo1c and the exocyst complex. RalA that is GTP-loaded (via insulin) interacts
with the exocyst complex. RalA interaction with Myo1c is GTP-independent.
Calmodulin binds GSVs and modulates the association between RalA and Myo1c
through IQ motifs in a manner that depends on calcium-bound calmodulin. Myo1c may
49

recognize RalA as a cargo receptor on GSVs [289]. CaMKII (calcium/calmodulindependent kinase II)-mediated phosphorylation of Myo1c is necessary for ISGT to
proceed. Myo1c phosphorylation is associated with elevated 14-3-3 binding and reduced
calmodulin binding [290]. Binding of 14-3-3 to Myo1c does not inhibit its ATPase
activity (which it obtained via phosphorylation). Insulin causes a calcium influx just
below the plasma membrane which activates CaMKII. Interestingly, Rictor associates
with Myo1c during insulin signaling and may provide a link for the regulated interaction
of Myo1c and actin [291]. The interaction between Rictor and Myo1c is insulin
independent. Their association is necessary for phosphorylation of actin filament
regulatory protein paxillin and promotes cortical actin remodeling [292]. In addition to
Myo1c, myosin Va and myosin Vb are also actin-based motors implicated in GLUT4
trafficking. Va is phosphorylated by Akt2, enhancing its association with actin [152].
Vb can bind Rab8A which is critical for localization of Rab8A and GLUT4 translocation
[254]. How GSVs associate with the cytoskeleton (cortical actin mesh) is not clearly
known. A prime candidate is α-actinin 4 (ACTN4). This protein is found only within
remodeled actin but not along filaments in unstimulated cells. Insulin promotes colocalization of actin filaments, ACTN4 and GLUT4 as well as physical association
between GLUT4 and ACTN4. It is thought that insulin-stimulated release of TUG
(tether, containing a UBX domain, for GLUT4) from GLUT4 enables its interaction with
ACTN4 [152]. TUG is responsible for sequestration of GLUT4 in GSVs in unstimulated
3T3-L1 adipocytes [293; 294].
The preceding insulin signaling cascades as it relates to glucose uptake are
illustrated in Figure 18 [129; 133; 175; 225; 252; 276; 289; 290; 293; 295].
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Peroxisome Proliferator-Activated Recpeptor γ
Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear
hormone receptor superfamily of transcription factors that exist as three isoforms.
PPARα is expressed mainly in brown adipose tissue, liver, kidney, heart and skeletal
muscle and plays a major role in lipid catabolism [296]. PPARδ, expressed in many
tissues, is involved in lipid metabolism and energy utilization [297]. PPARγ exists as
two isoforms, PPARγ1 and PPAR2 resulting from alternative promoter usage and
mRNA splicing. PPAR1 is more ubiquitously expressed, whereas PPAR2 is to be
found mainly in adipocytes. PPAR2 is critical for adipogenesis and regulates genes
involved in lipid storage and glucose metabolism. To list a few; acyl-CoA oxidase, aP2,
PEPCK, malic enzyme, leptin, resistin, lipoprotein lipase and adiponectin [296; 298].
PPARγ1 has also shown to have some adipogenic action but not as much as PPARγ2
[299]. PPARγ3 has also been observed. Its expression seems to be confined to
macrophages [300].
The structure of PPARγ is shown in Figure 19 [297; 301]. At the N-terminal end
of PPARγ is the AF-1 region which is a ligand-independent activation function (AF-1)
domain. The AF-1 domain can functionally synergize with the AF-2 domain [302]. The
AF-1 region contains serine and threonine residues that can be phosphorylated. For
example, MAPK (mitogen-activated protein kinase) family member ERK (extracellular
signal-regulated protein kinase) can phosphorylate PPARγ at serine112 and cause
inhibition of transcriptional activation [303].
After the AF-1 domain is the DNA-binding domain (DBD). Glucocorticoid
receptor (GR) DBD is the current model representing the nuclear receptor superfamily.
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Briefly, DBD folds into a globular domain made up of two nonequivalent zinc-finger
structures. Each zinc atom is coordinated by four cyteines. The zinc-finger structure is
necessary for DNA-binding activity [304]. Important are two α-helices. The N-terminal
helix (P-box) directly interacts with the major groove of each DNA half-site (base
specific contact). The C-terminal helix aids in stabilization. Residues that make up the
dimmer interface are located in the C-terminal zinc finger (D-box) (Figure 19) [301].
DNA binding is coupled to structural changes necessary for heterodimer formation.
Heterodimerization depends on helical unfolding which occurs in the C-terminal
extension (CTE) of the DBD. In the case of thyroid receptor (TR), two helices within the
CTE are crucial for DNA binding and heterodimer assembly. A helix in the T-box
completes the heterodimeric interface with the second zinc-finger helix of retinoid X
receptor (RXR). A helix in the A-box makes extensive contacts with the DNA [301].
Next is the ligand binding domain (LBD). It is composed of many 12 α-helical
globular domains. These domains form three anti-parallel helical sheets that combine to
make an α-helical sandwich. The ligand binding pocket is located in the interior of this
structure. Binding strength and specificity are based on hydrophobic interactions,
hydrogen bonding and the steric size and shape of the binding pocket. For hormone
receptors, the smaller the size the more discerning the binding pocket is towards ligands
[301]. PPARγ has a relatively disordered pocket to accommodate different ligands [305].
At the end of the LBD is the ligand-dependent activation function (AF-2) that can bind
coactivators. The coactivator interface of this domain is a hydrophobic groove formed by
several helices of the LBD including helix 12 (called AF-2 helix). Coactivators can bind
this groove through a LXXLL motif [301]. Agonists regulate LBD-coactivator
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interactions by modulating both LBD and helix 12 conformations. Non-agonist bound
PPARγ would inactivate the LBD causing it to exist in many conformations, few of
which are the active [306]. Corepressor binding to PPARγ can also inhibit coactivator
recruitment. Corepressors also contain LXXLL binding motifs enabling them to bind to
the groove formed by the LBD and helix 12. However, unlike coactivators, the
corepressor binding motif forms a long three-turn helix sterically blocking helix 12 from
obtaining an active conformation [307]. Further stabilization of the LBD-corepressor
complex occurs via antagonist ligand binding. This prevents helix 12 from gaining an
active conformation as well as creates a larger binding surface for the corepressor
LXXLL motif [301].
PPARγ heterodimerizes with RXR alpha (RXRα) to regulate transcription of
PPARγ-responsive genes. PPARγ/RXR heterodimers bind to direct repeats (DR) of the
consensus sequence (AGGTCA) separated by a single nucleotide sequence (DR1) called
the PPARγ Response Element (PPRE). PPARγ binds to the 5′ half site while RXRα
binds to the 3′ half site (polarity) [296; 308]. The PPRE contains an additional AAACT
motif upstream of the DR1 [309]. Generally, PPREs reside in upstream enhancer
regions as opposed to the proximal promoter [310]. The heterodimer binds to the PPRE
in a head-to-tail orientation, allowing them to accommodate small changes in the number
of nucleotides spacing the two hexanucleotides [301]. In fact, binding of the heterodimer
pair has been observed in DR0 and DR2 PPRE′s [311]. The heterodimer pair is able to
bind to DNA without ligand activation. However, gene activation is inhibited due to the
binding of corepressors. Upon ligand binding, corepressors are released and coactivators
are recruited leading to transcriptional activation [309].
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The PPARγ-RXRα complex structure was recently reported. In PPARγ, the CTE
forms significant DNA interactions and is followed by two helical segments that reach
the LBD. The RXRα CTE forms one of the dimer contacts with the PPARγ DBD.
Otherwise, RXRα has no secondary structure which may be the reason it can
promiscuously bind other nuclear receptors. Both DBDs have α-helices that directly bind
to the half sites. Hydrogen-bonding occurs between the DBD and the major groove of
the half-sites. The PPARγ LBD and DBD are closely positioned whereas the RXRα LBD
and DBD are far apart with the space between them being occupied by PPARγ LBD.
PPARγ LBD is the target of most drugs since it is the centerpiece around which all other
domains are positioned.
Polarity (as mentioned above) is mainly determined by the PPARγ CTE′s affinity
for the 5′ flanking sequence. Another determinant of polarity is that both receptors have
tight binding between their DBDs. Both DBDs have α-helices that can bind with the half
sites. Hydrogen-bonding occurs between the DBD and major groove of the half sites.
PPARγ makes more base and phosphate backbone contacts than RXRα. The PPARγ
hinge region also has extensive DNA interactions, binding to the upstream AAACT
sequence. Besides the DBD-DBD interface, an additional dimer interface is created by
the two LBDs. A third interface occurs between PPARγ LBD and the DBD CTE region
of RXRα.
Heterodimerized PPARγ has a “Y′” shaped pocket in its LBD that binds ligands.
As alluded to before, the active conformation for the PPARγ-RXRα have their helix 12
properly positioned by ligands thereby facilitating coactivator docking. Coactivator
binding is far from other protein-protein interaction sites. The PPRE is also far from
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coactivator binding. This suggests that in order to recruit promoter-specific coactivators,
PPREs may have to cooperate with other promoter elements [309]. Adding more
complexity is the fact that an intact PPRE is not required for heterodimer binding and
subsequent activation for some PPREs [296]. A phenomenon called the phantom effect
has been reported whereby an RXR ligand can cause dissociation of corepressors and
recruitment of coactivators. Here, the binding of a ligand to one receptor can cause a
similar activating conformational change in the other receptor. The RXR-RAR (retinoic
acid receptor) heterodimer has reported to undergo this type of activation [312].
However, it has not been observed yet for the PPARγ heterodimer.
Polyunsaturated fats and their metabolites have been identified as PPARγ ligands
although none have established physiological relevance. The best characterized is 15deoxy prostaglandin J2 (15-d-PGJ2). It binds PPARγ with a Kd (dissociation constant) in
the low micromolar range and can activate PPARγ target genes at concentrations near the
Kd. The problems with this ligand are that it has never been shown to exist in vivo and it
may not be specific to PPARγ [313; 314]. Other natural ligands of PPARγ include
component of oxidized low-density lipoprotein 9- and 13-hydroxyoctadecadienoic acid
(HODE) and 12- and 15-hydroxyeicosatetraenoic acid (HETE) [313]. Recently,
unsaturated nitrated fatty acids (nitroalkenes) have been shown to activate PPARγ.
Specifically, nitrolinoleic acid (NO2-LA) and nitrooleic acid (NO2-OA) are potent
PPARγ activators. They can activate PPARγ-dependent transcription in the nanomolar
range [315]. The regioisomer 12-NO2-LA was identified as the most potent with an IC50
(0.41-0.6 μM) comparable to synthetic PPARγ agonist Rosiglitazone (IC50 = 0.25 μM)
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[316]. Lysophosphatidic acid has also been suggested to be an endogenous PPARγ
ligand [317].
PPARγ shares many of the same coactivators with other members of the nuclear
receptor family. These include CBP/p300, the SRC family, TRAP220, PGC1α etc. [318].
Some coactivators, such as PGC1α, can bind in a ligand-independent manner [319].
Despite this, PGC1α′s activating role for PPARγ displays gene selectivity. Some of the
corepressors capable of suppressing PPARγ activity include SMART, NCoR and RIP140
(nuclear receptor interacting protein1) [318]. The general mechanism for PPARγ
associated gene regulation is shown in Figure 20 [320]. Ligand bound PPARγ
heterodimer activates target promoters whereas without ligand activation the heterodimer
is bound by corepressors that repress target promoters [320]. Another mode of PPARγmediated gene suppression is called ligand-dependent transrepression. This involves
repression of pro-inflammatory genes such as nuclear factor-κB (NF-κB). Here,
activated PPARγ monomer blocks the clearance of the corepressor complex. The
mechanism is not precisely defined but is thought to involve ligand-dependent
association with PIAS1 (protein inhibitor of STAT1). PIAS1 binding would induce
SUMOylation of the PPARγ LBD which would enable it to maintain NCoR (nuclear
repressor corepressor) on the promoter of inflammatory genes [297].
One of the most critical functions for PPARγ is being the “master” regulator of
adipogenesis. The adipocyte is at the nexus of energy balance and whole-body lipid
homoestasis. PPARγ is induced during the differentiation from fibroblasts to adipocytes
(both white and brown fat) [298; 318]. Adipose cells can not form without PPARγ.
PPARγ advances adipogenesis by inducing a transcriptional cascade that includes such
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members as CAAT/enhancer binding proteins (C/EBP) [318]. Adipogenesis initially
starts by induction of C/EBPβ and C/EBPδ. These proteins bind to the PPARγ promoter
and induce its expression [321]. PPARγ, upon ligand activation, induces expression of
target genes involved in lipogenesis and adipogenesis. It also activates C/EBPα which
can positively regulate PPARγ expression [318]. C/EBPα can not induce adipogenesis
without PPARγ [299]. Many genes are involved in lipogenesis and insulin sensitivity
which have PPREs. Of interest is GLUT4, which is responsible for attaining full insulin
responsiveness. Deletion of PPARγ in mature adipocytes leads to lipodystrophy and
insulin resistance [322]. PPARγ2 deletion in obese and insulin-resistant ob/ob mice leads
to decreased fat mass, severe insulin resistance and dyslipidemia [323].
Thiazolidinediones
Thiazolidinediones (TZDs) are a class of drugs that are used to treat T2DM by
reversing insulin resistance in target tissues and reduce hyperinsulinemia [324]. Today,
two members of this drug class, rosiglitazone and pioglitazone, are currently approved by
the FDA to treat T2DM [318]. Lehmann et al. was the first to discover that TZDs were
direct ligands for PPARγ [325]. TZDs are believed to increase insulin sensitivity mainly
through binding PPARγ. There are three main reasons for this. First, clinical potencies
of different TZDs correlate with potency of PPARγ activation [326; 327]. Second, nonTZD agonists for PPARγ also improve insulin sensitivity [328]. Third, mutations in
PPARγ in humans are associated with insulin resistance [322; 329; 330].
Current evidence suggests that adipose tissue is the consequential tissue target
responsible for TZD beneficial effects (Figure 21). The “lipid steal” hypothesis has been
used to explain the mechanism of TZD. The rationale is as follows. Type 2 diabetes
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correlates with increased plasma free fatty acids (FFA) and their inappropriate deposition
on liver and skeletal muscle [318; 331; 332]. FFA and triglyceride (TG) accumulation in
skeletal muscle translates to insulin resistance and compromised systemic glucose
homeostasis [333]. Nonalcoholic fatty liver disease (NALFD) has a high correlation with
the metabolic syndrome (which includes insulin resistance) [334]. White fat cell PPARγ
activation is believed to boost its capacity to store dietary FFAs. As a consequence, the
FFAs are turned into fat deposits and partitioned away from tissues thereby enhancing
peripheral tissue insulin sensitivity. Consistent with this model, TZDs lower circulating
FFA levels [335]. It has also been proposed that TZDs exert their anti-diabetic effect
through modulation of cytokine expression.
The “lipid steal” contends that the primary site of TZD action is adipose tissue.
This is evidenced by a study showing that the presence of white adipose tissue (WAT) is
necessary for TZDs effects to materialize. However, in this study, TZDs was still able to
reduce circulating lipid levels in mice suggesting other sites may play a role in lipid
removal via fatty acid oxidation etc. [336]. Also, adipose specific PPARγ knockdown
mice do not respond to TZD treatment. In this study, TZDs were not able to lower
plasma FFAs without adipose tissue that expressed PPARγ [322]. Compensatory
mechanisms such as oxidation may kick in when WAT is not around.
Another question that arises from the “lipid steal” hypothesis is whether there is
adipose hyperplasia or hypertrophy. In cultured cells, PPARγ agonists induce
adipogenesis. Patients taking TZDs tend to gain weight, some of which is attributable to
an increase in fat mass [337]. This might seem at odds with helping improve insulin
sensitivity. However, TZDs simulate fat cell differentiation of smaller, more insulin58

sensitive adipocytes that promote adipocyte glucose uptake [338; 339]. In addition, the
added adipocyte load is predominantly in the subcutaneous fat with a slight decrease in
visceral fat [338; 340]. Individuals with upper-body (central) obesity (excess
subcutaneous abdominal and especially visceral fat) tend to be have metabolic and
cardiovascular complications [341]. This can partly be explained due to the fact that
visceral fat is more lipolytically active. This means excess FFAs are released from
triglyceride stores into the circulation. This is compounded by the fact that visceral fat
drains directly into the hepatic portal vein, thereby delivering FFA to the liver causing
hepatic insulin resistance [341]. The excess FFA will also reach skeletal muscle [338].
There is another mechanism by which activated PPARγ can induce whole-body
insulin sensitivity which does not contradict “lipid steal.” This involves alteration of the
adipokines secreted from adipocytes. One of the most critical is adiponectin.
Adiponectin is produced exclusively from adipocytes and is a direct target for regulation
by PPARγ [342]. TZDs induce adiponectin mRNA and plasma protein levels in rodents
and humans [343]. Further, TZDs induce a preferential switch to the high molecular
weight adiponectin (as opposed to the low molecular weight type), which is the active
form responsible for reducing serum glucose levels [344]. In mice, adiponectin
treatment leads to suppression of hepatic glucose output and improved glucose disposal
[345]. Mice lacking adiponectin display impaired TZD responses [346]. TZD activation
of PPARγ can also repress expression of adipokines inversely related to insulin
sensitivity. These include tumor necrosis factor (TNF) α and resistin which are thought
to cause insulin resistance [347].
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Skeletal muscle is the largest importer of glucose. TZD ability to improve overall
insulin sensitivity must affect skeletal muscle glucose uptake. However, PPARγ has very
limited expression levels in skeletal muscle. This means that the TZD effect is likely
indirect. The “lipid steal” hypothesis would explain this through less circulating FFA and
increased insulin sensitizing adipokines. Liver also express low levels of PPARγ and its
activation in liver is associated with steatosis. However, overall TZD benefits most
likely outweigh this side effect [318].
Another area of PPARγ activation affected by TZDs is macrophages. Infiltration
of adipocytes by macrophages is thought to lead to increased inflammatory factors that
cause insulin resistance such as IL-1β, TNFα and IL-6. PPARγ is induced during the
differentiation of monocytes into macrophages and is highly expressed in activated
macrophages [348]. Macrophages can undergo activation to inflammatory (M1)
macrophages which are characterized by production of IFN-γ (Interferon) and IL-12.
They can also undergo alternative activation to anti-inflammatory M2 macrophages
characterized by the production of arginase I and IL-10 [348]. Macrophage-specific
PPARγ expression was shown to inhibit inflammation and increase insulin sensitivity
(muscle and liver) as well as reduce atherosclerotic lesion size [349; 350]. Figure 21
illustrates the global as well as molecular insulin sensitizing benefits of TZD action on
the major TZD target tissues.
Peroxisome Proliferator-Activated Receptor γ Coactivator 1 α
Peroxisome proliferator-activated receptor γ coactivator 1α (PGC1α) was
originally identified as the coactivator of PPARγ [319]. PGC1α has since been shown to
increase the transcriptional activity of PPARγ and variety of nuclear receptor families
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including oestrogen receptor, retinoid X receptor, mineralocorticoid receptor (MCR),
glucocorticoid receptor (GR), liver X receptor (LXR), pregnane X receptor (PXR), the
consititutive androstane receptor (CAR), vitamin D and thyroid hormone receptor
families [351; 352]. PGC1α can also bind unliganded nuclear receptors such as PPARγ,
orphan hepatocyte nuclear factor (HNF) 4α, farnesoid X receptor (FXR), and oestrogenrelated receptor (ERR) α [352; 353]. PGC1α also targets non-nuclear receptors involved
in the insulin signaling pathway including FOXO1 (forkhead box O1), whose activation
is required for gluconeogensis [354]. Most receptor binding takes place through
PGC1α′s three LXXLL (L1-L3) motifs (Figure 22). The L3 motif marks the beginning of
the negative regulatory (NR) regions which aids in anchoring to PPARγ [352]. Recently,
Li et al. showed that rosiglitazone-stimulated PPARγ has a preference for the PGC1α ID1
motif (L1 aa 144-148). This combined with the fact that PGC1α expression increases
with Rosiglitazone treatment (via coactivation of PPARγ on the PGC1α promoter),
suggests that the interaction between PPARγ and PGC1α is critical in mediating TZD
benefits [355; 356]. After the PGC1α NR region is the central hinge region (amino acids
400-500), which contains the tetrapeptide DHDY. This is the host cell factor docking site
[352]. Of interest, PGC1α has the MADS box transcription enhancer factor (MEF) 2C
binding site which is required for coactivation of GLUT4 [357].
Besides being a powerful transcriptional coactivator, PGC1α can also bind histone
acetyltransferase (HAT)-containing proteins at their N-terminal such as CBP, p300 and
SRC-1 [358]. HATs acetylate histones and remodel chromatin allowing access for
factors of transcription. Concomitant with recruitment of transcription activators, PGC1α
is able displace repressor proteins such as histone deacetylase (HDAC) and small
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heterodimer partner (SHP) [359; 360]. The C-terminal region of PGC1α binds the
mediator complex (TRAP/DRIP complex) which is responsible for coupling pre-mRNA
splicing and transcription due to its Ser/Arg-rich domain as well as its RNA binding
domain [361; 362]. PGC1α′s C-terminal region also has two RS domains (to bind SR
proteins) and an RRM domain. Binding to SR proteins influences splice site selection
during splicing. The RRM is implicated in the control of translational elongation as well
as splicing. Both the RS and RRM synergize with the nuclear localization sequence
(NLS) in translocating PGC1α to the nucleus [363].

PGC1α is diffusely distributed in

the nucleoplasm including nuclear speckles, where hypophosphorylated inactive SR
proteins concentrate [362]. Just like the RS of other proteins (e.g. SRp proteins), those of
PGC1α harbor several Akt consensus site (RXRXXS/T) [352]. SRp40, for example,
(which can bind to PGC1α) can be phosphorylated in this manner and participates in
alternative splicing of PKCβII in an insulin-dependent manner [211; 362]. The ability of
PGC1α to bind proteins involved in transcription and splicing suggests that it is a key
mediator of co-transcriptional gene processing [362]. PGC1α affects alternative splicing
only when it is recruited to complexes that interact with gene promoters [362].
Coactivation of mitochondrial gene transcription factors allows PGC1α (as well
as PGC1β) to stimulate mitochondrial biogenesis. Some of the most critical are NRF-1,
NRF-2, PPARα, PPARδ, ERRα and TR [364]. NRF-1 and NRF-2 are not only targets as
transcription factors but their genes are subject to regulation by PGC1α. These genes are
able to simulate the expression of mitochondrial transcription factor A (Tfam), a
mitochondrial matrix protein necessary for replication and transcription of mitochondrial
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DNA [365]. Control of both nuclear and mitochondrial genes leads to increased activity
in fatty-acid β-oxidation, Krebs cycle, and oxidative phosphorylation (OXPHOS) [364].
White fat cells are needed for energy storage while brown fat cells are used for
energy dissipation. PPARγ is needed for formation of brown fat and white fat. TZD
stimulation has even been shown to promote the differentiation of brown fat [366].
PGC1α was discovered to turn on adaptive thermogenesis in brown fat. These processes
include fuel intake, mitochondrial fatty-acid oxidation and heat production through
uncoupling protein-1 (UCP1). PRDM16 is a coregulator necessary and sufficient for
brown fat cell differentiation. PRDM16 dramatically increases PGC1α expression, UCP1
and other brown fat genes. PGC1α and PGC1β exhibit complementary function during
brown fat differentiation through genes such as UCP1 as well as mitochondrial
biogenesis. However, after development of brown fat, PGC1α and PGC1β do not always
share complementarity in terms of function. For instance, PGC1α regulates cold
inducible UCP1 in mature brown fat, PGC1β does not. Recently, LRP130 has been
shown to be critical for the complementary actions of the PGC1′s during brown fat
development [367].
Exercise training promotes switching of muscle type fiber. It increases the
number of type I and type IIA muscle fibers which are red in appearance and contain a
large number of mitochondria, more myoglobin and vascularization than type II B and
type IIX muscle fibers. The former muscle type are resistant to fatigue and contract
slower with a low peak force [368]. Endurance training or strength training both result in
the release of calcium from the sarcoplasmic reticulum. This activates several important
transcription factors such as cyclic-AMP-responsive-element-binding protein (CREB),
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myocyte-enhancer factor 2C (MEF2C) and MEF2D, and members of the nuclear factor
of activated T cells (NFAT) family. These factors lead to an increase in PGC1α which is
probably involved in modulating metabolic fluxes in skeletal muscle in response to a
decrease in ATP and altered fuel demands [369; 370]. PGC1α′s interaction with AMPactivated protein kinase (AMPK) may mediate these metabolic fluxes. Activated AMPK
phosphorylates PGC1α and induces de novo synthesis of additional PGC1α [370; 371].
Transgenic mice encoding PGC1α in skeletal muscle at levels of those in type I muscle
fibers, show a definite switch towards both typeI and type IIA muscle fiber [372]. These
fibers are more resistant to fatigue than wild-type mice and are characterized by an
increase in mitochondrial density and function, increased oxidative metabolism,
increased expression of myofibrillar proteins characteristic of type I and type IIA muscle
fibers [372]. PGC1α also increases glucose uptake which leads to an increase in
glycogen stores post-exercise for future expenditure [373]. Substrate usage for energy
shifts to fatty-acid oxidation [374]. Mice with skeletal muscle ablation of PGC1α have
more type IIB and type IIX (glycolytic) muscle fibers and a lower capacity for endurance
exercise compared with wild-type mice [375]. There is wide variation in the PGC1α
expression in people′s human muscle. This may have implications in terms of
susceptibility to metabolic diseases such as insulin-resistance [376].
Serine/Arginine-rich Proteins
Serine/arginine-rich (SR) proteins are splicing factors characterized by their
arginine/serine (RS) dipeptide rich domain [377]. SF2/ASF was the first SR protein
identified [378]. The term ′SR protein′ was coined following identification of RS
domain-containing proteins using the antibody mAb 104. These SR proteins were bound
64

to active sites of RNA polymerase II transcription [379]. Those SR proteins were SRp20,
SRp40, SRp55 and SRp75, named after their molecular mass on an SDS/PAGE gel [380].
SR proteins have a modular structure with one or two copies of an N-terminal RRM
(RNA recognition motif) that provides RNA-binding specificity (SRp40 has two RRMs).
The C-terminal RS domain facilitates protein-protein interactions that bring the SR
proteins to the spliceosome [381; 382]. Once localized to pre-mRNA, SR proteins can
make contact via the BP (branch point) and the 5′ ss (splice site) [363; 383]. Also in the
RS domain repertoire is the ability to act as an nuclear localization sequence (NLS)
which shuttles SR proteins into the nucleus via the SR protein nuclear import receptor,
transportin-SR [384; 385].
Classical SR proteins include SF2/ASF, SC35, SRp20, SRp75, SRp40, SRp55,
9G8. The criteria used to define classical SR proteins are structural similarity, dual
function in constitutive and alternative splicing, presence of a phosphoepitope recognized
by mAb104 and purification using magnesium chloride [377]. Additional SR proteins
have been classified as well as SR-related proteins that may have additional roles besides
splicing such as chromatin remodeling, transcription and cell cycle progression [386].
SR proteins are concentrated in nuclear speckles and are recruited to RNA
polymerase II (RNAP II) during transcription [387]. Interactions between SR-related
proteins and the CTD (C-terminal domain) of RNAPII have been reported [388]. Also,
SR proteins are among the hundreds of proteins present in the RNAPII complex [389].
SC35 has recently been reported to promote RNAP II elongation in certain genes. This
demonstrates the potential of SR proteins to couple transcription and splicing, even
bidirectionally [390]. The importance of the transcriptional machinery in splicing has
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produced a kinetic co-transcriptional coupling model whereby the rate of transcriptional
elongation determines splice site selection, and this rate is partially determined by the
recruitment of splicing factors to the CTD of RNAP II [391].
SR proteins influence splicing by binding to ESE′s and ISEs (exonic and intronic
splicing enhancers) or ESSs and ISSs (exonic and intronic splicing silencers). Binding of
SR protein to ESEs prevents exon skipping [392]. Cooper et al. has shown SRp40 binds
to an ISE downstream of the PKCβII exon and promotes insulin-stimulated PKCβII exon
inclusion [38]. Two models have been proposed to explain how SR proteins regulate
exon inclusion. The ′recruitment model′ proposes that ESE-bound SR proteins recruit
and stabilize binding of U1 snRNP (small nuclear ribonucloprotein) at the 5′ ss as well as
U2AF65 at the 3′ss [393]. This is referred to as exon definition [394]. In the second
model, ′inhibitor model′, ESE-bound SR proteins antagonize activity of hnRNP-ESE
recognition. The hnRNP (heterogeneous nuclear RNP) family of proteins binds RNA
and is known to negatively regulate alternative splicing [377]. In addition to these two
models, it has been shown that SR proteins can form a network of protein-protein
interactions spanning the intron boundries early in spliceosomal assembly. They can also
bind ISEs at the branch point to promote pre-spliceosomal assembly [363; 383]. SRrelated proteins can recruit U4/U6.U5 tri-snRNP to the pre-spliceosome via the RS
domain [395].
SR proteins can also function in mRNA processing, mRNA nuclear export, NMD
(nonsense-mediated decay) and translation [377]. Some of these processes are partly
aided by nuclear SR proteins localized in nuclear speckles [396]. A subset of SR proteins
(SF2/ASF, SRp20 and 9G8) are able to shuttle between the nucleus and the cytoplasm
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that can further progress these processes [396]. Increased expression of SRp40, along
with others, is implicated in nuclear aspects of NMD [397].
SR protein phosphorylation dynamics have an important part in pre-mRNA
splicing. The RS domain of SR proteins is heavily phosphorylated on serine residues
[377]. This regulates both subcellular localization and activity. Phosphorylation of the
RS domain in SF2/ASF stimulates protein-protein binding with other RS domaincontaining splicing factors such as U1-70K [398]. Dephosphorylation of SR and SRrelated proteins is required for the splicing reaction to progress [399]. Insulin-induced
PKCβII alternative splicing occurs as a result of SRp40 phosphorylation by Akt [211].
The phosphorylation status of the RS domain is important in post-splicing activities of
SR proteins. A hypophosphorylated RS domain is needed for the interaction of
nucleocytoplasmic shuttling of SR proteins with TAP/NFX1 nuclear export receptor
[400].

SR protein kinases re-phosphorylate the RS domains enabling reentry into the

nucleus [401]. Both shuttling and non-shuttling SR proteins associate with the premRNA when hyperphosphorylated. Non-shuttling SR proteins are released after initial
spliceosomal assembly. Dephosphorylation of the RS domain determines the sorting
within the nucleus. Shuttling SR proteins are likely dephosphorylated during the
transition from prespliceosomal complexes (E and A) to mature spliceosomal complexes
(B and C). The shuttling SR protein may remain bound to aid in RNA export. Shuttling
SR proteins must be dephosphorylated to be moved to the cytoplasm. Shuttling and
non-shuttling SR proteins are recycled via different pathways [402].
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PU.1/Spi1
PU.1/Spi1 is a hematopoietic-specific ETS (E26 transformation-specific) family
member transcription factor involved in the development of all hematopoietic lineages
[403]. ETS proteins are characterized by a conserved 85-residue domain that binds
DNA. This domain recognizes purine-rich sequences containing 5′-(A/T)GGA(A/T)-3′
consensus. ETS proteins can tolerate variation in the flanking bases [404]. PU.1 is able
to partner with spliceosomal proteins [405]. One such factor is TLS (translocated in
liposarcoma) which binds PU.1 in vivo. TLS is an RNA-binding protein that influences
the choice of alternative splice sites by favoring the selection of the proximal 5′-splice
site of E1A pre-mRNA. In, addition the C-terminal region of TLS can bind SR proteins
which will also influence splicing [406]. The DBD of Spi-1 is able to interact with
poly(A) + RNAs and homoribonucleotide poly (G) polymers. However, it does not have
RNA recognition specificity [405; 407].
Co-transcriptional Splicing
Pre-mRNA processing (capping, splicing and cleavage/polyadenylation) can be
tightly coupled to transcription through RNA polymerase II allowing for much greater
efficiency, both spatially and energetically [408]. However, co-transcriptional splicing is
not obligatory. Introns can not serve as splicing substrates until both the 3′ and the 5′
ends are synthesized. Therefore, the time it takes for RNA pol II to synthesize each
intron, defines a minimal time and distance along the gene where splicing factors can be
recruited and spliceosomes formed. The time that it takes for RNA pol II to reach the end
of the TU (transcription unit) defines the maximal time that splicing could occur cotranscriptionally [409]. Introns in the 5′ part of the transcript will likely be co68

transcriptionally spliced. However, modulation of RNAP II elongation rates by
transcriptional activators influences alternative splicing [408].
Co-transcriptional splicing occurs due to RNA pol II being able to recruit both
transcription and splicing factors by acting as a landing pad. In particular, the CTD of
RNA pol II plays a central role in the coupling process. Dynamic changes in CTD
phosphorylation play a role in RNA processing. Transcriptional activation of RNA pol II
results in recruitment of splicing factors to sites of transcription [408]. This does not
occur if the CTD is mutated [387].
Promoter identity is critical in determining alternative splicing. Factors recruited
to the promoter affect the type of SR proteins recruited [408]. PGC1α, as mentioned
before, is a pertinent example because it can bind SRp40 [362]. Promoters, through the
factors they recruit, also affect RNA pol II elongation rates. This is important because a
slower pol II elongation rate or internal pauses favors inclusion of alternative exons
where there is a weak 3′ ss upstream of a strong 3′ ss [408]. It has been suggested that
the rate of RNA synthesis affects its secondary structure which in turn affects splicing.
This model suggests that pre-mRNA is free to fold within a limited timeframe after
transcription [410].
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Figure 7. Biphasic cPKC translocation in short- and long-term exposure to agonists. (A) Activation of either G protein-coupled receptor
or tyrosine kinase receptor (e.g. insulin receptor) leads to activation of PLC and subsequent hydrolysis of PIP2 to membrane-bound DAG and
soluble IP3. IP3 leads to an elevation of Ca2+ which then recruits PKC to the plasma membrane where it binds DAG and PS in the presence of
Ca2+ and becomes activated. Activated PKC can then phosphorylate target substrates. PKCs return to the cytosol within 120s, which
correlates with the metabolism and loss of DAG and the autophosphorylation of PKC C-terminus. (B) In chronic PKC stimulation, stimulation
of receptors leads to activation of PLD. PLD cleaves PC to generate PA and free choline. PA can be converted to DAG via PAP. This type
of DAG (mimicked by long term PMA treatment) is stable in the plasma membrane for over 1 hour and induces prolonged PKC translocation.
PKC can translocate (among other areas) to a novel juxtanuclear compartment, termed the “pericentron.”
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Figure 8. Spatial, temporal and conformational regulation of cPKC. Newly synthesized cPKC associates with PM in an open
conformation in which the pseudosubstrate (orange rectangle) is dislodged from the substrate-binding cavity on the kinase domain (green
circle). The upstream kinase, PDK1 (light blue circle with rectangular PH domain) is docked on the C-terminal tail and initiates
phosphorylation at the activation loop (Thr 500 in PKCβII). This is followed by mTORC2 mediated phosphorylation at the turn motif (Thr
641 in PKCβII) and then autophosphorylation of the hydrophobic motif (Ser 660 in PKCβII). Fully phosphorylated “mature” PKC is released
into the cytosol in a closed conformation in which the pseudosubstrate occupies the substrate-binding cavity, thereby inhibiting the kinase
(bottom left). External signals causing hydrolysis of phosphatidylinositol 4,5 bisphosphate (PIP2) cause PKC translocation to the PM.
Binding of Ca2+ to the C2 domain (red) recruits PKC to the PM via a low-affinity interaction where the C1 (brown) domain binds DAG. The
C1 domain (post calcium binding) also interacts with PIP2 and phosphatidylserine. Engagement of both C1 and C2 domains on the PM results
in pseudosubstrate release allowing downstream signaling to take place. This membrane translocation is reversible determined by second
messenger levels. The membrane-bound PKC conformation is highly sensitive to phosphatases. Prolonged exposure in this conformation
results in dephosphoryolation of PKC by PH domain Leucine-rich repeat protein phosphatase (PHLPP) (red) as well as PP2A which can
potentially lead to degradation. Binding of Hsp70 (dark yellow) to the dephosphorylated turn motif on the PKC C-terminus causes
stabilization and the ability to be re-phosphorylated, thus re-entering the pool of signaling-competent PKC. The phosphorylation step is
constitutive* and the translocation and dephosphorylation are agonist-induced. PKC that is not rescued by Hsp70 is ubiquitinated by E3
ligases (e.g. RINCK) and degraded.
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Figure 9. The main pathways of DAG generation and catalysis. DAG is inside the blue box (dashed). The principle enzymes involved are
green. The enzymes dependent of extracellular signaling are circled. Groups that are changed during the reaction are shown in red (OH is
hydroxyl; R, R′ and R′′ are fatty acids; P is a phospho group). The three-carbon backbone is in black. AT, acyltransferase; CDP, cytidine
diphosphate; CEPT`, choline/ethanolamine phosphotransferase 1; CPT1, choline phosphotransferase; DGAT, diacylglycerol acyltransferase;
TAG, triacylglycerol; MAG, monoacylglycerol; LPA, lyso-phosphatidic acid; PLA, phospholipase A; PAP, phosphatidic acid
phosphohydrolase; LPP, lipid phosphate phosphatase; LPAAT, lysophosphatidic acid acyltransferase; DGK, diacylglycerol kinase; PLD,
phospholipase D; PLC, phospholipase C; DGK, diacylglycerol kinase; SMS, sphingomyelin synthase; SM, sphingomyelin.
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Figure 10. Agonist-induced membrane phospholipid degradation for acute and sustained PKC activation. Phospholipase C is
responsible for acute DAG production by converting phosphatidyl 4,5 bisphosphate (PIP2) to inositol 1,4,5-triphosphate (IP3).
Phosphatidylcholine (PC) is the starting material for sustained agonist-induced DAG production. Phospholipase D converts PC to DAG.
Phospholipase A2 hydrolysis of PC generates free fatty acids (FFAs) or lysophosphatidylcholine (LysoPC). These products help potentiate
PKC activation in the presence of DAG.
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Figure 11. GLUT family PM insertion structure. There are 13 GLUT family members. All span the plasma membrane 12 times with both
amino- and carboxyl-termini cytosolic. GLUT4 belongs to Class I GLUTs (1-4) which are glucose transporters. Class II GLUTs (5, 7, 9, and
11) are fructose transporters. Class III GLUTs (6, 8, 10, 12 and HMIT1) are structurally atypical and poorly defined. This diagram shows a
homology plot between GLUT1 and GLUT4. Residues shown in red are unique to GLUT4.
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Figure 12. GLUT4 trafficking itinerary. GLUT4 trafficking can be divided into six discreet steps. 1) Budding [biogenesis of GLUT storage
vesicles (GSVs)], 2) Movement, 3) Tethering, 4) Docking, 5) Fusion and 6) endocytosis.
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Figure 13. Proposed GLUT4 compartments and trafficking. GLUT4 (purple) and other rapidly recycling proteins such as transferrin
receptors (red) are removed from the plasma membrane in clathrin-coated vesicles and enter the endosome system (1). Depending on celltype, this recycling endosomal system can be both beneath the plasma membrane and perinuclear. GLUT4 can either enter the endosomal
recycling compartment (2) or be sorted away from tranferrin receptors and shuttled to the perinuclear reticular GLUT4 storage compartment
[PR-GSC] (3). The PR-GSC is similar to the Trans-Golgi network (TGN) (5) but has a more restricted population of stored proteins. GLUT4
is in constant flux between the PR-GSC and the dispersed vesicular GLUT4 storage compartment [DV-GSC] (4). The DV-GSC is available
for quick fusion with the PM. Newly synthesized GLUT4 from the TGN mostly goes to the PR-GSV. The PR-GSV can become saturated
and is available within the endosome system for rapid translocation in response to insulin. Mutated GLUT4 (alterations in targeting domains)
are targeted to the late endosomes and lysosomes (6). Black arrows indicate trafficking steps that lead to GLUT4 storage. This includes the
biosynthetic route (TGN) as well as from the PM via the endosome system. Red arrows indicate probable route from storage to the PM and
the route stimulated by insulin. Blue arrows indicate possible route of GLUT4 from storage to the endosomes and to the PM. Green arrows
indicate routes mutant GLUT4 might take if it can not be retained in the PR-GSC or endosome compartment.
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Figure 14. Domain structure of mammalian PKB/Akt isoforms. The N-terminal region contains the PH domain.
The lysine (K) indicates the residue involved in catalysis. Regulatory phosphorylations in the catalytic and C-terminal
domain are indicated.
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Figure 15. Mechanism of Akt activation. Newly synthesized Akt (light blue circle) is phosphorylated on the turn motif (Thr 450 in Akt1) in
an mTORC2 (dark orange) dependent manner. Signals generating phosphatidylinositol-3,4,5-triphosphate (PIP3) engage Akt PH domain at the
PM. Now the Akt activation loop (Thr 308) is exposed leading to PDK1 mediated phosphorylation and subsequent phosphorylation of
hydrophobic motif (Ser 473) via mTORC2. Fully phosphorylated Akt is locked in an active conformation and translocates throughout the cell
influencing downstream signaling (bottom right). Signaling is terminated by dephosphorylation of the lipid second messengers (via PTEN)
and direct dephosphorylation of Akt. PHLPP (red) directly dephosphorylates the hydrophobic motif. Protein phosphastase 2 (PP2A) (red) has
been shown to dephosphorylate Thr 308. Whether phosphorylation of Thr 308 or Ser 473 comes first is still being debated. It has recently
been proposed that Ser 473 precedes phosphorylation of Thr 308.
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Figure 16. Functional role of Akt in various tissues. The role of Akt in liver, pancreas, muscle and adipocyte is shown. Images courtesy of
iStockphoto.com.
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Figure 17. Mechanism of mTORC activation. mTORC1 phosphotransferase activity is stimulated by GTP-bound RHEB. RHEB is
negatively regulated by the TSC heterodimer complex. TSC2 converts RHEB to its GDP-bound form (inactive). Amino acids cause the Rag
protein complex to be in its GTP (active) form and subsequently activate mTORC1. The PI3K-Akt, Ras-ERK and IKK pathways converge and
activate mTORC1 by inhibiting the TSC complex or PRAS40. RSK kinase and IKKα can activate mTORC1. The AMPK and GSK3β
pathways negatively regulate mTORC1 by activating TSC2. AMPK can also directly inhibit Raptor. Both mTORC1 and mTORC2 can turn
off PRAS40 inhibition of mTORC1. Activated by growth factors, mTORC2 is the kinase complex responsible for phosphorylating Akt on
Serine 473 and thus full Akt activation. However, by activating mTORC1, mTORC2 causes a negative feedback loop that will blunt the
PI3K-Akt signaling pathway. This is because mTORC1 activates S6K1 which will phosphorylate and inhibit IRS1. Downstream targets of
mTORC1 are components of the translational machinery. mTORC1 is potently inhibited by rapamycin. Green arrows indicate activation. Red
arrows indicate inhibition.
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Figure 19. Generalized structure of PPARγ1 and PPARγ2. Starting at the N-terminus, the AF-1 domain is a
ligand-independent transcriptional activation function domain. Then the DNA-binding domain consisting of two
highly conserved zinc-finger motifs. In the middle is a hinge region allowing flexibility for PPARγ to dimerize and
bind DNA. Next is the ligand-binding domain (LBD) which has a second dimerization interface. Finally, the liganddependent activation function domain (AF-2). Numbers on top indicate amino acid number. Below is the detailed
structure of the DBD.
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Figure 20. Ligand-dependent transactivation and active repression. PPARγ heterodimerizes with RXRα. (A) In the presence of ligands
(natural or synthetic), PPARγ binds to coactivator complexes which result in the activation of target genes. (B) In the absence of ligands,
PPARγ associates with corepressor complexes on target genes. These corepressors that also include histone deacetylases (HDACs) which
lead to active repression of the promoter.
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Figure 21. Improved insulin sensitivity via TZD mediated adipocyte PPARγ
activation. TZD activation of PPARγ leads to lipid storage in adipose tissue through
target gene activation. Adipokine secretion profile (center blue box) is also altered
leading to increased peripheral tissue insulin sensitivity. Overall effects of reduced serum
FFAs and beneficial adipokines include reduced hepatic glucose output and increased
skeletal muscle glucose uptake. PPARγ also siphons macrophages towards an antiinflammatory M2 phenotype and reduces their infiltration into fat. Reprinted with
permission, from the Annual Review of Biochemistry, Volume 77 © 2008 by Annual
Reviews www.annualreviews.org
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Figure 22. Human PGC1α protein structure. The N-terminal region contains the activation domain (AD). Two of the
LXXLL motifs are present in the AD. The third LXXLL motif lies in the negative regulatory region. After L3 there are three
p38 MAPK phosphorylation sites located within the negative regulatory (NR) region. Host cell factor (HCB) is in a region that
binds MEF2C protein. A novel DEAD box is located in human PGC1α (not mouse or rat). Directly downstream of the DEAD
box are two putative casein kinase (CK) phosphorylation sites (CK1 and CK2). Rat and mouse contain only CK2. RS protein
interaction domains followed by a nuclear localization (NL) signal and the RNA recognition motif (RRM). The C-terminal
region has been shown to bind the TRAP220 mediator complex, splicing factors (U1-70K) and some transcription factors.
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EXPERIMENTAL PROCEDURES
Cell Culture
Mouse 3T3-L1 preadipocytes obtained from American Type Tissue Culture
repository, ATCC (Manassas, VA) were maintained and passaged as preconfluent
cultures in DMEM high glucose 4.5g/L (Invitrogen, Carlsbad, CA) with 10% newborn
calf serum (Sigma-Aldrich, St. Louis, MO) at 37oC and 10% CO2. Once confluent, cells
were differentiated (day 0) in DMEM high glucose with 10% fetal bovine serum (Atlas
Biological, Fort Collins, CO), 10μg/mL bovine insulin (Sigma), 1mM dexamethasone
(Sigma), and 0.5mM isobutyl-1-methylxanthine (Sigma). On day 2, media was replaced
with DMEM high glucose, 10% FBS, and bovine insulin. Day 4 and afterwards, cells
were cultured in DMEM high glucose plus 10% FBS. Media was changed every two
days. Prior to insulin treatment for glucose uptake or other assay, 4 hour serum
starvation was accomplished by using DMEM high glucose without FBS.
L6 rat skeletal myoblasts (obtained from Dr. Amira Klip, The Hospital for Sick
Children, Toronto, Canada) were grown in αMEM (Invitrogen) with 10% FBS to
confluence at 37oC and 5% CO2. Myoblasts were fused into myotubes by changing
media to αMEM with 2% FBS for 2-4 days post confluence. Serum starvation was
accomplished by using αMEM for 6 hours.
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Rat aortic vascular smooth muscle cells (A10, ATCC CRL 1476) were grown in
DMEM low glucose with 10% FBS at 37oC and 5% CO2. Once confluency was reached,
cell synchronization was achieved by serum deprivation (with 0.5% FBS) for 48 hours.
HeLa cells (ATCC CCL-2) were grown in MEM (Invitrogen) with 10% FBS until
confluent at 37oC and 5% CO2. Serum starvation was achieved by incubation with MEM
(no serum) for 6 hours.
Overexpression/Minigene Transient Transfection
Transient transfection was accomplished using TransIT-LT1 transfection reagent
(Mirus Bio Corporation, Madison, WI) according to manufacturer′s protocol. Briefly, L6
cells were cultured in 6-well plates until 60-75% confluent. 250μL serum-free αMEM
was mixed with 2.5μL TransIT-LT1transfection reagent per 1μg DNA. DNA was added
to this mixture and incubated for 30 minutes at room temperature. TransIT-LT1 Reagent
– DNA complex was added to cells (with complete growth medium) and incubated for
48-72 hours. Plasmids used were as follows:
Gene of Interest
pcDNA3.1/myc-His A
vector control
PPARγ
PPARγ E499Q
PGC1α
PGC1α delta CTD
SRp40 cDNA
SRp40 (myc)
HRS (myc)
pCMV GFP

Donor
Invitrogen

ID #
V800-20

Addgene Inc., (Cambridge
MA)
Addgene
Addgene
Addgene
Dr. Rebecca Taub
Hercules Apostolatos
Hercules Apostolatos
Addgene

8895
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8896
1026
1030
PMID: 9199345
PMID: 15684423
N/A
11153

siRNA Knockdown in L6 Skeletal Muscle Cells
L6 skeletal muscle cells were grown in 6-well plates. Cells were ready for
transfection at 60-75% confluency. In one tube (per well), 5μL siPORT NeoFX
Transfection Reagent (Applied Biosystems/Ambion, Austin, TX) was mixed with 95μL
αMEM (no serum). This was incubated 10 minutes room temperature. In another tube,
RNA and αMEM (no serum) were combined up to 100μL. Two tubes were mixed and
incubated 10 minutes. siPORT NeoFX – RNA solution was added to cells. αMEM (no
serum) was added to a final volume of 2.5mL. After 6-8 hours, media was replaced with
serum containing αMEM.
Gene silenced
PPARγ
(ID#197812)
PGC1α
(ID#114748)
SRp40
(ID#198849)
Silencer
Negative
Control #1
siRNA (#4611)

Species
Rat

5′ – 3′ Silencer siRNA (Ambion) Sense Sequence
GCAUUUGUAUGACUCAUACtt

Human

GCCAACACUCAGCUAAGUUtt

Rat

GCUCUUUUAUAACUAAACGtt

Rat, Mouse,
Human

Proprietary

siRNA Knockdown in 3T3-L1 Adipocytes
Transfection of differentiated 3T3-L1 adipocytes was attempted using DeliverX
Plus siRNA Reagent Solution (Panomics Inc., Fremont, CA). Day 8 3T3-L1 adipocytes
were trypsinized and thinned on a 6-well plate. Transfection was performed the next day.
The following is for transfection of 1 well of a 6-well plate. The siRNA working stocks
were prepared in one tube by adding siRNA and Buffer-1 up to 50μL. The DeliverX Plus
siRNA Transfection Reagent was sonicated (P/N DX0400, Panomics) for 5 minutes
before usage to achieve a homogeneous solution. In another tube, 8μL DeliverX Plus
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siRNA Transfection Reagent and 42μL Buffer-2 were combined. This second tube was
vortexed and sonicated for 5 minutes as before. The two tubes were combined, vortexed
and incubated at 37oC for 20 minutes. 100μL Buffer-1 and 100μL Buffer-2 were added
to the siRNA-DeliverX Plus Transfection Reagent mixture. Just prior to usage, cells
were washed several times with DMEM high glucose (no serum) to remove traces of
serum. 300uL mixture was added to each well along with an additional 300μL DMEM
high glucose (no serum) and incubated for 4 hours. After, 1mLof DMEM high glucose
with 10% FBS was added. Medium was changed the next day. Knockdown was
assessed at time points described. This transfection protocol was also attempted on cells
not trypsinized (100% confluent) without success.
Gene Silenced
PKCβII
PKCβII
Silencer Select
Negative
Control #1
siRNA
(#4390843)

Species
Mouse
Mouse
Rat,
Mouse,
Human

5′ – 3′ Silencer Select siRNA (Ambion) Sense Sequence
CAAUCAGAAUUCGAAGGAUtt (Custom)
AGAGCUAAGUAGAUCCGUAtt (Custom)
Proprietary

Oil Red O Staining
3T3-L1 adipocytes were cultured on chamber slides and fixed with 10% formalin
in PBS, washed with PBS, and stained for 1 hour at room temperature with 0.15% Oil
Red O (Sigma) (60:40 mix of isopropanol and water). Slides were evaluated for the
accumulation of lipid droplets.
Cloning the Minigene
Construction of the PKCβ heterologous minigene was initiated by Hercules
Apostolatos (H.A.). PCRs were performed on rat cell DNA extracts to obtain the βII and
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βI exonic sequence and their flanking intronic sequence (as depicted in Figure 36). The
primers (sequences listed with rest of primers) used and the products (visualized in
Figure 36) obtained are summarized in the following table (performed by H.A.):
Primer pair

Restriction
Enzymes
(RE) Inserted

Exon length

5′ intronic
length (not
including
RE)
103bp

3′ intronic
length (not
including
RE)
80bp

Total size

BII sense &
5′ XhoI, 3′
216bp
399bp
ss1 antisense BamHI
BII sense &
5′ XhoI, 3′
103bp
216bp
120bp
439bp
ss2 antisense BamHI
BII sense &
5′ XhoI, 3′
103bp
216bp
346bp
665bp
ss3 antisense BamHI
BII sense &
5′ XhoI, 3′
103bp
216bp
684bp
1003bp
ss4 antisense BamHI
BI sense &
5′ BamHI, 3′
422bp
150bp
7bp
579bp
BI antisense XbaI
BII and BI fragments were digested with BamHI and ligated to produce a BII-BI
fragment with relevant flanking intronic sequence (H.A.). These fragments were in turn
digested with XhoI and XbaI (H.A.). The pTNT cloning vector (Promega, Madison, WI
#L5610) was also digested with XhoI and XbaI (H.A.). The BII-BI fragments, now with
overhangs were ligated into the pTNT cloning vector (Figure 37)(H.A. and E.K.). The
resulting vectors were used by H.A. to perform in vitro transcripion/splicing assays. For
use in mammalian cells, the BII-BI fragments would have to be cloned into a vector
containing a promoter responsive to mammalian cells. The pCMVTNT vector (Promega,
#L5620) was used (Figure 38 & 39). The BII-BI fragments inside the pTNT vector were
digested with XhoI and XbaI as was the pCMVTNT vector. The two were ligated.
pCMVTNT BII-BI ss3 was tested by transfecting it into L6 skeletal muscle cells.
However, using the CMV_FP1 and CMVRP1 primers (sequence listed below), many
products were observed (Figure 40) due to the presence of a chimeric intron and T7-SP696

β-globin exon within the pCMVTNT vector (Figure 41). To bypass this obstacle,
pCMVTNT BII-BI plasmids were cut with BbsI and XhoI (Figure 40). The BII-BI
fragments inside the pCMVTNT vector were PCRed out by using BbsI_CMV_F and ss1ss4 reverse primers (sequence listed below). This PCR fragment was digested with BbsI
and XbaI and ligated to the digested pCMVTNT BII-BI vector (Figure 42). Of the
resultant clones pCMVTNT BII-BI ss1 and ss4 (minus the chimeric intron) were tested.
Both the resultant ss1and ss4 clones were transfected into L6 skeletal muscle cells and
resulted in appropriate splice products (Figure 43 & 44) using CMV_FP1 & B1R3
primers (sequence listed below). The ss4 clone was the most desired clone because it
had the most intronic sequence thereby allowing for more potential SR protein binding
analysis. Because the ss4 splice products were in low abundance, the decision was made
to use the more responsive ss1 plasmid and reclone the additional splice sites into the ss1
clone (Figure 45). pCMVTNT ss4 was PCRed using BbsI_CMV_F & ss4 antisense
primers to release the BII half of the ss4 fragment. Before this experiment could
proceed, an additional BamHI located on the pCMVTNT ss1, had to be eliminated. This
was done by starting from scratch and digesting the original pCMVTNT vector with
BamHI. This was blunted by Klenow fill-in and blunt ligated. The ss1 fragment was
recloned from the pTNT ss1 vector as before (Figures 45). Now the PCR product and
the pCMVTNT ss1 (-Chimeric intron) were digested with BbsI and BamHI. The two
were ligated. The resultant vector, pCMVTNT ss4 (-CI, -BamHI), was proven to be
functional.
To study the relationship between the PKCβ promoter and gene splicing, the CMV
promoter was replaced with the human PKCβ promoter (Figure 46). To do this, PCR was
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performed using bprom_5 and bprom_AS primers (sequence listed below) on Construct 5
PKCβ promoter Luciferase vector [121]. The resultant PCR product contained 2243bp of
the human PKCβ promoter including the transcriptional and translational start site. The
PCR product and pCMVTNT ss4 (-CI, -BamHI) were digested with BsrGI and PstI, then
ligated. The resultant vector was named Bprom 2243 BII-BI ss4 (Figure 46). A
subsequent truncated version was made to study a putative PPRE. To do this Bprom BIIBI ss4 was digested with BsrGI and SacI restriction enzymes, then subsequently blunted
and relegated. The resultant clone was named Bprom 1143 BII-BI ss4 (Figure 47). Both
Bprom clones were verified by restriction digestion and sequencing (Moffitt Cancer
Center Sequencing Core). The splice products of Bprom 2243 BII-BI ss4 were compared
to that of the vector with the CMV promoter by sequencing and were found to be
identical (Figure 48).
Mutation of Putative PKCβ Minigene PPRE
Mutation of the putative PPRE within the minigene PKCβ promoter was
accomplished using the QuikChange Lightning Site Directed Mutagenesis kit #210515
(Stratagene, La Jolla, CA) according to manufacturer manual. The putative PPRE was a
DR2 (direct repeat with 2 base pairs separating). The putative PKCβ promoter DR2 was
5′ – AGCTCATCAGTTCA – 3′. This DR2 PPRE was -1848bp upstream of the PKCβ
transcript start sequence as defined by Vega Human TransView. The mutagenic forward
primer named DR2_60_sense had the sequence of 5′ – AAG GCA GGA TGT GGG CTG
TGA GCT TCC CTT GTG TCA GTT CAA AGG AAA TCT ACT TCA GCA – 3′ (red
font denoting mutated nucleotides). The mutagenic reverse primer was named
DR2_60_anti with a sequence of 5′ – TGC TGA AGT AGA TTT CCT TTG AAC TGA
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CAC AAG GGA AGC TCA CAG CCC ACA TCC TGC CTT – 3′. The resultant clone
was named Bprom 2243 DR2 mut BII-BI ss4.
RT-PCR
RNA was extracted using RNA Bee (Tel Test Inc., Friendswood, TX), according
to manufacturer′s protocol. Reverse Transcriptase was performed using Omniscript RT
kit (Qiagen, Valencia, CA, #205113) according to manufacturer′s protocol. PCR was
performed using rTaq PCR kit (#R001A, Taqara Bio Inc., Japan). Primers used for PCR
reactions were as follows:
Gene of
Interest
PKCβII &
PKCβI
(endogenous)
PKCβII &
PKCβI
(endogenous)
PKCβII only
(endogenous)
PKCβII only
(endogenous)
PGC1α

Species
Rat

Primer
Direction
Forward

Rat

Reverse

GGG TTA GTA TAC GAG AAG CCA
GC

Rat

Forward

Rat

Reverse

Rat

Forward

PGC1α

Rat

Reverse

PPARγ

Rat

Forward

PPARγ

Rat

Reverse

SRp40

Rat

Forward

SRp40

Rat

Reverse

PKCβ
promoter
PKCβ
promoter
GFP

Human

Forward

Human

Reverse

ATG AAA CTG ACC GAT TTT AAC
TTC CTG
CGG AGG TCT ACA GAT CTA CTT
AGC TCT
CCC ACG ACT CCT CCT CAT AAA
GC
GGC GCT CTT CAA TTG CTT TCT
GC
GGC CCA CCA ACT TCG GAA TCA
GC
CCG CCA ACA GCT TCT CCT TCT
CG
CGC AGA CCT CGA AAT GAT AGA
CG
CGC CAC CCA CTT GAA GGA TAC
TAC C
TTC TGT ACA GTT TAA CAG TAT
CTG GAA C
TTA CTG CAG GGG CTG TCA CTC
GCC CAG CTG CTG
CGT GCA GTG CTT CAG CCG CTA

Forward

5′ – 3′ Primer Sequence
GGC GTA TCC CAA GTC CAT GTC
TA
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Overhang

GFP

Reverse

GATA 2

Mouse

Forward

GATA 2

Mouse

Reverse

RUNX1

Mouse

Forward

RUNX1

Mouse

Reverse

HnrnpG

Mouse

Forward

HnrnpG

Mouse

Reverse

MZF1

Mouse

Forward

MZF1

Mouse

Reverse

Nkx2-5

Mouse

Forward

Nkx2-5

Mouse

Reverse

Prrx2

Mouse

Forward

Prrx2

Mouse

Reverse

AP2α

Mouse

Forward

AP2α
GATA 1

Mouse
Mouse

Reverse
Forward

GATA 1

Mouse

Reverse

GATA 3
GATA 3

Mouse
Mouse

Forward
Reverse

SpiB

Mouse

Forward

SpiB

Mouse

Reverse

Spi1

Mouse

Forward

Spi1

Mouse

Reverse

CC
CGG CGG CGG TCA CGA ACT CCA
GC
CCG GGC TCT CCT GGT GTC TCT
TAC
GGC GGG CAC ATA GGA GGG ATA
GG
CGG CCT CTC GCT ACC ACA CCT
AC
TCA GCT CAG TAG GGC CGC CAC
AC
CCG GGA AAC CAA CAA ATC AAG
AG
CGT GGT GGA CCC CCG TAG CTA
TC
GCT TTG CCC ATG CCC TTG TAC
TC
CGC CAC ACA CGA ACG GTC TCT
C
GGG CGG ATA AAA AAG AGC TGT
GC
TGG GGT AGG GGT AGG CGT TGT
AG
GCT CGC CGT GTC AAC CTC AGT
G
GAT GGA GAA AAG GCA CGG GAG
AG
CCC CGC CCT ACC AGC CTA TCT
AC
TTC CGC CAC CGT GAC CTT GTA C
CGC CCA CTG ACC ATG AGG AAA
G
CCG GTG GGG AAG GAG GTT GTA
G
CGG CCA CTC CAG TCC TCA TCT C
CGG GTC TGG ATG CCT TCT TTC
TTC
GGG GGA TGT GTG GCA GAG GTA
TG
CGG CCA GGG CTA CAC AGA GAA
AC
TTC CAG TTC TCG TCC AAG CAC
AAG
GGG CGA CGG GTT AAT GCT ATG
G
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FOXC1

Mouse

Forward

TGC CCC GGA CAA GAA GAT CAC
TG
CCG TTC TCC GTC TTG ATG TCC
TG
GAT GAT GGA GGA CGT GAT GG
GGC TGC AGG AGA AGA AAA TG
CGG TTC CTC ATT GGC GCC TAC
TC
CGA CTC GAA GAT GCT GGT TGA
ATA G
GTG GGC CGC TCT AGG CAC CAA
CTC TTT GAT GTC ACG CAC GAT
TTC
AGC CAC AAA CCA AAG AGA GGG
AC
GTC AAT CAC CTT ACC TGG CTT
AC
GTG TTA GCT TGC TTG AGG GTG
TC

FOXC1

Mouse

Reverse

GAPDH
GAPDH
GLUT4

Mouse
Mouse
Mouse

Forward
Reverse
Forward

GLUT4

Mouse

Reverse

β-actin
β-actin

Rat
Rat

Forward
Reverse

β-actin
promoter
β-actin
promoter
PKCβ
promoter 7091
PKCβ
promoter 6903
PKCβ
promoter 4384
PKCβ
promoter 4183
PKCβ
promoter 1440
PKCβ
promoter 1271
PKCβ
promoter -676
PKCβ
promoter -492
PKCβ C4B2

Mouse

Forward

Mouse

Reverse

Mouse

Forward

Mouse

Reverse

GGA AAG GTA CCA CAA CTA AAA
CAG

Mouse

Forward

GTG TTG CCT GCA TTG GAG AGT
AC

Mouse

Reverse

CAC AAA CAA CAA AGC AGA ATA
GC

Mouse

Forward

GAC CGA ATG AGA CAG TGC ACA
AG

Mouse

Reverse

CCT GGT GTT GAG TTT AGC ATC
TG

Mouse

Forward

Mouse

Reverse

Mouse

Forward

PKCβ B2i

Mouse

Reverse

PKCβ B1

Mouse

Reverse

TCC GGA TGA GTG ACA ATG AAA
GC
CCA GCA ATG ACC AAA CGC CTA
AG
TTA TAA ACC AAA AGC TTG TGG
GCG
GGA GGG ATT CCC TCT AGG GCA
AAG CAG CC
GGG AGT CAG TTC CAC AGG CTG
CC
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Minigene
primers
BII sense

Rat

Forward

Ss1 antisense

Rat

Reverse

Ss2 antisense

Rat

Reverse

Ss3 antisense

Rat

Reverse

Ss4 antisense

Rat

Reverse

Bbs_CMV_F

Forward

BI sense

pCMV
TNT
Rat

Forward

BI antisense

Rat

Reverse

Bprom_5

Human

Forward

Bprom_AS
CMV_FP1

Human
pCMV
TNT
pCMV
TNT
pCMV
TNT
Rat

Reverse
Forward

T7flgFP5
CMV_RP1
B1R3

Forward

GGG CTC GAG GAA AAA CCA CAC
CCG GTT CC
CTA GAG TGG CCA TGT TTC AGT
GAT CAA AT
GTT TGG AGC CAT CTT CGA GGT
GAT CAA AT
CAT TCT TCC ACC TTC CCG GCT
GAT CAA AT
CAT TTG GCA CTG TTC TTA GAT
GAT CAA AT
GCG AAG ACT CTT GCG AAA AAC
CAC ACC CGG TTC C
CTC GGA TCC ACA GGC GTT GTC
ATT GAG TT
CAT TAA TGT GTA GGT GAA TGT
CTA GAC CA
TTC TGT ACA GTT TAA CAG TAT
CTG GAA
TTA CTG CAG GGG CTG
AGC TTT ATT GCG GTA GTT TAT C

Reverse

CAC CTG CAG AAG TTG GTC GTT
AGG CAC TGG G
GGC CGC CCG GGT CGA CTC TAG

Reverse

AGT TTG TCA GTG GGA GTC AG

XhoI
BamHI
BamHI
BamHI
BamHI
BbsI
BamHI
XbaI
BsrGI/
Bsp1407I
PstI

Silver Staining
6% polyacrylamide (using 40% Acrylamide/Bis cat# 1610146 from Bio-Rad
Laboratories, Hercules, CA) gel was prepared. Samples were run on gel and put in 10%
ethanol (Fisher) for 3 minutes. The ethanol was replaced with 1% nitric acid (Fisher) for
3 minutes. Gel was then rinsed three times with water and soaked in 0.1% silver nitrate
(Sigma) for 10 minutes.

After a quick wash with water, gel was developed using 6%

sodium carbonate (Fisher) with 0.2% formaldehyde 37% solution (Fisher). Reaction was
terminated with addition of 10N glacial acetic acid (Fisher).
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Agarose Gel
1% agarose gel (Fisher Scientific, Agarose Molecular Biology Grade cat#
BP1356) was made with ethidium bromide to detect nucleic acids.
Western Blot Analysis
Cell lysates were combined with 2X Laemmli Buffer (Bio-Rad Laboratories) with
additional SDS up to 8%. Lysates were subjected to 10% SDS-polyacrylamide gel
electrophoresis (SDS-PAGE). Gel proteins were electrophoretically transferred to
Hybond-C Extra nitrocellulose membranes (Amersham, Piscataway, NJ). Membranes
were blocked with Tris-buffered saline (Bio-Rad), 0.05% Tween 20 (Bio-Rad) containing
5% nonfat dried milk, and then incubated with primary and secondary antibodies. The
only exception was when probing for PKCβII, where pig gelatin (Bio-Rad) was used for
the blocking (3%), primary (1%) and secondary (1%). Detection was performed using
SuperSignal West Pico Chemiluminescent substrate (Pierce Biotechnology, Rockford,
IL). Antibodies used are as follows: PKCγ C-19, PKCζ C-20, PKCδ C-17, PKCβI C-16,
pPKCβII/δ Ser660, pPKCζ Thr 410, Akt1/2/3 H-136, pAkt1/2/3 Thr308, GLUT4 sc1608
(Santa Cruz Biotechnology Inc., Santa Cruz, CA), PPARγ 81B8, pIRβ Tyr 1150/1151,
PKCα #2056, phospho mTOR Serine 2481, PGC1α 3G6, PU.1 9G7, pAkt Ser473 #4058,
Adiponectin C45B10 (Cell Signaling, Boston, MA), GLUT4 C-Terminus 07-1404
(Millipore, Billerica, MA), β-actin A5441, anti-flag M2 (Sigma). PKCβII (NH2–(GC)
EGFSFVNSEFLKPEVKS-COOH), SRp40 (NH2-(GC) EVTFADAHRPKLNE-COOH),
and SRp55 NH2-(GC) GERVIVEHARGPRRDRD-COOH) were raised by BioSynthesis
Inc. (Lewisville, TX) and purified using Nab Protein A Plus Spin Kit (Pierce #89948).
Film bands were quantified using UnScan software (Silk Scientific, Orem, UT).
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Co-immunoprecipitation
3T3-L1 adipocytes were harvested with Cell Lysis Buffer (Cell Signaling #9803)
with added protease inhibitors (SigmaFast Protease Inhibitor Tablet, Sigma). 500μg cell
lysate was pre-cleared with 50μL Protein A Magnetic Beads #S1425S (New England
Biolabs, NEB, Ipswich, MA) for 1 hour 4oC with rotation. This step eliminated nonspecific binding of protein to magnetic beads. Lysate was separated from beads using
Magnetic Separation Rack (#S1506S, NEB). 5μg PKCβII antibody (sc-210, Santa Cruz)
or GLUT4 (sc-7936, Santa Cruz) was incubated with pre-cleared lysate O/N 4oC with
rotation. Lysates were now incubated with 50μL Protein A Magnetic Beads for 1 hour
4oC. Magnetic field was applied to separate beads from unbound lysate. Beads were
washed three times with cell lysis buffer. 75μL 2X Laemmli Buffer (Bio-Rad) with DTT
was added to the beads. Samples were boiled for 10 minutes and loaded onto a 10% SDS
PAGE gel.
Real-time PCR
Real-Time PCR reactions were performed using TaqMan Universal PCR
MasterMix (Applied Biosystems (AB) Inc., Foster City, CA, #4304437) according to
manufacturer′s protocol. Vic-labeled mouse β-actin was the endogenous control (AB,
#4352341E). PKCβII primers and probe were custom made from AB. Forward primer 5′
- GGAGATTCAGCCACCTTATAAACCA - 3′. Reverse primer 5′ GGTGGATGGCGGGTGAAAA - 3′. Fam-labeled probe (PKCβ2/PKCβ1 junction) 5′ TTCGCCCACAAGCTT - 3′. Real-Time PCR was analyzed on the ABI PRISM 7900HT
Sequence Detection System (AB).
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Glucose Uptake
[3H]2-deoxyglucose uptake into differentiated 3T3-L1 cells was measured in sixwell plates [411]. Briefly, cells were serum starved with DMEM high glucose for 4 h.
Media was then changed to 1mL Krebs-Ringer HEPES (121mM NaCl; 4.9mM KCl;
1.2mM MgSO4; 0.33mM CaCl2; 12mM HEPES, pH 7.4) ± CGP53353 (Novartis, Basel,
Switzerland) for 30 min ± 100nM pig insulin (Sigma) for 15 min. [3H]2-deoxyglucose
(1μCi per well) was added for another 4 min. The reaction was terminated by addition of
KRH with 25mM D-glucose (Sigma) containing 10μM cytochalasin B (Sigma). Cells
were washed, lysed with 0.1% sodium dodecyl sulfate, and radioactivity was counted
using a Beckman Coulter LS 6500 Multi-Purpose Scintillation Counter. Carrier-specific
uptake was obtained by subtracting nonspecific diffusion of [3H]2-deoxyglucose into the
cells in the presence of 10μM cytochalasin B. Counts were normalized to protein
concentration using the BCA protein assay (Pierce).
Subcellular Fractionation
Subcellular fractionation was performed essentially by the method of Elmendorf
et al. [412]. Three 25cm plates of cells were used per condition in order to generate
enough protein yield for the PM fractions. After treatment, cells were rinsed with
HEPES-EDTA-sucrose (HES) buffer. All subsequence steps were performed at 4oC.
Each plate was scraped in 2mL HES buffer with 1X protease (Sigma) and 1X
phosphatase (Sigma) inhibitors. This was followed by dounce homogenizing with 50
strokes using a Potter-Elvehjem grinder. The homogenate was centrifuged at 19,000 g
for 20 min. The resulting supernatant was centrifuged at 41,000 g for 20 min. The highdensity microsomal fraction (HDM) pellet was resuspended in HES buffer. The
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supernatant was centrifuged at 180,000 g for 75 min, yielding the low-density
microsomal (LDM) fraction pellet. The pellet from the initial 19,000 g spin was layered
onto 1.12M sucrose cushion in HES buffer and centrifuged 100,000 g for 60 min. This
yielded a white band at the interface [plasma membrane (PM) fraction] and pellet
consisting of nuclei/mitochondria (M/N fraction). The PM fraction was resuspended in
HES buffer and pelleted at 40,000 g for 20 min. Protein levels in each fraction were
quantified using the BCA protein assay (Pierce).
Plasma Membrane Sheet Assay
3T3-L1 cells were differentiated to day 8 on BD BioCoat Collagen Type I 8-well
CultureSlides. PM sheets were obtained using a modified protocol of Olson et al. [140].
Cells were swelled with three rinses of hypotonic buffer (23mM KCl, 10mM HEPES,
2mM MgCl2, 1mM EGTA [pH 7.5]). Swollen cells were sonicated and washed two
times with sonication buffer (70mM KCl, 30mM HEPES, 5mM MgCl2, 3mM EGTA,
1mM dithiothreitol, 0.1mM PMSF [pH7.5]). PM sheets were fixed with 2%
formaldehyde (70mM KCl, 30mM HEPES (pH7.5), 5mM MgCl2, and 3mM EGTA) at
room temperature 20 min. Fixed membranes were quenched 15 min at 25oC in 100mM
glycine-PBS (pH7.5). PM sheets were rinsed three times PBS and blocked 5% donkey
serum (Sigma) 4oC O/N. They were then incubated with GLUT4 C-20 (Santa Cruz
#1608) 1 hour, washed three times in PBS and incubated with donkey anti goat Alexa
Fluor 488 secondary antibody (Molecular Probes). PM sheets were washed three times in
PBS and incubated 15 min with Deep Red Cell Mask Plasma Membrane Stain
(Molecular Probes) as an internal marker of membrane amount. Stained PM sheets were
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visualized with Leica SP2 laser confocal microscope and analyzed using Leica Confocal
Software (Leica Microsystems Wetzlar GmbH, Germany).
GLUT4 Exofacial Loop Translocation/Fusion Immunofluorescence Assay
3T3-L1 cells were differentiated to day 8 to day 12 on BD BioCoat Collagen
Type I 8-well CultureSlides. This experiment was modeled after that of Yashamoti et al.
[413]. After treatment, cells were washed quickly with PBS buffer and fixed with 4%
formaldehyde 15 minutes room temperature. Cells were washed three times with PBS
and incubated O/N 4oC with goat GLUT4 N-20 antibody (sc-1606 , Santa Cruz) diluted
in 3% donkey serum. Cells were washed three times with PBS and incubated 45 minutes
with donkey anti-goat Alexa Fluor 594 (Molecular Probes) diluted in 3% donkey serum.
Cells were washed three times with PBS, dried completely and mixed with Vectashield
mounting media with DAPI (Vector Laboratories, Inc., Burlingame, CA) just before
coverglass application. Cells were imaged and analyzed as mentioned in the plasma
membrane sheet assay. Experiment was also attempted by incubating live cells with
primary antibody immediately after treatment for 30 minutes (with or without Cell Mask
Plasma Membrane Stain, Molecular Probes), fixing 15 minutes after treatment and then
incubating with secondary. This was done because even without detergent, GLUT4
antibody was penetrating the plasma membrane. However, even with these modification,
GLUT4 antibody was still able to penetrate the plasma membrane.
Immunofluorescence Measure of pAkt Ser473
3T3-L1 cells were differentiated to day 8 through day 12 on BD BioCoat
Collagen Type I 8-well CultureSlides. After treatment, cells were washed quickly with
PBS buffer and fixed with 4% formaldehyde 15 minutes room temperature. Cells were
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then blocked 60 min 1% BSA blocking solution with 0.05% saponin. Cells were then
incubated with pAkt Serine 473 Antibody (#4058, Cell Signaling) in blocking buffer 4oC
O/N. After washing three times with PBS, cells were incubated with combination of antirabbit Alexa Fluor 568 Secondary Antibody (#A11011, Molecular Probes), TO-PRO-3
nucleic acid stain (Molecular Probes) and RNase A (#19101, Qiagen) 45 minutes, room
temperature in the dark. The RNase A digested the RNA so only the DNA (thus the
nucleus) will show. Cells were washed five times for five minutes with PBS.
Vectashield mounting media without DAPI (Vector Labs) was applied. Approximately
10 arbitrary fields were pictured per condition. Experiment was repeated four times.
Images in figure were processed using Image J software. Z-stack series from each field
were stacked and shown as Z projection with maximum intensity.
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RESULTS
TZDs and Alternative Splicing (A) Hela Cells
TZDs are a class of drugs used for the treatment of non-insulin dependent
diabetes mellitus. The molecular target of these drugs is PPARγ. The main tissue target
is adipose, which has robust PPARγ expression. PPARγ activation in this cell type leads
to overall increased insulin sensitivity in peripheral insulin sensitive tissues. Insulin
resistance occurs despite qualitatively and quantitatively normal insulin receptors.
Therefore, the mechanism for increased glucose disposal lies downstream of the insulin
receptor [414]. Initial experiments focused on determining whether there was a link
between TZD treatment and increased alternative splicing of PKCβII, which had been
shown to be involved in mediating insulin-stimulated glucose uptake in skeletal muscle
cells [36; 40; 113]. The HeLa cervical cancer cell line was first tested. Cells were grown
to confluency and serum starved for 6 hours. Cells were either treated with 50nM of
bovine insulin or 1μM Pioglitazone for 24 hours. Pioglitazone was able to mimic the
effects of insulin (30 min) on PKCβ alternative splicing. Relative to control, both insulin
and Pioglitazone treated cells were able to regulate PKCβ such that PKCβI mRNA
decreased concomitant with increased PKCβII mRNA expression (Figure 23). This was
also novel in that it showed that HeLa cells expressed insulin receptors and that they were
insulin responsive.
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TZDs and Alternative Splicing (B) Vascular Smooth Muscle Cells
TZDs increase insulin sensitivity in insulin-resistant patients and animal models.
However, they also beget other benefits that may not be mutually exclusive to one
another. These benefits include lower blood glucose, decreased circulating free fatty
acids and triglycerides, lower blood pressure, reduced inflammatory markers, and
reduced atherosclerosis [313]. PPARγ is expressed in vascular endothelial cells and
vascular smooth muscle cells (VSMCs). Proliferation and migration of VSMCs are
essential in the progression of atherosclerosis. Inflammation is considered a key
stimulator of this proliferation and migration. PPARγ activation can suppress the
expression of TNFα-induced expression of inflammatory genes such as VCAM-1, MCP1 and fractalkine via inhibition of NFκB [415]. Yamamoto et al. has shown that PKCβII
expression is associated with decreased VSMC proliferation [41]. A possible link
between TZDs and PKCβII mediated effects on VSMCs was examined. Figure 24 shows
A10 rat VSMCs treated with 1μM Pioglitazone for 26 hours increased the mRNA
expression of PKCβII while decreasing the mRNA expression of PKCβI. However, A10
cells proved difficult to culture and synchronize. The focus turned to L6 rat skeletal
muscle cells which represent the main insulin responsive tissue responsible for glucose
disposal. These cells divide and differentiate rapidly making them an ideal cell line.
TZDs and Alternative Splicing (C) L6 Skeletal Muscle Cells
Skeletal muscle represents a major insulin-reponsive tissue where most glucose
disposal occurs. TZDs result in improved whole-body glucose disposal which includes
skeletal muscle [416]. However, it is unclear whether this effect on skeletal muscle is a
result of indirect actions such as lowering FFAs or TZDs can actually exert effects on
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skeletal muscle signaling. Thus, a possible link between TZDs and skeletal muscle
signaling was explored. Using L6 cells, 1μM Pioglitazone for 24 hours was able to
mimic 100nM bovine insulin for 30 minutes in terms of PKCβII mRNA expression
(Figure 25). When Pioglitazone and insulin were combined, there was a synergistic
increase in PKCβII mRNA expression. Protein expression of PKCβII revealed a similar
trend whereby 1μM Pioglitazone was able to mimic 45 or 60 minutes of 100nM bovine
insulin (Figure 26). SRp40 overexpression was also able to increase PKCβII expression.
Three SRp40 constructs were used. After this experiment, only the construct donated by
Dr. Rebecca Taub was used. This data is in concurrence with previous Cooper lab data
showing SRp40 enhancement of PKCβII alternative splicing [37; 38; 211]. RT-PCR
detection of PKCβI using primers for both PKCβI and PKCβII was sporadic and not
reliable.
PKCβII mRNA Regulated by Overexpression of PPARγ, PGC1α and SRp40
Since the main target of TZDs is PPARγ, overexpression of PPARγ was next
assessed along with overexpression of PGC1α and SRp40. PGC1α expression favors the
slow twich, oxidative muscle fiber type [372] and this fiber type has increased insulinstimulated glucose uptake [417]. Possible regulation of PKCβ via PGC1α would explain
the enhanced ability for glucose uptake muscles obtain during TZD treatment. As shown
in Figure 27, overexpression of PPARγ, PGC1α and SRp40 and combinations of the three
resulted in increased mRNA expression of PKCβII compared to control. The
combination of all three constructs may have been too much and thus created an
imbalance. This is maybe why there is a slight decrease in PKCβII levels compared with
combinations of two constructs.
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Functionality of PGC1α C-terminal Domain
PGC1α upregulation of PKCβII mRNA necessitated the question of which
domain was critical in mediating this effect. The C-terminal domain was thought to be
the critical effector because it provided the bridge between nuclear receptors and the
mediator complex as well as serving as a landing pad for splicing factors [361]. In fact,
SRp40 has been confirmed to bind PGC1α [362]. Figure 28 shows that overexpression of
CTD mutant PGC1α led to a decrease in PKCβII mRNA expression (compared with
control) versus wild-type PGC1α which resulted in an expected increase in PKCβII
mRNA in L6 cells.
TZDs Influence PKCβ Expression Level and Alternative Splicing
Since PGC1α is able to participate in both transcription and splicing, it seemed
reasonable that TZD treatment may work in a similar mechanism in relation to the PKCβ
gene. L6 cells were treated with either 1μM Pioglitazone or Rosiglitazone for 24 hours.
Both TZDs were able to increase the protein expression of PKCβII while keeping PKCβI
relatively constant (Figure 29). This suggested TZDs could influence transcription and
splicing preferentially selecting the PKCβII isoform. Rosiglitazone seemed to perform
even better than Pioglitazone in terms of PKCβII induction.
Hypothesis #1: TZDs Co-transcriptionally Regulate PKCβ Gene Expression
Data obtained up to this point led to the hypothesis that TZDs were able to cotranscriptionally regulate the PKCβ gene, thereby mimicking the insulin signaling
cascade (Figure 30). This would result in increased transcription as well as increased
alternative splicing that would favor the PKCβII isoform. This phenomenon would come
to fruition via TZD-mediated activation of PPARγ. PGC1α would bind PPARγ. Even
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though PPARγ does not have to be active to bind PGC1α, PPARγ activation would be
required for PKCβ promoter activation. PPARγ-bound PGC1α C-terminal domain would
serve as a landing pad for splicing factors that have a positive regulatory effect on
PKCβII exon inclusion. These splicing factors would eventually be dropped off to the
CTD of RNA polymerase II. Selective SR protein recruitment (e.g. SRp40) would result
in RNA polymerase II pausing at the weak PKCβII 3′ splice site (intronic sequence just
before PKCβII exon). This pause would result in enhanced recognition of the weak
splice site and thus greater PKCβII exon inclusion. TZD treatment could regulate factors
downstream of the insulin signaling pathway, bypassing upstream insulin signaling that
may be dysfunctional in the insulin-resistant or diabetic state.
Role of Overexpressed PPARγ on PKCβ Protein Levels
The ability of PPARγ overexpression to induce PKCβ co-transcripional splicing
was assessed. 1 or 3μg PPARγ cDNA construct was transfected into L6 cells for 72
hours. Figure 31 shows that PPARγ overexpression (regardless of dosage) was able to
increase protein expression of both PKCβI and PKCβII isoforms. However, this is not
the same mechanism of control as compared with TZD treatment. PPARγ expression
appears to exert more of a transcriptional effect on the PKCβ gene since PKCβI is
increased too. The ligand-dependent AF2 transcriptional activator domain appears to be
necessary for the increase in PKCβII protein levels. Overexpression of an AF2 mutated
PPARγ construct resulted in an increase in PKCβI protein expression but no increase in
PKCβII protein expression (Figure 32).
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Role of Overexpressed PGC1α on PKCβ Protein Levels
PGC1α overexpression was utilized to determine whether it could more closely
mimic the effects of TZD treatment in terms of PKCβ co-transcriptional splicing in L6
cells. As shown in Figure 33, PGC1α overexpression (both 2 and 4μg) mimicked TZD
treatment and resulted in increased PKCβII protein expression while PKCβI protein
expression was little changed. Establishing PGC1α overexpression was difficult. The
flag antibody did not work for this tagged protein and the endogenous PGC1α antibody
could barely be detected.
Effect of siRNA Knockdown of PPARγ, PGC1α and SRp40 on PKCβII mRNA
A knockdown strategy using 24 hour transfected siRNA was next employed to
determine whether endogenous levels of PPARγ, PGC1α or SRp40 are influential in
generating PKCβII. In Figure 34, knockdown of PPARγ and PGC1α resulted in reduced
PKCβII mRNA levels. In the case of PPARγ knockdown, PKCβII mRNA levels went
further down with 24 hour treated 1μM Rosiglitazone. However, this may be due to
experimental design. Since the drug was added near the time of transfection, the
transfection reagent may have reacted with Rosiglitazone causing a change in L6
signaling. Rosiglitazone treatment could not rescue PKCβII mRNA levels in PGC1α
knockdown cells. Figure 35 shows that SRp40 is necessary for PKCβII alternative
splicing. This had been predicted based on earlier Cooper lab data but had not been
shown with SRp40 siRNA. Again, Rosiglitazone treatment was unable to rescue PKCβII
mRNA levels most likely because of the same experimental design flaws described
above. Even Rosiglitazone with scrambled siRNA had no effect on PKCβII, suggesting
inhibition of the drug by the transfection reagent.
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Generation of Heterologous PKCβ Promoter-driven PKCβ Minigene
To determine whether PPARγ had a direct effect (via binding) on the PKCβ
promoter, a heterologous PKCβ minigene was created as outlined in the Experimental
Procedures section and illustrated in Figures 36-48. This ultimately resulted in a
minigene that had the BI and BII exons with sufficient flanking intronic sequences. In
addition, the minigene was under the control of 2243bp of the human PKCβ promoter.
Figure 48 shows that this PKCβ minigene was functional since transcriptional products
mimicked those of the CMV promoter construct. The BI and BII mRNA products were
confirmed by sequencing . The minigene was also shown to be responsive to 2nM
phorbol ester treatment (Figure 49). TPA activated the promoter and increased both BI
and BII products. GFP expression is used to assess transfection efficiency because its
expression is not governed by TPA treatment.
Effect of TZD on PKCβ Minigene
TZD treatment results in co-transcriptional splicing of endogenous PKCβ. To
assess if this effect was related to a direct effect on the PKCβ promoter, the minigene was
transfected for 48 hours and concomitantly the cells were treated with 1μM Pioglitazone
for 24 hours as seen in Figure 50. Pioglitazone was able to directly affect the PKCβ
promoter and increase alternative splicing. The result is dramatically increased BII
minigene product.
PPARγ-mediated PKCβ Transcriptional Regulation: Direct vs. Indirect?
Logical progression led to co-transfection of the minigene and PPARγ to assess
whether PPARγ may be able to bind to a putative PPRE on the PKCβ promoter. The
minigene construct without the PKCβ promoter co-transfected with PPARγ had no effect
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on either the BI or BII minigene products. Conversely, the minigene construct with the
PKCβ promoter co-transfected with PPARγ had a dramatic effect on both minigene
products (Figure 51). The only caveat of this experiment is that vector control was able
to increase the BI minigene product. This may be due to unintended effects of the control
vector on the PKCβ promoter. Still, PPARγ overexpression was able to elicit expression
of the BII minigene product. Compared with vector control, PPARγ decreased minigene
BI expression. This data indicates that PPARγ affects the PKCβ promoter and regulates
alternative splicing as well as transcription.
To test whether there was a direct binding between PPARγ and the PKCβ
promoter, the truncated PKCβ promoter minigene construct was utilized. Within the
upstream region of the PKCβ promoter insert, there is a putative DR2 PPRE as described
in Experimental Procedures. From bioinformatic analysis (Nuclear Hormone Receptor
Scan software), this putative PPRE was the most promising of the 2243 PKCβ promoter
sequence. The truncated PKCβ promoter construct lacked this DR2 PPRE. PPARγ was
co-transfected with both PKCβ promoter constructs. Figure 52 revealed that PPARγ was
not acting through this putative DR2 PPRE. Either PPARγ was acting on a more distal
PPRE or PPARγ was affecting the PKCβ promoter indirectly through regulation of other
transcription factor or coactivators.
Role of TZDs in 3T3-L1 PKCβII Expression
It was determined that the mouse 3T3-L1 pre-adipocyte cells might be a better
system for examining effects of TZDs on PKCβ co-transcriptional splicing in 3T3-L1
mouse pre-adipocyte cells. This cell model seemed a good candidate because during
differentiation into adipocytes, they express high levels of PPARγ which is the target of
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TZDs [418; 419; 420]. In addition, 3T3-L1 cells synthesize PPARγ agonists such as 15dPGJ2 [421] and a yet to be identified potent ligand that materializes at the onset of
differentiation, lasts 48 hours, then disappears [422]. Figure 53 a-d demonstrated 3T3-L1
differentiation (day 0 to day 6) using phase contrast microscopy. Figure 53 e-h depicted
accumulation of lipid droplets (red) from day 4 to day 6 via Oil Red O staining. Oil Red
O is a fat soluble dye (lysochrome) that stains triglycerides. The purpose of this stain
was to confirm differentiation protocol before proceeding to further experimentation.
The first experiment in 3T3-L1 cells focused on establishing a link between TZD
treatment and PKCβ co-transcriptional splicing based on the experiments performed in
L6 skeletal muscle cells. As depicted in Figure 54, differentiating 3T3-L1 cells at day 4
and 6 were chosen for TZD treatment. It was known that by day 4, copious amounts of
PPARγ were expressed. Because culture conditions had not yet been completely
established, both low and high glucose media were used. 1μM rosiglitazone for 24 hours
activated PPARγ. The evidence of this is that the level of PPARγ (both 1 and 2) decrease
with Rosiglitazone treatment. PPARγ activation via TZDs increased PPARγ proteasomal
degradation. This effect is not necessarily dependent on transcriptional activation but is
dependent on the AF2 domain [423].

PPARγ activation had no discernable effect on

either PKCβI or PKCβII protein levels on day 4 or day 6. However, there was a dramatic
change in the expression of PKCβ isoforms during the span of these two days. From day
4 to day 6, PKCβII expression increased over 6.6 fold while PKCβI expression was
reduced roughly 1.5 fold. This data was consistent with a report stating that the
expression of PKCβ (no isoform distinction) increased at least 10 fold from pre-
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adipocytes to adipocytes [419]. This appeared to be a novel finding which represented
developmentally regulated PKCβ co-transcriptional splicing.
Discovery of Novel Differentiation-regulated PKCβ Alternative Splicing in 3T3-L1
Cells
The experiment was repeated but included more days of differentiation. Figure
55 shows that again, 1μM Rosiglitazone failed to change the ratio of PKCβ isoforms
during differentiation even though PPARγ was being activated. But it was clear that
PKCβII was heavily induced during differentiation while PKCβI was concomitantly
decreased. PPARγ and GLUT4 both served as markers of adipocyte differentiation. This
experiment was again repeated (without TZD treatment) but probed for additional
proteins of interest. Figure 56 spans from day 0 to day 12. PKCβ was regulated as
before. PKCβII expression peaks at day 8 and then expression plateaus. PKCδ has a
similar expression pattern as PKCβII with very low levels at day 0, peaks at day 8 and
then plateaus. Longer exposures of the PKCδ blot revealed possible additional splice
variants. Seven splice variants have been reported in mice testis [424]. From the 20 sec
exposure, four putative PKCδ splice variants were visible. From the 15 min exposure,
the remaining three putative PKCδ splice variants were visible. Phospho PKCβII/δ
antibody probing was very interesting. This antibody detects the phospho epitope of
PKCβII S660 and PKCδ S662. The band displayed was almost certainly that of phospho
PKCδ. PKCβ was not expressed on day 0 and should not be phosphorylated regardless of
the day in the absence of external stimuli such as insuln. PKCδ has been reported to
undergo biphasic serum-mediated phosphorylation in fibroblasts [425]. PKCα peaked at
day 2 then tappers off. This was consistant with the literature which states that PKCα is
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downregulated during adipogenesis [426]. PKCγ also has a similar expression pattern to
that of PKCβII. However, its expression was very low in the early days with a dramatic
jump from day 6 to day 8. After day 8, there was a precipitous fall in PKCγ expression.
Initially, PKCγ was reported to be only in the brain and spinal cord [11]. However, a
recent paper has described PKCγ expression in 3T3-F442A cells [48]. We believe this to
be the first report of PKCγ expression in 3T3-L1 cells. PKCζ expression steadily
increased during adipogenesis peaking at day 6, afterwhich is precipitously drops. This
pattern is similar to that described by Ways et al.[426]. PPARγ, GLUT4 and adiponectin
are used as markers of differentiation. β-actin indicates relatively equal loading.
Real-Time PCR Confirms PKCβII Adipogenesis Protein Expression Patterns
Real-Time PCR following the mRNA expression pattern of PKCβII during
adipogenesis revealed a similar expression profile to protein with a peak at day 6 then
plateauing (Figure 57). Real-Time PCR was also performed using primers specific for
PKCβI but this was unsuccessful. Hence, PKC isozyme-specific expression, with peaks
of PKCβII, PKCγ and PKCδ, were a hallmark of adipocyte differentiation.
Use of Distal PKCβII polyA Tail During 3T3-L1 Differentiation
The PKCβII mRNA transcript has two possible polyA tails to use as reported
[427] and illustrated in Figure 5. To determine which polyA tail was used by adipocytic
PKCβII, RT-PCR was performed with indicated primers (Figure 58) that distinguish
polyA tail usage. RNA was collected from both day 0 and day 8 3T3-L1 cells. Only the
PKCβII transcript containing the distal polyA tail showed up. GAPDH is a housekeeping
gene used as a loading control and PPARγ indicates adipocyte differentiation.
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Hypothesis #2: PKCβII Can Regulate GLUT4 Expression
Previous Cooper lab data had shown that knockdown of PKCβII in L6 skeletal
muscle cells resulted in reduced GLUT4 protein expression levels (unpublished). In 3T3L1 cells, PKCβII and GLUT4 expression appear at roughly the same time. It was thought
that PKCβII may regulate GLUT4 expression.
To test this hypothesis, knockdown of PKCβII would be necessary. Transfection
of one of two PKCβII specific silencer select siRNA was attempted using siRNA
transfection reagents from Ambion (siPORT NeoFX), Mirus Bio (TransIT-TKO) and
Panomics (DeliverX Plus). In the case of DeliverX Plus, this reagent is supposedly
tailored for differentiated 3T3-L1 adipocytes. However, none of the above reagents gave
any significant knockdown of PKCβII (Figure 59).

Further research into the literature

revealed that differentiated 3T3-L1 adipocytes are notoriously difficult to transfect if not
impossible [428; 429]. Electroporation is also not feasible for this cell line with very low
efficiency and low cell survival. Lentiviral transduction has been reported to have
success [430]. However, there is only one available construct for the PKCβII. Due to
this uncertainty, this aim was put on hold.
Regulation of PKCβ Promoter During 3T3-L1 Differentiation
Differentially regulated PKCβ alternative splicing suggests an important role for
PKCβII in adipogenesis and adipocyte function. Therefore, the factors that regulate this
differential alternative splicing necessitated further inspection. The mouse PKCβ
promoter was examined for putative transcription factors that also had expression
patterns similar or opposite (for negative regulators) to those of PKCβII during
adipogenesis. Figure 60 shows RT-PCR of RNA samples from day 0 to day 6 for factors
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that had their respective consensus binding sites on the PKCβ promoter. AP2, also
known as fatty acid-binding protein 4 (FABP4), is responsible for fatty acid transport in
adipocyte. It is a marker of terminal adipocyte differentiation. It can also influence
transcription. Interestingly, FABP4 can cooperate with PPARγ to regulate gene
expression [431]. GATA1 is a transcription factor that can inhibit PU.1 transcriptional
activity [432]. GATA2 (assayed for later) and GATA3 are transcription factors known to
inhibit adipocyte differentiation [433]. Surprisingly, GATA3 expression goes up even
though it is supposed to inhibit differentiation. hnRNP G can influence alternative
splicing [434] and is downregulated at least ten fold from the pre-adipocyte to adipocyte
stage [419]. RUNX1 is a transcription factor that was reveal by a chromatin
immunoprecipitation screen to bind the human PKCβ promoter [435]. MZF-1 is a
transcription factor belonging to the Kruppel family of zinc finger proteins [436].
Figure 61 shows RT-PCR and protein expression of PU.1. PU.1 was considered
the most promising transcription factor due its many putative consensus binding sites
blanketing the PKCβ promoter as well as its confirmed role in bridging transcription and
splicing [405]. PU.1 has been reported to inhibit the differentiation of 3T3-L1 cells in
concert with GATA2. However, this was done using overexpression systems which may
indicate threshold dynamics. In this same paper, PU.1 mRNA and protein expression
were shown to increase over the course of differentiation which is consistent with data
shown in Figure 61 [437]. Also shown in Figure 61 is the protein expression of SRp40, a
splicing factor that could possibly contribute to PKCβ alternative splicing during
adipogenesis based on its role in L6 skeletal muscle cells [37; 38; 211]. SRp55, another
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splicing factor that is regulated by insulin [38], may influence PKCβ alternative splicing
(unpublished).
Using the Chromatin Immunoprecipitation assay, PU.1 is shown to bind the 3T3L1 PKCβ promoter at various spots at both day 0 and day 8. SRp40 seems to also display
affinity for the PKCβ promoter (Figure 62). This led to a third hypothesis.
Hypothesis #3: Developmental Regulation of PKCβ Splicing by PU.1
PU.1 would be able to bind the PKCβ promoter during the course of 3T3-L1
adipocyte differentiation and influence the developmental regulation of PKCβ alternative
splicing. It would accomplish this by recruiting coactivators (while simultaneously
displacing corepressors), which would then bind splicing factors such as SRp40 that
would ultimately result in the PKCβII exon inclusion.
The next step would have been to knockdown PU.1 during differentiation and
assess PKCβ mRNA and protein levels. However, due to the extreme difficulties in
transfecting differentiated 3T3-L1 cells (as mentioned above), this aim was postponed.
Linking PKCβII with 3T3-L1 Adipocyte Insulin-stimulated Glucose Transport
At the same time, the possibility of PKCβII regulation of glucose uptake in 3T3L1 adipocytes, was being explored. Previous studies show that PKCβII was critical in
mediating glucose uptake in skeletal muscle cells, another insulin-sensitive tissue [40].
CGP53353 is an inhibitor of cPKCs with greatest affinity for PKCβII (see Table 7). It
was anticipated that the inhibitor might provide evidence of a role for PKCβII in 3T3-L1
adipocyte ISGT. Figure 63a is a dose curve showing 50μM CGP53353 attained an 85%
inhibition of ISGT compared to insulin alone in 3T3-L1 adipocytes day 8 to day 12.
Figure 63b shows this 50μM dose within a complete experiment with control and drug
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control. CGP53353 inhibited ISGT over 6 fold compared to insulin alone. Drug alone
had no effect on basal glucose uptake levels compared with control. In addition to this,
LY379196, another PKCβ selective inhibitor, was used. Figure 64a is a dose curve
showing that LY379196 (with insulin) can inhibit ISGT at 50μM. Next, both 25 and
50μM LY379196 were able to significantly inhibit ISGT (3 fold and ~4.3 fold
respectively) with no effect on basal glucose uptake (Figure 64b).
CGP53353 Specificity
A kinase assay via western blot was next pursued to affirm that CGP53353 was
specifically inhibiting PKCβII and not other critical insulin signaling effectors. Figure 65
shows that insulin caused phosphorylation of both PKCβII S660 and insulin receptor
Y1150/1151. Only PKCβII S660 phosphorylation is inhibited with drug. The antibody
targeting PKCβII also targets phospho PKCδ S662 (thick lower band). Phospho PKCδ
migrates at 78kDa on the gel whereas phospho PKCβII migrates at 80kDa on the gel.
Large gels were run longer in order to obtain reasonable separation between the two
bands. The phosphorylation status of PKCδ, PKCζ and the insulin receptor were
unaffected by the drug. Total PKCβII levels remained constant. This led to the last
hypothesis.
Hypothesis #4: PKCβII Regulates 3T3-L1 Adipocyte ISGT in Part via GLUT4
Trafficking or GLUT4 Fusion
PKCβII′s ability to regulate ISGT in adipocytes was likely due to an effect on
GLUT4 translocation or late-stage GLUT4 fusion. The rationale behind this was a report
demonstrating the ability of PKCβII to phosphorylate Akt at S473 [438]. Fully active
Akt is required for late stage GLUT4 translocation [184]. Also, in 3T3-L1 adipocytes,
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PLD1 mediates GLUT4 fusion to the PM [141]. PKCβII (not PKCβI) has been shown to
bind and activate PLD1. PLD1 activity caused PKCβII (not PKCβI) to translocate to a
juxtanuclear subset of recycling endosomes (presumably where GLUT4 is located) [439].
In skeletal muscle cells, PLD1 membrane localization is regulated via insulin-stimulated
PKCβII [113].
Subcellular Fractionation Points to a Role for PKCβII in GLUT4 Translocation
To test whether GLUT4 translocation was being affected by CGP53353
inhibition, subcellular fractionation assays were performed. As shown in Figure 66,
insulin caused a redistribution of GLUT4 from the low-density microsomes (LDM) to the
plasma membrane (PM). Without insulin stimulation, GLUT4 remained in the LDM.
Addition of CGP53353 dramatically blocked insulin-stimulated GLUT4 translocation to
the PM. Cytoplasmic fractions were also western blotted and probed for β-actin to show
that protein concentrations measured by the BCA protein assay were accurate. It also
shows that cell death was not responsible for the trends observed. Numerous other
proteins were tested as internal controls of protein loading. For the PM fraction, insulin
receptor, TNFα Receptor 1 & 2, APMAP (adipocyte plasma membrane associated
protein) were tested. For the LDM fraction, IRS1 levels were tested. However, insulin
and/or CGP53353 treatment affected the expression and/or stability of these proteins and
thus they could not be used as controls. In addition to cell surface GLUT4,
phosphorylated GLUT4 was assessed by probing the PM fraction for pGLUT4 S488
(Santa Cruz). Earlier reports indicated that PM GLUT4 C-terminal phosphoserine is
reduced in insulin-stimulated rat adipocytes. This has led to speculation that
phosphorylation of the GLUT4 C-terminus may actually inhibit its intrinsic activity
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[440]. We were interested to see if PKCβII inhibition altered GLUT4′s phosphorylation
status and likely its folding/binding partners. However, we were unable to detect any
phospho GLUT4. This was also the case in whole cell lysate. Other methods are needed
to increase antibody sensitivity.
PM Sheet Assay Affirms a Role for PKCβII in GLUT4 Translocation
A second method was sought to definitively link PKCβII to GLUT4 translocation.
The PM sheet assay (Figure 67) reveals a similar trend to that of subcellular fractionation
in 3T3-L1 adipocytes day 8 to day 12. Insulin treatment illuminated GLUT4 staining
(Figure 67b). However, this staining was abrogated (~3.8 fold) when treated with
CGP53353 (Figure 67d). Staining with Deep Red Cell Mask Plasma Membrane Stain
shows relatively equal PM protein content (Figure 67e-h). The merger of insulinstimulated GLUT4 can be seen with PM proteins (Figure 67j). Hence, PKCβII is likely
regulating adipocyte ISGT through regulation of GLUT4 translocation.
In addition to regulating GLUT4 translocation, PKCβII was believed to regulate
GLUT4 fusion to the PM. This was because PKCβII can bind and activate PLD1 which
is responsible for insulin-stimulated GLUT4 fusion to the PM [19; 141].
Immunofluorescence was used to measure GLUT4 that had fused to the PM. When
GLUT4 is fused to the membrane, there is a large exofacial N-terminal loop that
protrudes into the extracellular space (Figure 11). Santa Cruz Biotechnology has an
antibody that recognizes this exofacial loop. The protocol for this experiment was based
on that performed by Fulcher et al. [413] (Experimental Procedures). Formaldehyde
fixed cells were incubated with the antibody with no permeabilizing detergents.
However, the antibody was still able to penetrate the PM and stain the entire cell.
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Despite this, there was a suttle trend. Insulin was often able to aggregate GLUT4 near
the nucleus, possibly the perinuclear region where GLUT4 resides before translocating to
the PM in an insulin-dependent manner (Figure 68b). CGP53353 treatment prevented
this formation resulting in a more dispersed localization around the nucleus (Figure 68d).
PKCβII (and possibly other cPKCs) may have a role in basal state and insulin-stimulated
GLUT4 intracellular trafficking. Bioinformatic analysis of GLUT4 protein sequence
revealed a putative PKC phosphorylation site beside the C-terminal insulin-responsive
motif (IRM), LXXLXPDEX(D/E). The GLUT4 IRM has been shown to be crucial for
insulin-stimulated GLUT4 redistribution to the PM [441]. Another attempt to use
immuno-fluorescence was made by first incubating the live pre-formaldehyde fixed cells
with the GLUT4 antibody followed by fixation (fixation was also attempted after
secondary antibody). The antibody was still able to penetrate the PM. Primary or
secondary antibodies that are bulkier must be made in order to perform this assay. The
GLUT4 exofacial loop can be glycosylated (Figure 11). N-glycosylation at this site
(possibly mediated by Golgin-160) may be necessary for ISGT [442]. It is possible that
the antibody was made to recognize only the unglycosylated loop. This would mean a
new antibody that recognizes that glycosylated loop would have to be raised and
developed.
PKCβII Regulation of Akt Activity
As mentioned earlier, activated Akt is required for GLUT4 translocation [184].
PKCβII has been shown to regulate Akt S473 (S473) phosphorylation in a cell and
stimulus-specific manner [438]. To that extent, we investigated whether PKCβII could
regulate Akt activity in 3T3-L1 adipocytes. Insulin treatment induced the dramatic
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appearance of T308 and S473 phosphorylation (Figure 69). CGP53353 treatment
decreased S473 phosphorylation over 17 fold. Phosphorylation of T308 remained
relatively constant with CGP53353 treatment. This was consistent with the literature
where T308 is regulated by PDK1 (via insulin) and S473 is regulated by a separate PDK2
(possibly PKCβII) and that S473 phosphorylation is not dependent on T308
phosphorylation [174; 175; 229]. It is important to note that PKCβII may be regulating
phosphorylation of mouse Akt1 at S473, Akt2 at S474, Akt3 at S472 or any combination
thereof since this antibody recognizes the phosphorylated hydrophobic motif of all three
Akt isoforms. From here on, Akt phosphorylation at the hydrophobic motif will be
referred to as Akt S473 since the antibody was labeled as phospho Akt S473.
Immunofluorescence Confirms Role for PKCβII in Phosphorylation of Akt S473
To confirm PKCβII as a possible PDK2 that regulates Akt S473 phosphorylation,
immunofluorescence was performed on 3T3-L1 adipocytes from day 8 to day 12. Insulin
stimulated dramatic staining of phospho Akt S473 (Figure 70b) as expected. PM staining
as well as intracellular aggregation staining near the nucleus was apparent. Treatment
with CGP53353 eliminated staining of phospho Akt S473 (Figure 70d). DAPI staining
for nuclei could not be used because the short wavelengths caused high background
fluorescence of CGP53353 drug. TO-PRO3 was used to avoid this problem with an
emission spectrum around 633nm. TO-PRO3 stains nucleic acid, DNA and RNA. In
order to select for DNA (nucleus), incubation of TO-PRO3 was performed along with
RNaseA treatment (Figure 70e-h).
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PKCβII Downstream of mTORC2 but Upstream of Akt
The mTORC2 complex was shown by Sarbassov et al. to regulate
phosphorylation of Akt S473 [174]. Phosphorylation of mTOR kinase at S2481
distinguishes activated mTORC2 from mTORC1 [61]. However, it is known that
mTORC2 is also responsible for phosphorylation of PKCβII/PKCα at the turn motif
which allows the kinases to undergo autophosphorylation at the hydrophobic motif [54;
55]. This suggested that PKCβII is activated by mTORC2 and then goes on
phosphorylate Akt S473, thus fully activating Akt. Figure 71 shows insulin stimulated
mTORC2 activation via phosphorylation of mTOR S2481. Insulin has been shown to
similarily activate mTORC2 in HEK293 cells [61]. CGP53353 treatment did not alter the
phosphorylation status of mTOR S2481. This indicated that PKCβII was likely
downstream of mTORC2.
Integrating the role of mTORC2 represented a more mechanistic overview of how
PKCβII was exerting its effects. Before mTORC2 was pursued, another promising
putative PKCβII substrate was examined. PLD1 is critical in 3T3-L1 adipocyte ISGT by
enabling fusion of GLUT4 to the PM [141]. PKCβII is capable of phosphorylating and
activating PLD1 [19]. Using two commercial antibodies for both PLD1 and phospho
PLD1, detection was attempted by western blotting whole cell lysates, western blotting
PM and cytosolic fractions and immunofluorescence. An in vitro PLD1 activity assay
(Amplex Red, Invitrogen) was also performed. None of these experiments could detect
PLD1 or its activity. This could have been due to low abundance of PLD1 or low PLD1
anitgenicity or low stoichiometric activity.
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Insulin-stimulated Binding of PKCβII to mTORC2
Data from Figure 71 showed that PKCβII (using Santa Cruz antibody for IP
which is different than the custom made PKCβII antibody used in Figures 56 & 65) was
likely being activated by mTORC2 before having the capability to phosphorylate Akt
S473. Co-immunoprecipitation showed that insulin stimulated direct binding between
PKCβII and mTORC2 (Figure 72 lane 3). This binding was dramatically reduced by
CGP53353-mediated inhibition of PKCβII (lane 5). Immunoblotting for PKCβII with the
same antibody used for co-immunoprecipitation was unsuccessful. Several additional
antibodies were utilized without success including a mouse PKCβII antibody (Sigma
P2584) and a mouse PKC antibody (PKC A-9 Santa Cruz #17804) that recognizes all
PKC isoforms. Perhaps PKCβII is extremely sensitive to degradation or antigenicity is
severely reduced upon cell lysis.
Insulin-stimulated Binding of PKCβII to Akt
Figure 73 provides preliminary evidence that PKCβII is able to bind Akt. PKCβII
co-immunoprecipitates with Akt that is phosphorylated at S473 suggesting that PKCβII
could be the kinase that directly phosphorylates Akt at S473. The membrane was
reprobed with PKCβII. This was unsuccessful due to reasons discussed. The conditions
for the reverse co-immunoprecipitation are being worked out.
Co-immunoprecipitation Between PKCβII and GLUT4
Co-immunoprecipitation was performed to assess possible binding of PKCβII to
GLUT4. As mentioned earlier, bioinformatic analysis indicated multiple PKC substrate
sites spanning murine GLUT4. Akt had been shown to bind GLUT4-containing vesicles
and then phosphorylate their component proteins in response to insulin [182]. It was
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hypothesized that PKCβII could act in a similar fashion. Figure 74 shows that IP with
PKCβII resulted in increased GLUT4 band intensity compared to rabbit IgG control.
However, probing for PKCβII (after IPing with PKCβII) yielded nothing, which was
expected. IP with GLUT4 antibody was able to pick up PKCβII and this was stimulation
independent. GLUT4 band intensity for this was weak but still slightly higher than IgG
control. Whole cell lysate probing for GLUT4 using the specified antibody was
unsuccessful. This was unexpected for GLUT4 and is probably due to using an antibody
different than the one used on other blots. Repeating this assay yielded similar results.
This experiment still leaves open the possibility that PKCβII is able to directly influence
insulin-stimulated GLUT4 trafficking, possibly through phosphorylation of vesicle
component proteins in addition to regulating Akt activity.
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Figure 23. TZD Pioglitazone mimics insulin’s effect of increased
PKCβII exon inclusion in HeLa cells. HeLa cells were grown as
described and serum starved for 6 hours. Cells were treated with
either 50nM bovine Insulin (15 or 30 minutes) or 1μM Pioglitazone
22 hours. Total RNA was extracted followed by RT-PCR using the
endogenous PKCβII-PKCβI primers (compatible with rat). Samples
were run on a PAGE gel and silver stained. Experiment was
repeated twice.
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Figure 24.
Pioglitazone increases PKCβII exon
inclusion in A10 vascular smooth muscle cells. A10 cells
were grown as described and serum starved for 48 hours.
26 hours prior to harvesting, cells were treated ± 1μM
Pioglitazone 26 hours. Total RNA was extracted followed
by RT-PCR using the endogenous PKCβII-PKCβI primers
or β-actin primers. Samples were run on a PAGE gel and
silver stained.
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Figure 25. Pioglitazone combined with insulin synergistically increases PKCβII exon
inclusion in L6 skeletal muscle cells. L6 skeletal muscle cells were grown as described and
serum starved 6 hours prior to treatment with 100nM bovine insulin (15 or 30 minutes). For
wells treated with 1μM Pioglitazone 24 hours, treatment began 24 hours before harvesting.
Pioglitazone was re-added to appropriate wells during serum starvation. (a) Total RNA was
extracted followed by RT-PCR using the endogenous PKCβII-PKCβI primers (compatible with
rat). Samples were run on a PAGE gel and silver stained. (b) Graphical representation of
PKCβII mRNA expression in arbitrary scan units derived from pixels. Experiment was repeated
twice.
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Figure 26. Pioglitazone treatment and SRp40 overexpression mimic insulin’s upregulation of PKCβII protein
levels. (a) L6 skeletal muscle cells were grown as described and serum starved for 6 hours. Cells were either treated
with 100nM bovine insulin (15, 30, 45 or 60 minutes), treated with 1μM Pioglitazone 24 hours (re-added after serum
starvation) or transfected with 1.6μg SRp40 (constructs). Protein was harvested and western blot performed. (b)
Graphical representation of PKCβII protein levels in arbitrary units.
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Figure 27. Overexpression of PPARγ, PGC1α and SRp40 individually or in combination are
able to increase PKCβII protein expression. (a) L6 skeletal muscle cells were transfected with
2ug of either PPARγ, PGC1α or SRp40 (name construct for SRp40) for 48 hours. Total RNA was
extracted followed by RT-PCR using PKCβII only primers or β-actin primers. Samples were run
on a PAGE gel and silver stained. (b) Graphical representation of PKCβII protein levels in
arbitrary units.
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Figure 28. CTD of PGC1α is necessary for PKCβII exon inclusion. L6 cells were transiently transfected with
transfection reagent alone, 2μg PPARg, PGC1-a, or PGC∆CTD for 48 hours as indicated above. (a) Total RNA was
extracted followed by RT-PCR using endogenous PKCbII specific primers. PCR for b-actin serves as an internal
control. (b) Graphical representation of PKCβII mRNA expression in arbitrary units.
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Figure 29.
TZDs Rosiglitazone and Pioglitazone stimulate PKCβ cotranscriptional splicing. (a) L6 skeletal muscle cells were treated with either
DMSO vehicle control, 1μM Rosiglitazone or 1μM Pioglitazone for 24 hours.
Protein was harvested and western blot was performed. Experiment was repeated
two times. (b) Graphical representation of PKCβII/PKCβI protein levels in arbitrary
units.
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Figure 30. Hypothetical model of TZD mechanism. Pioglitazone would activate PPARγ, allowing it to bind to the PKCβ PPRE.
PPARγ would recruit PGC1α which would then serve as a landing pad for SRp40 and other splicing factors, thereby influencing the
alternative splicing of PKCβ.
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Figure 31. PPARγ overexpression increases both PKCβI and PKCβII protein levels. (a) L6 skeletal
muscle cells were transfected with either 3μg vector control, 1μg PPARγ, or 3μg PPARγ for 72 hours. Whole
cell lysate was run on gel for western blot detection. Experiment was repeated two times. (b) Graphical
representation of PKCβII/Actin protein levels in arbitrary units. (c) Graphical representation of PKCβI/Actin
protein levels in arbitrary units.

139

(a)

VC
PPARγ
E499Q

-

+
-

+
-

+

IB:
PKCβII
PKCβI
Flag
β-actin

(c)

0.8

3
PKC I/Actin

2
1

0.4
0.2

Q
E
49
9


R

PP
A
R

PP
A

VC

E
49
9
PP
A
R

PP
A

R



Q

0.0

VC

C
on
tr
ol

0

0.6

C
on
tr
ol

PKC II/Actin

(b)

4

Figure 32. Ligand-binding domain is necessary for PPARγ mediated upregulation of PKCβII protein levels.
(a) L6 skeletal muscle cells were transfected with either 2μg vector control, PPARγ or mutant PPARγE499Q for
72hrs. Protein was harvested and western blot was performed. PPARγE499Q is a mutant in the AF2 domain. It
binds PPARγ ligands with comparable affinity as wild-type, but no ligand-dependent transcriptional activation. (b)
Graphical representation of PKCβII/Actin protein levels in arbitrary units. (c) Graphical representation of
PKCβI/Actin protein levels in arbitrary units.
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Figure 33. PGC1α overexpression mimics TZD stimulation of PKCβII co-transcriptional
splicing. (a) L6 skeletal muscle cells were transfected 72 hours with 4μg vector control, 2 or
4μg PGC1α. Whole cell lysate was run on gel for western blot detection. Experiment was
repeated two times. (b) Graphical representation of PKCβII/PKCβI protein levels in arbitrary
units.
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Figure 34. PPARγ or PGC1α knockdown reduces basal PKCβII mRNA. L6 skeletal muscle cells were transfected
with 10nM of either scrambled siRNA, PPARγ siRNA or PGC1α siRNA for 24 hours and concomitantly treated ± 1uM
Rosiglitazone for 24 hours. (a) Total RNA was harvested followed by RT-PCR using specified primers. PKCβII was
detected using primers that detected endogenous PKCβII & PKCβI. (b) Graphical representation of PKCβII protein
expression levels in arbitrary units.
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Figure 35. SRp40 knockdown results in lower basal PKCβII protein levels. L6 skeletal muscle cells were
transfected with 10nM scrambled siRNA or SRp40 siRNA for 24 hours and concomitantly treated ± 1uM Rosiglitazone
for 24 hours. (a) Total RNA was harvested followed by RT-PCR. PKCβII was detected using primers that detected
endogenous PKCβII & PKCβI. (b) Graphical representation of PKCβII protein expression levels in arbitrary units.
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Figure 36. PCR on rat genomic DNA. PCR yielded the PKCβII and PKCβI exons with their respective flanking intronic
sequences.
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Figure 37. The BII-BI fragment digested and inserted into the pTNT cloning vector.
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Figure 38. pCMVTNT vector used for mammalian cell expression.
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Figure 39. BII-BI fragments cloned into pCMVTNT vector for mammalian cell expression.
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Figure 40. Multiple minigene products. L6 skeletal muscle cells were transfected for 48 hours 0.7ug GFP or 2ug CMVTNT BIIBI ss3 (Mss3) and treated ± 100nM bovine insulin for indicated time points. RNA was extracted followed by RT-PCR using
CMV_FP1 and CMV_RP1 primers. Product prediction to the right represents best guess. BII* represents a possible BII product with
an additional splice site(s) or has a cryptic splice site.
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Figure 41. Chimeric intron removed. Chimeric intron removed from the CMVTNT BII-BI clones via digestion.

149

pCMVTNT
vector

3’ss 5’ss
BbsI

BP

βII

3’ss
BP

βI

XbaI

5’ss
CMV
promoter

XbaI

BbsI

Poly-A

AMPr
Figure 42. PCR generates BII-BI fragment with different overhangs. PCR was performed on CMVTNT BII-BI clones
to lift out the BII-BI fragments with BbsI restriction site on the 5′ end and a XbaI restriction site on the 3′ end. These were
then inserted into the CMVTNT vectors missing their chimeric introns.
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Figure 43. Predicted splicing events from CMVTNT BII-BI ss1 clone (-CI). Two main hypothetical products, BII (top right) and
BI (bottom right) are shown from CMVTNT BII-BI ss1 clone without chimeric intron (-CI).
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Figure 44. Products observed after transfection of CMVTNT BII-BI clones. L6 skeletal muscle cells were
transfected with 0.7ug GFP ± 1.5ug pCMVTNT (-CI) BII-BI ss1 (Mss1) or pCMVTNT (-CI) BII-BI ss4 (Mss4). In
addition each well was serum starved and treated with 100nM bovine insulin 60 min. Total RNA was extracted
followed by RT-PCR using CMV_FP1& B1R3 primers. 54oC or 52oC was used as the annealing temperature.
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Figure 45. Cloning ss4 fragment into ss1 vector. BamHI site was removed from the original pCMVTNT vector. BIIBI ss1 was re-cloned into the pCMVTNT vector, again losing the chimeric intron. Now, the ss4 fragment was lifted out
via PCR and inserted into the pCMVTNT BII-BI ss1 vector.
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Figure 46. Replacing CMV promoter with human PKCβ promoter. Human PKCβ promoter was lifted
out from another a Luciferase vector using PCR and then cloned into the pCMVTNT (-BamHI, -CI) BII-BI
ss4 vector.
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Figure 48. PKCβ promoter-driven expression of BII and BI minigene products. L6 skeletal
muscle cells were transfected with either 2μg CMVTNT (-)BamHI BII-BI ss4 or βprom 2243 BIIBI ss4 for 48 hours. RNA was harvested and RT-PCR was performed for both PKC beta minigene
products using CMV_FP1 and CMV_RP1 primers. Product legend is shown to the right. Product
identity was confirmed by sequencing.
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Figure 49. TPA induces transcription of PKCβ promoter minigene. L6 skeletal muscle cells were
transfected with GFP expression vector ± βprom 2243 BII-BI ss4 vector for 48 hours. Additionally, one
plate was treated for 24hrs with 2nM TPA (phorbol ester) dissolved in ethanol. (a) Total RNA was
extracted followed by RT-PCR using T7flgFP5 & CMV_RP1 primers. PCR for GFP shows transfection
efficiency. (b) Graphical representation of BII expression in arbitrary units. (c) Graphical representation of
BI expression in arbitrary units.
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Figure 50. TZD induces co-transcriptional splicing of minigene. L6 skeletal muscle cells transfected with βprom 2243 BII-BI ss4 vector
for 48 hours and were treated with either DMSO solvent control (24hrs) or 1uM Pioglitazone (24hrs). (a) RNA was harvested followed by
RT-PCR using CMV_FP1 & B1R3 primers. GFP was a measure of transfection efficiency. (b) Graphical representation of BII expression
in arbitrary units. (c) Graphical representation of BI expression in arbitrary units.
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Figure 51. PKCβ promoter responsive to PPARγ overexpression. L6 skeletal muscle cells transfected 48
hours with 0.5μg GFP ± either 2.5μg CMVTNT BII-BI ss4 or 2.5μg Bprom 2243 BII-BI ss4 ± 1μg PPARγ or
1μg vector control. RNA was harvested followed by RT-PCR using CMV_FP1 & B1R3 primers.
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Figure 52. PPARγ does not target putative DR2 on PKCβ promoter of minigene. L6 skeletal muscle
cells were transfected with GFP, ± βprom 2243 BII-BI ss4 or βprom 1143 BII-BI ss4 ± 2μg PPARγ. (a)
Total RNA was extracted followed by RT-PCR using CMV_FP1 & B1R3 primers. GFP shows transfection
efficiency. (b) Graphical representation of BII expression in arbitrary units. (c) Graphical representation of
BI expression in arbitrary units.
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Figure 53. 3T3-L1 differentiation. (a-d) Phase contrast of 3T3-L1 differentiating cells from day 0 to day 6. (e-h) Oil red O
staining of 3T3-L1 differentiating cells from day 0 to day 6.
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Figure 54. PKCβ splicing is developmentally regulated. 3T3L1 pre-adipocyte cells were cultured in
DMEM high (4.5g/L) or low (1g/L) glucose for 4 or 6 days and treated ± 24 hours with 1μM Rosiglitazone.
(a) Whole cell lysate was extracted followed by Western blot analysis. (b) Graphical representation of
PKCβII protein expression in arbitrary units. (c) Graphical representation of PKCβI protein expression in
arbitrary units.
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Figure 55: Rosiglitazone has no effect on developmentally regulated
PKCβ splicing. 3T3L1 pre-adipocyte cells were cultured in DMEM low
glucose (1g/L) for 0 to 8 days treated ± 24hrs with 1μM Rosiglitazone.
Whole cell lysate was extracted followed by Western blot analysis.
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Figure 56. 3T3-L1 PKCβ (and other PKC isoform) protein expression during differentiation. (a) 3T3-L1 pre-adipocytes were
differentiated from day 0 through day 12. Whole cell lysates (50μg protein) from each day were run on an SDS-PAGE gel and probed with
the indicated antibodies via western blotting. Experiments were repeated three times. (b) Graphical representation shows PKCβII/actin,
where * represents a statistically significant increase in PKCβII protein level as compared with day 0 using arbitrary units. (c) Graphical
representation of PKCβI/actin, where* represents a statistically significant decrease in PKCβI protein level as compared with day 0 using
arbitrary untis. Unpaired t-test (p<0.05) was performed using Prizm5 (GraphPad Software, Inc., LaJolla, CA, USA).
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Figure 57. Differentiating 3T3-L1 PKCβII mRNA expression mimics protein expression. 3T3-L1 preadipocytes were differentiated from day 0 through day 10. 2μg from each day was used for reverse
transcription. Real Time analysis was performed using arbitrary units as described in Materials and
Methods. * represents a statistical significance in terms of fold change of PKCβII/actin mRNA compared to
day 0 using unpaired t-test, p<0.05. Experiment was repeated three times.
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Figure 58. Differentiating 3T3-L1 adipocytes use distal polyA tail for PKCβII alternative splicing. RNA of 3T3-L1 pre-adipocytes
(Day 0) and 3T3-L1 adipocytes (Day 8) were extracted. RT-PCR from 2μg RNA was performed using indicated primers. C4B2 indicates
the forward primer spanning the C4 exon – PKCβII exon junction. B2i indicates the reverse primer binding on the intronic sequence
downstream of the PKCβII exon but upstream of the proximal polyA tail. B1 indicates the reverse primer that binds on the PKCβI exon.
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Figure 59. Differentiated 3T3-L1 adipocytes not transfectable. Day 5 3T3-L1 adipocytes
were transfected with 10nM siRNA targeting PKCβII and harvested on Day 8. Lysates were
run on SDS-PAGE gel and immunoblotted with indicated antibodies.
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Figure 60. 3T3-L1 transcription factor mRNA expression during adipogenesis. 3T3-L1 cell RNA was harvested
on the indicated day of differentiation. 2μg RNA was used for RT-PCR using primers for the gene indicated on the
right side.
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Figure 61. PU.1 expression through adipocyte differentiation. Day 0 through
Day 10 adipocytes were harvested for RT-PCR. Day 0 through Day 12
adipocytes were harvested for Western Blot analysis. 2μg RNA was used for
RT-PCR with primers for the product specified. 50μg protein was loaded on
SDS-PAGE and probed with indicated antibodies.
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Figure 62. ChIP of mouse PKCβ promoter. Day 0 pre-adipcoytes and Day 8 adipocytes
were harvested for ChIP analysis as mentioned in Materials and Methods. Antibodies
corresponding to the names given at the top of the figure were used to assess transcription
factor binding. Left Y axis numbers represent the forward and reverse primer positions
relative to the PKCβ1 transcript start as defined by Vega Mouse TransView (Mouse
Genome Informatics, MGI). All PCRs were performed with the same amount of cycles,
primers and template.
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Figure 63. PKCβII inhibition via CGP53353 attenuates adipocyte glucose uptake. Day 8 to day 12 3T3-L1 adipocytes were serum
starved for 4 hrs, ± 30 min 50μM CGP53353, ± 15 min 100nM insulin. Glucose uptake assay was performed as described in Methods
and Materials. (a) Dose curve shows the percentage decrease in glucose uptake when comparing insulin vs. drug with insulin. (b)
Graphical representation of 50μM treatment where * represents a statistically significant decrease (using arbitrary units) in glucose
uptake comparing insulin vs. drug with insulin, using unpaired t-test, p<0.05. Experiments were repeated three times.
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Figure 64. PKCβ inhibition via LY379196 attenuates adipocyte glucose uptake. Day 8 3T3-L1 adipocytes were serum starved for 4
hrs, ± 30 min 25 or 50μM LY379196, ± 15 min 100nM insulin. Glucose uptake assay was performed as described in Methods and
Materials. (a) Dose curve shows the effect of increasing drug concentrations on glucose uptake comparing insulin vs. drug with insulin.
(b) Effect of 25 or 50μM drug concentrations on glucose uptake. In both graphs, * represents a statistically significant decrease in
glucose uptake (using arbitrary units) comparing insulin vs. drug with insulin, using unpaired t-test, p<0.05. Experiments were repeated
three times.
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Figure 65. CGP53353 specifically targets PKCβII phosphorylation. Day 8 3T3-L1 adipocytes were serum starved for 4 hrs, ± 30 min
50μM CGP53353, ± 15 min 100nM insulin. (a) Whole cell lysates were run on an SDS-PAGE gel and probed with respective antibodies.
(b) Graphical representation shows the ratio of pPKCβII/pPKCδ, where * is a statistically significant decrease comparing insulin vs. drug
with insulin using unpaired t-test, p<0.05. Experiments were repeated three times.
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Figure 66. GLUT4 translocation is blocked by PKCβII inhibition. Day 8 3T3-L1 adipocytes were serum starved for 4 hrs, ± 30 min
50μM CGP53353, ± 100nM insulin 15 min. Subcellular fractionation was performed as described. 5μg for each sample of each fraction
(a,b,c) was loaded onto a SDS-PAGE gel and immunoblotted. Graphical representation of PM GLUT4 (d) and LDM GLUT4 (e), where *
represents a statistically significant change (using arbitrary units) comparing insulin vs. drug with insulin using an unpaired t-test, p<0.05.
Experiments were repeated on three occasions with similar results.
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Fig ure 67 . PM sheet as say confirms PKCß II role in GLU T4 translocation. Day 8 to day 12 3T3-L1 adipo cytes were s eru m starved for 4
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to ten arb itrary fields per cond ition were obtained , the average being show n. Images sho wn h ere are the representative sing le o ptical section
fro m z-series sectio ns taken at averag e 0 .2 µm step . (m) Graphical representatio n show s a s tatis tically sig nificant decrease (usin g arbitrary
units) in GLUT4 o ver PM stain ing co mparing ins ulin vs. d rug with in sulin us ing an u npaired t-test (*, p<0.05). E xperiment was repeated
th ree times.
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Figure 68. PKCβII may affect organization of GLUT4. Day 8 – Day 12 3T3-L1 adipocytes were treated ±
50uM CGP53353 30 min ± 100nM pig insulin 15 min. Cells were fixed and stained as described. Red staining
represents N terminal GLUT4. Blue (DAPI) staining represents the nucleus.
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Figure 69. Effect of PKCβII inhibition on Akt phosphorylation. Day 8 3T3-L1 adipocytes were serum starved for 4 hrs, ± 30 min
50μM CGP53353, ± 100nM insulin 15 min. (a) Whole cell lysates were run on an SDS-PAGE gel and probed with respective antibodies.
(b) Graphical depiction of pAkt/total Akt, where black bars represent pAkt Serine 473 / total Akt and white bars represent pAkt Threonine
308 / total Akt. * represents a statistically significant inhibition (using arbitrary units) of phosphorylation of Akt at Serine 473 comparing
insulin vs. drug with insulin using unpaired t-test, p<0.05. Experiments were repeated three times.
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Figure 70. PKCβII inhibition abolishes phosphorylation of Akt Serine 473 and its subcellular locations.
Day 8 – Day 12 3T3-L1 adipocytes were treated ± 50μM CGP53353 30 min ± 100nM pig insulin 15 min. Cells
were fixed and stained as described. (a-d) Red staining represents pAkt 473. (e-h) Blue staining indicates DNA.
(i-l) Colors were merged.
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Figure 71. CGP53353 treatment does not alter mTORC2 activation. Day 8 3T3-L1 adipocytes were treated ± 50uM CGP53353 30 min
± 100nM pig insulin 15 min. (a) Lysate were run on a SDS-PAGE gel and western blotted with indicated antibodies. (b) Graphical
representation of two independent experiments (measured using arbitrary units) using unpaired t-test, p<0.05.
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Figure 72. Insulin-dependent binding of PKCβII with activated mTORC2. Day 8 3T3-L1 adipocytes were
treated ± 50uM CGP53353 30 min ± 100nM pig insulin 15 min. Lysate was harvested under non-denaturing
conditions and co-immunoprecipitated with antibody listed. Co-immunoprecipitated proteins were combined with
Laemmli’s buffer and boiled. Samples were run on a SDS-PAGE gel and western blotted with indicated antibody.
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Figure 73. Insulin-dependent binding of PKCβII with phospho Akt S473. Day 8 3T3-L1 adipocytes
were treated ± 50uM CGP53353 30 min ± 100nM pig insulin 15 min. Lysate was harvested under nondenaturing conditions and co-immunoprecipitated with antibody listed. Co-immunoprecipitated proteins
were combined with Laemmli’s buffer and boiled. Samples were run on a SDS-PAGE gel and western
blotted with indicated antibody.
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Figure 74. Co-IP of GLUT4 and PKCβII. Day 8 3T3-L1 adipocytes were treated ± 50uM CGP53353 30 min ±
100nM pig insulin 15 min. Lysate was harvested under non-denaturing conditions and co-immunoprecipitated with
antibodies listed. Co-immunoprecipitated proteins were combined with Laemmli’s buffer and boiled. Samples were run
on a SDS-PAGE gel and western blotted with indicated antibodies.
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DISCUSSION
The major findings of my research are: 1) TZDs may be able to regulate cotranscriptional splicing of PKCβ in rat L6 skeletal muscle cells; 2) PGC1α also seems to
be able to mimic TZD’s effect on PKCβ co-transcriptional splicing; 3) the PGC1α Cterminal domain is necessary for bridging PKCβ transcription and splicing; 4) 3T3-L1
cells developmentally regulate PKCβ expression where PKCβII increases during
adipogenesis and PKCβI decreases during adipogenesis; 5) PU.1 binds to the PKCβ
promoter in 3T3-L1 adipocytes and may be responsible for developmental switching
between the two isoforms; 6) PKCβII is critical for ISGT by regulating GLUT4
translocation; and 7) PKCβII (being downstream of activated mTORC2) regulates
GLUT4 translocation by directly phosphorylating and fully activating Akt at Serine 473.
Thiazolidinediones have been used since 1997 to treat hyperglycemia in type 2
diabetes. Currently, Pioglitazone and Rosiglitazone are the only compounds licensed for
type 2 diabetic patients. [443]. TZDs work by decreasing insulin resistance. To elicit
their insulin-sensitizing effects, TZDs directly activate PPARγ. They seem to do this by
primarily working on adipose tissue even though the major effect on insulin-sensitization
occurs in skeletal muscle. This is in part due to altered free fatty acid supply. By
activating adipocyte PPARγ, TZDs promote differentiation of adipose tissue that is
smaller and more responsive to insulin, pre-dominantly subcutaneously. In addition,
TZDs reduce the output of inflammatory TNFα and FFAs while increasing output of
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adiponectin which increases peripheral insulin-sensitivity [338]. TZDs have also shown
benefit to the vasculature. Rat VSMCs undergo reduced migration and proliferation in
response to TZD treatment [444]. Yamamoto et al. showed that PKCβ isoforms have
opposing functions in A10 VSMCs. PKCβI was associated with accelerated cell
doubling time and increased S phase cell population whereas PKCβII was associated with
attenuation of cell doubling time and delayed entry into S phase [41]. Patel et al. showed
that acute hyperglycemia, which aggrevates cardiovascular tissue injury, posttranscriptionally destabilizes PKCβII mRNA [445; 446]. Here, we show that TZD
treatment is able to regulate alternative splicing, favoring the PKCβII isoform (Figure
24). PPARγ expression in VSMCs is associated with growth inhibition and
differentiation through a GATA-6 dependent transcriptional mechanism [447]. Whether
PPARγ is mediating the observed effects on VSMC PKCβ alternative splicing, remains to
be seen.
L6 cells represent a good model to study insulin signaling because skeletal muscle
accounts for the majority of post-prandial glucose disposal [420]. 24 hour treatment of
1μM Pioglitazone mimicked insulin′s effect on PKCβII exon inclusion, even synergizing
when combined with insulin stimulation (Figure 25). Western blotting confirmed that 24
hours 1μM Pioglitazone was able to stimulate PKCβII protein expression to a similar
extent as insulin (Figure 26). This is significant because the mechanism, in which TZD
benefits skeletal muscle signaling, as it pertains to glucose disposal, remains unknown
[448]. PKCβII is a critical regulator of L6 ISGT [40; 113]. TZD treatment could
possibly bypass a defective upstream insulin signaling pathway to upregulate PKCβII
expression. Since TZD treatment is supposedly ineffective at lowering serum glucose
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levels in the absence of insulin [414], TZDs could enhance L6 insulin sensitivity by
priming cells with PKCβII. This may lower the threshold of insulin signaling required
for full PKCβII activation and thus ISGT. It is even possible that some alternatively
spliced PKCβII, as a result of TZD stimulation, could become activated by another
pathway in the absence of insulin and therefore clear serum glucose in the basal state.
Non-insulin stimulated PKCζ (another PKC isoform involved in GLUT4 translocation)
activation and basal glucose uptake were increased in adipocytes with Rosiglitazone
treatment [449]. Rosiglitazone has been shown to enhance acute 5′AMP-Activated
Protein Kinase mediated glucose uptake (insulin independent) in muscle and adipose
tissue of high-fat fed rats [450]. Contraction-stimulated muscle glucose uptake is normal
in type 2 diabetics and signals through the AMPK pathway. AMPK (stimulated by
muscle contraction as well as hypoxia, ischaemia, heat shock, decreased pH, glycolysis
inhibition, and by uncouplers of oxidative phosphorylation) can stimulate skeletal muscle
glucose uptake in the absence of insulin and through a PI3K independent pathway.
aPKCs have been shown to have a role in AICAR (aminoimidazole carboxamide
ribonucleotide)-stimulated glucose uptake in both L6 cells and in isolated rat muscle
[451]. PKCα has been ruled out as a possible mediator of contraction-mediated glucose
uptake in mouse skeletal muscle cells. However, due to the fact that cPKC inhibitors
inhibit contraction-stimulated glucose uptake [452], other cPKC isoforms such as PKCβII
can not be ruled out. It is possible that TZDs could synergize with skeletal muscle
contraction-mediated glucose uptake in part by having PKCβII bioavailability which
could be a downstream target of AMPK.
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Overexpression of PPARγ, PGC1α and SRp40 all resulted in increased PKCβII
mRNA and protein levels (Figures 26, 27, 31, 33). Knockdown using siRNA further
stressed the importance of these factors in PKCβII exon inclusion (Figure 34-35).
Overexpression of the PPARγ E499Q mutant resulted in reduced PKCβII protein
expression with no effect on PKCβI levels (Figure 32). This PPARγ mutant can bind
ligands with affinity equal to wild-type but can not undergo ligand-dependent
transcriptional activation. However, PKCβI expression is unaffected which suggests that
basal transcriptional activity in this case is independent of PPARγ ligands. The most
plausible explanation for this is that the overexpressed PPARγ is becoming
transcriptionally active via its AF1 domain. PPARγ activation depends on the
conformation of its C-terminal AF2 helix. Ligands such as TZDs lock the AF2 in an
active conformation. The active AF2 conformation forms a charge-clamp pocket that
interacts with the LXXLL motif of coactivators. On the other hand, PPARγ in known to
have high basal ligand-independent activity [453]. Fibroblast overexpression of PPARγ
without a functional ligand binding domain was still able to drive adipogenesis. It is
possible that when PPARγ was overexpressed, there is a threshold that when crossed may
relieve the requirement for ligand activation [454]. There is no evidence of PPARγ
ligands being produced in cultured skeletal muscle cells; although it can not be ruled out
(different medium could make a difference). Even in adipose tissue, which abundantly
expresses PPARγ, endogenous ligands remain poorly characterized [455]. The structure
of ligand-free PPARγ assumes both active and inactive conformations. The active
conformation may be favored by increased amounts of PPARγ coactivators, such as
PGC1α, which can bind PPARγ in the absence of ligands [453]. To explain why the
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PPARγ E499Q mutant prevented PKCβII expression even though the ligand binding is
likely not needed for transcriptional activation of the PKCβ promoter, the mutation must
affect the ability of coactivators to bind PPARγ. Coactivators such as SRC-1/NCoA-1,
CBP/p300, pCAF, TRAP220 and PGC1α can activate PPARγ in a ligand-dependent as
well as ligand-independent manner. These coactivators dock on PPARγ on the AF2 or
helix 12 region of the LBD and this binding shows sequence conservation [456].
Without exogenous ligands, skeletal muscle cell PPARγ is required for normal rates of
fatty acid uptake [457] suggesting that forced PPARγ expression will be active. It is
possible that either the mutant PPARγ disrupts the sequence recognition of the
coactivator or it alters the folding/conformation of PPARγ such that it can not bind
certain coactivators or oscillate between the active-inactive conformations. In either
case, this would prevent it from binding coactivators that might potentially recruit
splicing factors to influence PKCβ alternative splicing.
Hypothesis #1 asserted that PPARγ would influence PKCβ alternative splicing by
directly binding to a PPRE located on the PKCβ promoter. In order to test this, we
devised a heterologous PKCβ minigene transcriptionally regulated by 2243bp of the
human PKCβ promoter (Figures 36-48). Initial experiments showed promising results
whereby PPARγ was able to influence both BI and BII exon inclusion when the plasmid
had the PKCβ promoter as opposed to the CMV promoter (Figure 51). However,
deletion of the putative DR2 proved to have no effect on overexpressed PPARγ′s
influence on the PKCβ promoter (Figure 52). It is possible that other putative PPREs that
were overlooked might have been better candidates. This is unlikely because the other
candidates were inverted repeats or everted repeats which are not standard PPREs.
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PPREs have been known to be located far away from the transcriptional start site [455].
The PKCβ promoter insert may have been too short and would therefore not harbor the
actual PPRE. To make matters more complicated, PPARγ exhibits promiscuity in
binding to the PPRE as opposed to RXRα which can not tolerate deviation from the
consensus sequence. The first three bases of the 5′ half site appear to be more critical
than the last three for PPARγ recognition [296]. The 2243bp of the human PKCβ
promoter insert may contain more putative PPREs (possibly even DR1s) if the emphasis
was put on only the 3′ half site.
PPARγ is still possibly a major player in regulating the PKCβ promoter in skeletal
muscle cells. Despite being detected by RT-PCR (Figure 34), PPARγ expression is
notoriously low in skeletal muscle. In addition, PPARγ does not account for all skeletal
muscle benefits via TZD treatment. Muscle-specific PPARγ deficient mice that are
insulin resistant still respond to TZD treatment [457]. The coactivators and other
activators present in skeletal muscle may alter the stoichiometry of PPARγ such that very
little is needed. An interesting point discussed by Lefterova et al. is that in some genes,
PPARγ is constitutively associated with coactivators, leading to high levels of
transcription [455]. Overexpressed PPARγ in skeletal muscle cells may be constitutively
bound to a coactivator on the PKCβ promoter causing constitutive co-transcriptional
splicing.
One experiment that would have given a more complete picture is PPARγ
overexpression combined with TZD treatment. The combined TZD treatment would
ensure PPARγ activation. However, one caveat with this is that PPARγ may not be
activated in the same manner. TZD is considered a full agonist [300]. For argument′s
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sake, we′ll ascribe PPARγ overexpression as a partial agonist. A partial agonist is a
compound that at saturating concentrations produces activity below that of saturating
concentrations of a full agonist. It is important to note that partial agonists do not
increase the interaction of PPARγ with corepressors. Depending on the level of
activation, PPARγ will differentially bind coactivators. By causing PPARγ to become
selective in terms of the coactivators it recruits, partial agonists will allow the induction
of some but not all PPARγ target genes. This is the concept behind “selective PPARγ
modulators” (SPPARγM). This is the idea that future PPARγ agonists will modulate the
metabolic genes necessary and sufficient for insulin sensitization while not affecting
genes involved in fat accretion and other side effects (e.g. edema) associated with TZD
treatment [300]. PA-082 was a novel partial agonist of PPARγ which selectively
recruited PGC1α. This drug was able to prevent Rosiglitazone-driven triglyceride
accumulation in mouse stem cells. At the same time, PA-082 was also able to induce
mRNAs of insulin signaling components and adipogenic differentiation pathways [458].
The point of this is that TZD activation of overexpressed PPARγ may have caused
PPARγ to associate with competing coactivators which may have hindered its ability to
stimulate PKCβ alternative splicing. Overexpressed PPARγ on its own may be able to
bind coactivators, without competition, that promote PKCβ alternative splicing.
The benefits of TZDs in skeletal muscle are largely independent of PPARγ [443].
A much more tantalizing prospect is TZD mediating its skeletal muscle effect through
PGC1α. PGC1α overexpression is able to closely mimic TZD treatment in terms of its
effects on PKCβ co-transcriptional splicing in muscle. 1μM Rosiglitazone and
Pioglitazone for 24 hours were able to increase overall transcription yet select the PKCβII
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isoform through alternative splicing (Figure 29). PGC1α was able to elicit a similar trend
(Figure 31), keeping PKCβI constant while increasing PKCβII exon inclusion. Although
PGC1α protein expression was very difficult to detect by western blotting, it is said to be
expressed heavily in skeletal muscle [459]. This problem with detection could be due to
the L6 cell line. PGC1α protein expression in rat skeletal muscles is highly correlated
with mitochondrial density and oxidative capacity. Muscles that express PGC1α switch
from a type IIb (fast twitch) muscle fiber type to a fast twitch type IIa and type I (slow
twitch) which contain more mitochondria and exhibit higher rates of oxidative
metabolism [376; 459]. In addition, PGC1α expression increases muscle glycogen stores
via increased glucose transport (also involves increased GLUT4 expression), suppression
of glycolytic flux and by inhibition of glycogen degradation pathway (down-regulation of
glycogen phosphorylase levels and activity). Muscles with forced expression of PGC1α
(similar to exercise-induced expression of PGC1α) energize by fatty acid oxidation
instead of glycolysis [357; 373]. Of interest here is the fact that PGC1α controls glucose
uptake. This could provide an explanation as to why PGC1α would regulate PKCβ cotranscriptional splicing. PKCβII is crucial in L6 insulin signaling. C-terminal deletion
PKCβII mutant expression as well as pharmacological inhibition using PKCβII-specific
CGP53353 (1μM) revealed that PKCβII was crucial for insulin-stimulated glucose uptake
[40]. PKCβII mediates these effects through MARCKS phosphorylation, increased
membrane PLD1 and cytoskeletal remodeling [113]. If TZD stimulation in skeletal
muscle cells were exerting their effect through PGC1α, it could do so either through
increased expression (coactivation) or increased activity/disabling repression. The
former has been demonstrated in mouse primary brown adipocytes and 3T3-L1
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adipcoytes. This regulation occurs via PPARγ-mediated transcriptional activation on the
PGC1α promoter PPRE [356]. Even though PPARγ in L6 cells is expressed in small
quantities, it is still possible that TZD-mediated PPARγ transcriptional activation could
induce increased PGC1α expression. Or TZD stimulation in skeletal muscle may activate
other transcription factors (which may even be coactivated by PGC1α) that will lead to
increased PGC1α protein levels. TZDs may also alter the activity of PGC1α. p38 stressactivated MAPK phosphorylates PGC1α at three residues (T262, S265, and T298) in the
negative regulatory domain. These phosphorylations lead to dissociation of repressorbound p160MBP. Ultimately, PGC1α becomes more stable with increased half-life as well
as possessing increased transcriptional activity [353; 460]. TZDs are capable of
activating p38 independent of PPARγ in rat GN4 liver epithelial cells [461]. Glucose
uptake in insulin resistant skeletal muscle cells in restored by TZD treatment in part by
activation of p38 [462]. PGC1α activity can be regulated by means other than
phosphorylation. Methylation via PRMT1 (protein arginine methyltransferase 1) has
been shown to positively regulate PGC1α transcriptional activity [463]. Acetylation
(nicotinamide-induced) has been reported to negatively regulate PGC1α transcriptional
activity (albeit in liver cells) [464]. TZD-induced PGC1α activation may affect cotranscriptional splicing of PKCβ. It is important to mention that the PGC1α and TZD
effect on splicing needs to be confirmed showing RNA data from both PKCβI and
PKCβII isoforms. Until then, it is possible that both treatments increase only PKCβII
mRNA translation. In that scenario both PKCβ transcripts could be transcriptionally
upregulated while splicing remained unaffected. Although unlikely, it is even possible

191

that the treatments aid in selectively stabilizing the PKCβII mRNA versus the PKCβI
mRNA.
PGC1α′s cited involvement in alternative splicing is another reason why it is an
attractive PKCβ modulator. Monsalve et al. evinced the role of PGC1α CTD in bridging
transcription and splicing. The CTD contains two RS domains and an RRM domain
(Figure 22). The RRM is required for induction of target genes. In the basal state,
PGC1α co-localizes with SR proteins at nuclear speckles. PGC1α, through its RS
domain is able to bind SR proteins, most prominently SRp40. Upon activation
(phosphorylation), both PGC1α and SR proteins alter their intracellular location within
the nucleus to sites of active mRNA synthesis. These proteins end up being part of the
hyperphosphorylated RNA polymerase II complex. It was shown that PGC1α (via CTD
deletion) was able to modulate splicing of a fibronectin minigene [362]. The CTD of
PGC1α is critical in mediating its effect on PKCβ alternative splicing (Figure 28). Cooverexpression of PGC1α and the PKCβ minigene would provide more insight as to
PGC1α′s role in PKCβ alternative splicing. SRp40 overexpression in another Cooper lab
PKCβ minigene (BII exon only) stimulates insulin-induced exon inclusion [37]. In vivo,
insulin induces Akt-mediated SRp40 phosphorylation which stimulates PKCβII exon
inclusion (assayed by RT-PCR) by direct binding to a SRp40-binding motif [38; 211].
Here, we further demonstrate that SRp40 overexpression leads to increased PKCβII
protein expression (Figure 26) and knocking down SRp40 decreases PKCβII exon
inclusion (Figure 35). It should be noted that the degree of SRp40 knockdown would
more closely mirror the knockdown of PKCβII if the number of SRp40 PCR cycles were
reduced. As far as hypothesis #1 is concerned (Figure 30), it is possible that TZD
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treatment activates PGC1α which recruits SRp40 (would likely have to be
phosphorylated) via PGC1α′s CTD. SRp40 would then associate with the RNAPII CTD
and influence splice site selection of the nascent PKCβ pre-mRNA. However, the
transcription factor that would initially bind PGC1α to the promoter is even less certain.
With respect to the minigene, it is possible that not enough SRp40 was available even if
PPARγ was bound to the minigene PKCβ promoter or even if PGC1α was able to
coactivate the minigene PKCβ promoter. It is also possible that some sort of stimulation
that promoted endogenous SRp40 hyperphosphorylation may be needed for translocation
and coactivator docking. Overexpression of SRp40 may induce its phosphorylation by
increasing the probability of interacting with an SR kinase such as Akt or Clk or possibly
increasing splicing of certain SR kinase genes (personal speculation). This could explain
why combined overexpression with either PPARγ or PGC1α resulted in higher
endogenous PKCβII mRNA levels than when overexpressed alone (Figure 27).
Work on skeletal muscle signaling has revealed PGC1α as the most promising
potential target of TZDs. Both PGC1α and PKCβII expression are associated with
enhanced skeletal muscle ISGT. Future experiments would focus on establishing
whether PGC1α is able to associate with the endogenous PKCβ promoter in skeletal
tissue (via ChIP assay). Assessing PGC1α’s activity levels with TZD treatment would
also give insight into whether its coactivation ability was enhanced as well as its ability to
bind SR proteins (e.g. phosphorylated RS domain). Knocking out PGC1α expression
(via siRNA transient transfection) and then treating with TZDs would reveal whether
PGC1α is necessary for the TZD effect on PKCβ co-transcriptional splicing.
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Additionally, performing a ChIP assay with the PGC1α antibody would confirm indirect
binding of PGC1α to the PKCβ promoter.
3T3-L1 pre-adipocytes were next used to assess possible TZD-mediated PKCβ
co-transcriptional splicing. When differentiated properly, 3T3-L1 cells become
adipocytes. Differentiation technique was verified by phase contrast microscopy as well
as oil red O staining. A conscious effect was made to avoid DMSO in dissolving the
differentiation compounds Dexamethasone and IBMX (insulin was dissolved in water).
This is because the action of DMSO is associated with increased expression of PKCβ, α,
γ isoenzymes and alternative splicing [121; 465]. For reasons that are apparent in the
results section, use of DMSO could have called into question the observed effects of
differentiation-regulated PKCβ alternative splicing (as well as differentiation-regulated
transcription of PKCα and γ). Ethanol was instead used to dissolve the two compounds
mentioned.
Glucose concentrations in the media were also examined. Most papers use high
glucose media to culture and differentiate 3T3-L1 cells. But because we were looking at
PKCβII expression, this presented a potential problem. Patel et al. had reported that
hyperglycemia can post-transcriptionally destabilize PKCβII mRNA (but not PKCβI
mRNA) in A10 VSMCs and primary human aorta cultures [466]. This is the reason why
both low and high glucose DMEM media was tested initially. If high glucose
destabilized PKCβII expression, then low glucose media would be opted for. However,
neither media had an effect on 3T3-L1 adipocyte PKCβII expression during development
(Figure 54-55). Therefore, we chose to stick with the mainstream culture media.
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The 3T3-L1 cell line is an ideal model for studying fat cell development and
signaling since results in 3T3-L1 adipocytes have repeatedly been confirmed in mouse
models [467]. During differentiation, many genes are programmed to initiate or cease.
cDNA microarray analysis of 3T3-L1 cells show PKCβ expression at least ten fold higher
in 3T3-L1 adipocytes versus 3T3-L1 fibroblasts [419]. This suggested a role for PKCβ in
adipogenesis and other adipocyte metabolic functions. Our results confirm that PKCβ is
regulated during 3T3-L1 differentiation (Figure 56-57). However, Guo et al. did not
address which PKCβ isoform was upregulated over ten fold. We believe this to be the
first example of differentiation-regulated PKCβ alternative splicing, whereby PKCβI
starts off as the predominant 3T3-L1 pre-adipocyte isoform and is later replaced during
differentiation with the PKCβII isoform. This form of regulation is almost certainly
disparate from the type of PKCβ alternative splicing that occurs in L6 skeletal muscle
cells within 15 min of insulin treatment [39]. The fact that PKCβII protein expression
peaks at day 8, the same time when robust lipid droplets can be observed under the
microscope, suggests that PKCβII could be involved in adipogenesis. This could explain
why protein and mRNA levels of PKCβII dip after peaking. PKCβII may be critical for
terminal differentiation. Once this occurs, PKCβII may be needed in lesser amounts. As
far as the mRNA of day 8 and day 10 falling below day 4, this could be explained by the
fact that a single PKCβII mRNA strand may be more frequently translated after terminal
differentiation. As to why PKCβII mRNA peaks at day 6 (Figure 56) and PKCβII protein
peaks at day 8 (Figure 57), this could be explained by differences in technique
sensitivities or other factors such as microRNAs regulating protein translation. Figure 58
indicates that the distal polyA tail (located downstream of the PKCβI exon) is used for
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both PKCβI and PKCβII mRNA expression. This may add stability to the mRNA
transcript. The expression pattern of PKCα and ζ (Figure 56) were congruent with
expression patterns reported by McGowan et al. [426]. PKCζ′s expression pattern is a
non-sequitur for a kinase confirmed to play a major role in 3T3-L1 adipocyte insulin
signaling [127; 129; 133; 145; 153; 283]. It is possible that heightened PKCζ expression
is needed for adipogenesis and then returns to a level that can still support insulinstimulated GLUT4 translocation. PKCδ (with all its possible isoforms) may also function
in promoting adipogenesis based on its expression pattern. PKCδ′s function in skeletal
muscle primary cultures suggests that it could provide a negative feedback to insulin
receptor tyrosine kinase activity [468]. The expression pattern of PKCγ, to our
knowledge, has not been reported in this cell line. It too could be involved in
differentiation but its expression rises and falls so precipitously from day 6 to day 8 and
then from day 8 to day 10 respectively, that it may only be needed for the terminal phase
of adipogenesis. PPARγ2 and PPARγ1 (which can compensate if PPARγ2 is deficient)
are essential for adipogenesis [455] and their presence confirms proper adipogenesic
signaling. Adiponectin is also a marker of adipocytes. GLUT4 protein expression
(Figure 56) signals the beginning of insulin responsiveness. PKCβII and GLUT4 protein
expression are very similar. Based on previous data from the Cooper lab in which
PKCβII knockdown resulted in reduced GLUT4 protein expression, it was hypothesized
(#2) that PKCβII could affect GLUT4 expression/stability.
Our inability to transfect 3T3-L1 adipocytes prevented this hypothesis from going
any further. Factors that could influence differentiation-regulated PKCβ alternative
splicing were next examined. As mentioned in the Results section, PU.1 was the lead
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candidate because it had consensus binding sites covering the PKCβ promoter as well as
being a factor that could regulate alternative splicing. PU.1 interacts with proteins
containing RNA binding motifs. One of these proteins is TLS/FUS, whose C-terminal
domain contains three RNA recognition motifs (RRMs) and two arginine glycine-rich
regions (RGGs). The RGG2-3 domain is capable of recruiting SR proteins [469]. We
hypothesized that if PU.1 bound the PKCβ promoter during differentiation, it could select
the SR proteins, and therefore the PKCβ isoform, based on coactivator recruitment. ChIP
assays revealed that PU.1 is likely associated with the PKCβ promoter. It was bound to
several spots on the promoter, although usually stronger on day 0 than on day 8. Several
possibilities exist as to PU.1′s function on the promoter. First, it could be a stimulator or
repressor of PKCβ alternative splicing depending on which site it occupies. Second, even
though PU.1 overexpression has been shown to inhibit overall 3T3-L1 differentiation, it
could be transcriptionaly repressive with respect to most adipogenic genes (allowing for
adipogenesis) but active with respect to PKCβ. This would explain why 3T3-L1
adipocytes continue to express PU.1 (Figure 61) even though it has anti-adipogenic
properties when overexpressed [437]. Also, as mentioned in the Results section,
overexpression of PU.1 in 3T3-L1 must be interpreted with caution as this may have
caused PU.1 to cross a threshold expression level to where it became anti-adipogenic.
PU.1 may behave like PPARγ. By this I mean that the binding of PU.1 to the PKCβ
promoter (whether day 0 or day 8) may be the same for a given site but its activation may
change due to differentiatial coactivator recruitment or post-translational modifications.
This change in activity may not be possible at day 0 due to the lack of a certain factor that
can only be expressed when the proper adipogenic signals are present.
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To our surprise, SRp40 precipitated with the PKCβ promoter. There were
noticeable differences between day 0 and day 8 depending on the region. Regardless,
association with the PKCβ promoter upstream of the transcriptional start site poses the
possibility that SRp40 is recruited via transcription factors and coactivators during
transcription. According to the literature, this is possible as long as SRp40 is serine
phosphorylated prior to arrival [470]. GATA2, like PU.1, is also a known antiadipogenic protein. Its expression could not be verified using RT-PCR, however, it did
appear in the ChIP assay showing binding preferences based on whether it was day 0 or
day 8. Of interest, from -4384 to -4183, GATA2 was bound strongly on day 0 and not
day 8. Perhaps, PKCβ needs this site to be free of GATA2 in order to accomplish
alternative splicing. GATA1 and AML1 did not bind in this assay, even though AML1
did bind in a previous assay. AML1/RUNX1 has been confirmed to bind the human
PKCβ promoter in U937 cells [435]. Perhaps the AML1 antibody had lost potency or
minute changes in cell culture conditions altered intracellular signaling to the point where
AML1 could no longer bind the PKCβ promoter.
Due to difficulties in transfecting 3T3-L1 adipocytes, PU.1 could not be knocked
down so we could not test directly whether PU.1 is needed for PKCβ alternative splicing
(hypothesis #3). Despite this, we moved on to test the physiological relevance of PKCβII
with respect to ISGT. Establishing a connection between PKCβII and ISGT would be
very significant. Adipose tissue accounts for only a fraction of glucose disposal after a
meal (~10-15%) with muscle accounting for much of the remainder. However, global
glucose homeostasis depends on adipocytes. This is not only based upon increased or
decreased adiposity but on the GLUT4 signaling inside the adipocyte [420]. Adipocyte
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GLUT4 signaling has effects on circulating serum adiponectin, an adipokine crucial for
peripheral insulin sensitivity [471]. Adipose–specific overexpression of GLUT4 has
been reported to reverse insulin resistance and diabetes in mice lacking muscular GLUT4
[472]. Adipose-selective targeting of the GLUT4 gene in mice impairs insulin action in
muscle and liver [473]. Regulation of adipocyte GLUT4 affects not only adipocyte
glucose uptake but global glucose homeostasis. The fact that PKCβII is critical in
skeletal muscle ISGT begs the question as to whether it holds a similar role in adipocytes.
Several lines of independent experimentation support the notion that insulin-dependent
GLUT4 translocation is similar or identical in skeletal muscle and adipocytes [474; 475].
In both cases, insulin-dependent GLUT4 translocation is PI3K dependent [476].
To establish this connection, experiments were modeled after Chalfant et al. using
PKCβII pharmacologic inhibition and [3H]2-deoxyglucose uptake [40]. 50μM
CGP53353 was able to significantly inhibit adipocyte ISGT (Figure 63). 25μM
LY379196 was also able to significantly inhibit adipocyte ISGT (Figure 64). Use of both
inhibitors has culminated in a narrow list of possible glucose uptake effectors. According
to the IC50 spectrum (in nM) of CGP53353, 50μM will inhibit PKCβII (IC50=0.41),
PKCβI (IC50=3.8), PKCα (IC50=1.9), PKCγ (IC50=22) and EGFR (IC50=0.7) [126].
Beyond 50μM, CGP53353 will not inhibit any other PKC isoform including PKCζ which
is considered the predominant PKC isoform involved in 3T3-L1 adipocyte ISGT [127].
Glucose uptake assays were performed on day 8 or later. At this point there is virtually
no PKCβI protein expression relative to day 0 (Figure 56). It is unlikely that it plays a
significant role in glucose uptake. In addition, there is no documented role for PKCβI in
insulin-stimulated glucose uptake in any cell line [40; 477]. CGP53353 at 20μM is able
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to inhibit ISGT by roughly 45%. Combined with the reality that intracellular
concentrations of the drug are likely much lower than 20μM, PKCγ can be ruled out as a
major drug target. Use of the LY379196 did not help to further eliminate cPKC
isoforms. However, the fact that 25μM was able to significantly inhibit ISGT confirmed
that there may be a novel PKC isoform involved in ISGT other than PKCζ (IC50=48μM).
LY379196 also helped to eliminate EGFR from possible CGP53353 effectors since
LY379196 does not inhibit this protein [125]. EGFR is downregulated during 3T3-L1
differentiation and was not considered to be a factor in ISGT [478]. PKCδ (IC50=0.7)
would also be inhibited by LY379196. However, inhibition of PKCδ activity does not
inhibit glucose transport in 3T3-L1 adipocytes [479]. Both drugs inhibit PKCα with
IC50s close to that of PKCβII and for this reason, PKCα can not be completely excluded.
On the other hand, PKCα has been shown to negatively regulate the insulin receptor
tyrosine kinase activity by interacting with IRS1 [480]. Angiontensin II inhibits insulininduced Akt activation through PKCα in VSMCs [481]. Hence, it would explain why
3T3-L1 cells downregulate PKCα during the course of adipogenesis and it is thus
unlikely that CGP53353 is mediating its effects through PKCα [426]. This leaves
PKCβII as the best candidate.
Hypothesis #4 asserted that PKCβII would regulate adipocyte ISGT through
GLUT4 translocation or GLUT4 fusion. In L6 cells, Chappell et al. showed that
CGP53353 at 1μM, a dose specific for PKCβII, was able to prevent GLUT4 fusion by
isolating PM fractions [113]. This result hinted at the possibility that PKCβII regulated
vesicle fusion but it was also assumed that this effect was due to inhibition of GLUT4
translocation. It is worth while to address the issue that the role of PKCβII in ISGT is
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controversial. Several papers have been published for and against a role for PKCβII in
ISGT regulation. The use of C-terminal mutant PKCβII and CGP53353 in L6 cells has
already been described [40]. In addition, LY379196 (at 3 X 10-8 mol/l) was able to
inhibit ISGT in 6 day-old cultured myotubes [482]. Interestingly, the same inhibitor was
used to make the case that cPKCs could not regulate L6 ISGT [483]. However, the same
group also showed that PKCα, PKCβ and PKCζ were activated by insulin in 3T3-L1 cells
[484]. This would suggest that PKCβ has some role in insulin signaling. Systemic
knockout of mouse PKCβ was reported to have no effect on glucose homeostasis in both
fat and skeletal muscle tissue [485]. This supposedly ruled out PKCβII as a player in fat
or muscle GLUT4 trafficking. However, caution must be exercised when drawing
conclusions from systemic knockouts. Systemic knockout of GLUT4 has only mild
perturbations in glucose homeostasis even though it is the bona fide transporter in
insulin-sensitive tissues. Tissue selective targeting of GLUT4, however, has dramatic
effects on ISGT [486]. Adipocyte-specific inducible knockout of PKCβII (future project)
needs to be performed to definitively determine the role of PKCβII in adipocyte ISGT.
However, work done here lays a foundation providing preliminary evidence that indeed,
PKCβII (or at the very least cPKC) is involved in GLUT4 translocation (possibly fusion)
and adipogenesis.
First, specificity of CGP53353 was determined using western blot analysis
(Figure 65). Phosphorylation of insulin receptor, PKCδ and PKCζ were not altered. It
was important to rule out PKCζ as this PKC isoform is involved in GLUT4 translocation
[127; 153]. PKCζ activation involves PDK1 mediated Thr410 phosphorylation. Based
on the literature we assumed this would be insulin-stimulated [487]. As is obvious, every
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condition demonstrated pPKCζ Thr410. Activation of PKCζ has been reported through
other stimuli including glucose in rat adipocytes [488]. The major activation pathway of
PKCζ is PI3K-manufactured PIP3. PDK1 binds with high affinity to PIP3 in order to
phosphorylate PKCζ.

PKCζ isolated from bovine kidney is phosphorylated via PI3K-

mediated PIP3 in response to growth factors [489]. Interestingly, Alessi et al. have shown
that PDK1 isolated from unstimulated or insulin-stimulated cells possess the same
activity towards the Akt target and others. In 293 cells, insulin stimulation did not
change the phosphorylation status of PDK1. It is proposed that PDK1 could be
constitutively active and that it is the substrate that needs to undergo a conversion in
order to become phosphorylated [490]. In this same cell line, ceramide was shown to
activate PKCζ in vitro [491]. 3T3-L1 adipocyte ceramide is associated with non-insulin
dependent glucose uptake. Ceramide can stimulate PI3K in 3T3-L1 cells [492]. Perhaps
PKCζ also has a role in basal glucose uptake and this necessitates its constitutive
phosphorylation. Phosphorylation of PKCβ S660 (hydrophobic motif) was dramatically
reduced with drug treatment with total PKCβ protein levels remaining constant. We also
attempted to assess the phosphorylation status of PKCα (even though it is almost
certainly inhibited as well) by using a Cell Signaling pPKCα/βII (T638/641) antibody.
Only one band materialized and since we did not possess a peptide inhibitor at the time,
this data could not be interpreted. Antibodies for pPKCγ were not practical as they crossreact with pPKCβII. pPKCβII (T641) (Abcam) was also probed for but there was too
much background.
The dosage used for CGP53353 also needs to be addressed. Differentiating 3T3L1 adipocytes develop impermeable cell membranes. During differentiation, more than
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90% of the adipocyte population have reduced junctional permeability [493]. This is
almost certainly the reason why pharmacologic inhibition can only be achieved by
spiking the dosage. Multiple investigators have used high drug concentrations in 3T3L1
adipocytes to block intracellular signaling. For example, PD-98059 at 50μM was used
to inhibit MEK activity and 100 µM naringenin to inhibit PI3K in 3T3-L1 adipocytes
[494]. LY294002 at 50μM was used to inhibit PI3K activity [495]. SP600125 at 50μM
was used to inhibition JNK activity and LY294002 at 100μM was used to inhibit PI3K
activity [496]. These are concentrations at least 10-fold higher than what is required in
skeletal muscle to block signaling.
CGP53353 administration abrogated GLUT4 translocation as evidenced by
subcellular fractionation and PM sheet assays (Figure 66-67). This implicates PKCβII as
a critical regulator of adipocyte ISGT. In addition, PKCβII may also have a role in
“priming” GLUT4 for translocation. Figure 68 (b & d) shows that insulin is able to
concentrate a pool of GLUT4, near what could possibly be the TGN. CGP53353
treatment causes GLUT4 to become more dispersed around the nucleus. This may
implicate PKCβII in insulin-stimulated GLUT4 trafficking leading up to translocation.
This data lends credence to part of Model 2 (Intro) concerning GLUT4 trafficking which
states that insulin causes more GLUT4 to accumulate at a non-cycling pool near the
TGN, which will translocate to the PM directly. Co-immunoprecipitation suggests that
PKCβII may be able to influence GLUT4 directly or act on the GSVs to direct trafficking
(Figure 73).
There are at least two discrete signaling pathways involved in insulin-regulated
GLUT4 translocation in muscle and fat cells. The first involves PI3K and the second
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involves the proto-oncogene c-Cbl. The two targets of PI3K that have been identified are
serine/threonine kinase Akt and PKCζ. PI3K activates Akt by generating
phosphoinositides in the inner leaflet of the plasma membrane. Akt docks to this through
a pleckstrin homology domain bringing it in close proximity with PDK1 [127]. The
mechanism of PKCζ activation is not known although it may involve dissociation from
14-3-3 proteins among other things [19]. Recent reviews describe PI3K signaling
diverging into two post-PDK pathways [133; 145; 254; 283; 497]. One pathway diverges
to an atypical PKC pathway shown to be crucial for activation of glucose transport in
both muscle and fat cells. The other Akt dependent pathway leads to AS160
phosphorylation. Five of six AS160 consensus Akt phosphorylation sites are
phosphorylated in response to insulin [498]. These phosphorylations render AS160′s
GAP domain inactive making it unable to negatively regulate Rab proteins. This allows
Rab-dependent GLUT4 translocation to occur [497]. Using western blot analysis and
immunofluorescent staining, CGP53353 selectively inhibited Akt phosphorylation at
S473 while phosphorylation at T308 remained undisturbed (Figure 69-70).
Immunofluorescent staining shows strong insulin-dependent recruitment of Akt to the
PM as well as intracellular deposits that could be part of the GSV trafficking itinerary
(Figure 70). This data suggests that PKCβII could be upstream of Akt during insulin
signaling. This is not unusual since it has been reported that PKCβII mediates Akt S473
phosphorylation in a cell type and stimulus-specific event [438]. The importance of Akt
in ISGT can not be overstated. James et al. reported that in 3T3-L1 adipocytes, fully
active Akt is involved in a late stage insulin-induced GLUT4 translocation to the PM.
This latter process involves docking and fusion of GLUT4 vesicles with the PM [499].
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Constitutively active Akt stimulated glucose uptake and GLUT4 translocation in 3T3-L1
adipocytes [180]. A kinase inactive, phosphorylation deficient Akt resulted in almost
complete loss of L6 cell surface GLUT4 [185]. A similar strategy was used to verify
Akt′s role in promoting insulin-stimulated cell surface GLUT4 in rat adipocytes [500].
More direct influence of Akt on GLUT4 has come from studies showing that insulin
increases association of Akt2 with GSVs and this leads to phosphorylation of GSV
component proteins [181; 182]. The functional consequence of this interaction, by use of
fusion constructs with Akt and GLUT4, results in insulin-stimulated GLUT4
translocation to the PM [501]. PKCβII, through Akt could direct GLUT4 traffic. If Akt
were to mimic GLUT4 localization, then PKCβII indirectly causes more GLUT4 to be
available near the TGN for direct translocation to the PM (Figure 68).
The mTORC2 complex is responsible for Akt S473 phosphorylation and thus full
activation in 3T3-L1 adipocytes. Phosphorylation of S473 results in the interaction
between the hydrophobic motif and the N-terminal lobe leading to activation [174; 175;
229]. mTORC2 can be distinguished from mTORC1 based on residue phosphorylation
of mTOR serine/threonine kinase. mTOR phosphorylation at S2481 defines the activate
mTORC2 complex [61]. To resolve the apparent discrepancy that PKCβII was needed
for S473 phosphorylation (in our model) and yet mTORC2 was the kinase responsible for
this (throughout most of the literature), we used CGP53353 inhibition to assess its effect
on mTORC2 activity. Figure 71 depicts an insignificant change in mTORC2 S2481
phosphorylation (and thus activity) when treated with CGP53353. This suggested few
possibilities. One was that PKCβII was downstream of mTORC2 and it was really
PKCβII that was phosphorylating Akt S473 in this cell line. Another possibility was that
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PKCβII associated with the mTORC2 complex and was needed for substrate specificity.
These assertions are reasonable given that PKCβII is phosphorylated at the turn motif by
mTORC2 in MEF cells [54]. In addition, the phosphorylation of Akt via mTORC2 has
not been shown to be direct [502]. Through co-immunoprecipitation, we provide
evidence that the turn motif phosphorylation of PKCβII is associated with direct binding
of mTOR (part of mTORC2) (Figure 72). This association increases with insulin
treatment compared to control (lane 3 vs. lane 2) and is dramatically reduced with
CGP53353 drug treatment (lane 3 vs. lane 5). PKCβII would then go on to
autophosphorylate itself and subsequently phosphorylate Akt. Preliminary data is shown
that suggests that this interaction between PKCβII and Akt is possible (Figure 73).
There is ample circumstantial evidence connecting PKCβII to GLUT4
translocation and ISGT alluded to throughout the introduction. PKCβII can be localized
to the pericontron to play a role in hormone responses by controlling the trafficking of
recycling endosomes containing Rabs. PKCβII can translocate to the pericentron in a
biphasic DAG response that depends on PLD-derived DAG [19]. 3T3-L1 adipocytes
undergo this biphasic DAG reponse [479].

PKCβII (not PKCβI) can activate PLD

(involved in GLUT4 fusion) [19]. It is important to note that it is the PLD1 isoform
which is activated by cPKCs in response to insulin. The PLD2 isoform has high basal
activity and is not stimulated to the same extent by PKC family members, ARF (ADProbosylation factor) and Rho [503]. 3T3-L1 adipocytes express both PLD isoforms
which are confined to LDM as detected by Millar et al. Within the LDM fraction, PLD2
is associated with intracellular membranes whereas PLD1 is associated with IRS1 and
PI3K [504]. Other reports have PLD1 at the perinuclear vesicles and PLD2 at the PM
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[505]. Subcellular localization of PLD needs further investigation. In HEK293 cells,
PKCα and PLCα are both involved in insulin-stimulated PLD1 and PLD2 activation
[503]. Human pulmonary artery endothelial cells (HPAEC) require PKCε for PLD2
activation which then goes on to activate PKCζ [506]. In human colon cancer cells, a
PKC/Ras/ERK/NFκB-pathway is responsible for PLD1 (not PLD2) activation [507].
Lastly, in the human-airway epithelial cell line (CFNPE9o-), Src and PKCδ are needed
for PLD1 activation [508]. Clearly, many factors converge on PLD isoforms to regulate
their activity as well as localization. Cell-type and agonist-type likely dictate which
factors are utilized. Therefore, if PKCβII was needed for PLD1 activation in 3T3-L1
adipocytes, other factors could compensate by either activating PLD1 or the cell could
switch to PLD2.
PKCβII binds to and is activatd by F-actin where it has been shown to
phosphorylate many cytoskeletal-associated proteins in vitro including adducin,
MARCKs, troponin, and vimentin. PKCβII association with F-actin resulted in a 5-fold
increase in F-actin phosphorylation, indicating F-actin is a PKCβII substrate [105].
Disruption of F-actin in 3T3-L1 cells, via cytochalasin D, depolymerizes actin thus
inhibiting GLUT4 translocation and ISGT. The dynamic rearrangements of F-actin and
the actin based cytoskeleton play a critical role in insulin-stimulated GSV translocation to
the PM [283].
As mentioned earlier, PKCβII can phosphorylate Akt S473 in a cell and stimulus
dependent manner [438]. Data presented leads to a final model whereby the insulin
signaling cascade in 3T3-L1 adipocytes results in mTORC2 activation. This leads to
direct mTORC2-mediated PKCβII phosphorylation and activation. PKCβII will then
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phosphorylate and fully activate Akt (S473). Fully active Akt perpetuates the insulin
signaling cascade eventually culminating in GLUT4 translocation and ISGT. Active
PKCβII may also act on GLUT4 or GSV components to positively regulate ISGT. Figure
75 represents a proposed model of 3T3-L1 adipocyte insulin signaling that is dependent
on PKCβII activity. Future directions would include studying other potential contributors
(e.g. AKAP and/or mTORC2 components) in the binding between mTORC2 and
PKCβII. Development of an inducible construct that specifically targets the PKCβII exon
would allow assessment of its role during adipogenesis as well as confirm PKCβII’s role
in GLUT4 translocation and ISGT.
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Figure 75. Hypothetical model for PKCβII-regulated ISGT via Akt activation in 3T3-L1 adipocytes. Differentiated 3T3-L1 adipocytes
are stimulated by insulin. Subsequent insulin receptor tyrosine kinase activity recruits IRS leading to PI3K generated PIP3 which sequesters
both PDK1 and Akt through their PH domains. Preceding PM localization, Akt is phosphorylated at Threonine 450 by a mechanism that
depends on mTORC2. Whether this is a direct phosphorylation by mTORC2 or involves PKCβII is uncertain. Once PM bound, PDK1
phosphorylates Akt at Threonine 308 as well as PKCβII at Threonine 500. Activated mTORC2 (which may require Ras-mediated
phosphorylation) includes mTOR, Rictor, Protor, Sin1, mLST8, phosphatidic acid (PA) and the TSC1/TSC2 complex. Since PKCβII can bind
and activate PLD1 in select cells, the possibility exists that PKCβII is involved in a positive feedback loop for enhanced insulin-stimulated
mTORC2 activation by indirectly generating PA. However, in spite of PKCβII inhibition, mTORC2 may still be able to assemble due to other
positive regulators of PLD1. High basal PLD2 activity could also compensate. Serine 2481 phosphorylation of mTOR during insulin
stimulation distinguishes mTORC2 activity allowing it to directly phosphorylate PKCβII at Threonine 641 leading to PKCβII
autophosphorylation at Serine 660. After PM translocation and pseudosubstrate release, fully active PKCβII phosphorylates Akt at Serine 473.
Akt is now fully active and able to elicit GLUT4 translocation to the PM culminating in glucose import. PKCβII may also be able to act on
GLUT4, or components of the GLUT4 storage vesicles, directly.
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